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act& as& transducers& of& extracellular& signals& across& the& lipid& bilayer.& & Their& location& and&
involvement& in&basic&and&pathological&physiological&processes&has&secured&thier&role&as&key&
targets& for& pharmaceutical& intervention.& & GPCRs& are& targeted& by&many& of& the& best& selling&
drugs& on& the& market& yet& there& are& a& substantial& number& of& GPCRs& that& are& yet& to& be&
characterised& and& could& offer& interest& for& therapeutic& intervention.& & GPR35& is& one& such&
receptor& that,& as& a& result& of& gene& knockout& and& genome& wide& association& studies,& has&
attracted& interest& through& its& association&with& cardiovascular& and& gastrointestinal& disease.&&
Elucidation&of& the&basic&physiological& function&of&GPR35&has,&however,&been&difficult&due&a&
paucity&of&potent&and&selective& ligands&and&a& lack&of&consensus&on&the&endogenous& ligand.&&
Herein,& a& focussed& drug& discovery& effort& was& carried& out& to& identify& agonists& of& GPR35.&&
Various& in# vitro& cellular& assays& were& employed& in& conjunction& with& NK& or& CKterminally&
manipulated&forms&of&the&receptor&to&investigate&GPR35’s&signalling&profile&and&to&provide&an&
assay&format&suitable&for&the&characterisation&of&newly& identified& ligands.& &Although&GPR35&
associates& with& both& Gαi/o& and& Gα13& families& of& small& heterotrimeric& G& proteins,& the& G&
protein& independent&βKarrestinK2& recruitment& format&was& found& to& be& the&most& suited& to&
drug&screening&efforts.&&Small&molecule&compound&screening,&carried&out&in&conjunction&with&
the&Medical&Research&Council&Technology,&identified&compound&1&as&the&most&potent&ligand&




human& and& rat&GPR35&with& equal& potency.& & This& finding& offered& –& for& the& first& time& –& the&
opportunity& to& employ& the& same& GPR35& ligand& between& species,& an& important& factor& to&
consider&when& translating& rodent& in# vivo& functional& studies& to& those& in&man.& &Additionally,&
using& molecular& modelling& and& site& directed& mutagenesis& studies,& these& newly& identified&
compounds&were&used&to&aid&characterisation&of& the& ligand&binding&pockets&of&human&and&
rat&GPR35&to&reveal&the&molecular&basis&of&species&selectivity&at&this&receptor.&&In&summary,&
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of& medicine& than& any& other& scientific& factor& during& the& past& century& (Drews,& 2000).&&
Nonetheless,&currently&marketed&drugs&mediate&their&effects&through&only&a&small&number&of&
the& potential& human& target& proteins,& estimated& to& be& between& 200& and& 300& in& number,&
targeted& by& some& 1000& pharmaceutical& agents& (Drews& and& Ryser,& 1997;& Golden,& 2003;&
Imming& et& al.,& 2006;& Overington& et& al.,& 2006;& RaskKAndersen& et& al.,& 2011).& & Human& drug&
targets,& separated& from& the& pharmaceutical& arm& of& antiKinfectives,& include& receptors& (G&
proteinKcoupled&receptors&(GPCRs),&ligand&gated&ion&channels,&receptor&tyrosine&kinases,&and&
nuclear& receptors),& which& form& the& largest& group& of& drug& targets& at& 44& %& market& share,&
followed& by& enzymes& (29& %),& and& the& transporter& proteins& (voltage& gated& ion& channels,&
symporters,&antiporters&and&uniporters),&(15&%)&(RaskKAndersen&et&al.,&2011).&
& Considerable& efforts& have& been& undertaken& to& expand& target& diversification,& with&
emphasis& on& firstKinKclass& products& and& new&molecular& entities& (NMEs)& (Paul& et& al.,& 2010;&
Barker&et&al.,&2013;&Sharma&and&Tan,&2013).&&Oncology&drug&discovery&has&paved&the&way&in&
this& regard& and& is& followed& by& orphan& drugs& for& the& treatment& of& rare& diseases,& which&
together&these&account&for&an&approximate&60K70&%&share&of&approved&applications&by&the&
Centre&for&Drug&Evaluation&and&Research&(Mullard,&2012,&2013,&2014).& &Treatment&of&other&







%&of&approved&drugs&on& the&market& today& (Drews,&2000,&Hopkins&and&Groom,&2002;&RaskK
Andersen&et& al.,& 2011).& & Indeed,& several&GPCR& ligands&are&among& the&worldwide&100&bestK
selling& pharmaceuticals& (Zambrowicz& and& Sands& 2003).& & GPCRs& are& the& largest& and& most&








Figure! 1.1! G! protein9coupled! receptors! display! a! characteristic! membrane! spanning! structural!
motif& GPCRs& are& integral& membrane& proteins& that& share& a& seven& alphaKhelical& domain& structural&
motif.&By&virtue&of& this&structure,&GPCRs&are&also&known&as&seven&transmembrane&proteins& (7TMs),&
serpentine& or& heptahelical& receptors.& & In& addition& to& containing& seven& αKhelical& hydrophobic&
transmembrane&(TM)&domains&that&span&the&lipid&bilayer,&the&GPCR&structure&is&connected&by&a&series&

















Penn& et& al.,& 2014;& Baker& et& al.,& 2014;& Vischer& et& al.,& 2014),& cancer& (O’Hayre& et& al.,& 2014),&
diabetes&and&obesity&(Milligan&et&al.,&2014;&Bouvier,&2014;&Miller&et&al.,&2014;&Kimple&et&al.,&
2014),& and& many& others.& & Equally,& the& ligands& that& activate& GPCRs& are& as& diverse& as& the&
receptors&and&the&functions&that&they&modulate,&thereby&creating&vast&potential&to&modulate&
intracellular&signalling&and&abrogate&disease.&&&
GPCR& ligands& include& endogenous& molecules& such& as& neuropeptides,& amino& acids,&
biogenic& amines,& chemokines,& lipid& mediators,& nucleotides,& polypeptide& hormones& and&
exogenous&molecules& including&viruses,&photons&of& light,&olfactory&and&gustatory&molecules&
(Civelli& et& al.,& 2013).& & GPCR& ligands& include& endogenous&molecules& such& as& neuropeptides,&
amino& acids,& biogenic& amines,& chemokines,& lipid& mediators,& nucleotides,& polypeptide&
hormones,& and& exogenous& molecules& including& viruses,& photons& of& light,& olfactory& and&
gustatory&molecules&(Civelli&et&al.,&2013).&&Synthetic&counterparts&of&these&molecules&account&
for&up& to&90&%&of& FDA&approved&drugs& (Koehn,&2009);& the&majority&of&which&are& synthetic&
small& compounds.& & This& is,& in& part,& due& to& the& increased& likelihood& of& small& molecules& of&
being& orally& bioavailable& (i.e.& conforming& to& Lipinski’s& Rule& of& Five;& Liprinski,& 1997)& and&
because&they&are&suitable&for&enhancement&through&chemical&engineering&to&deliver&a&high&
degree&of& specificity& into& the& structure& (Mason&et&al.,& 2012).& & Small&peptides,&proteins&and&
lipids& also& act& as& ligands& at& GPCRs,& although& they& typically& have& proven& more& difficult& to&
progress& as& drugs& given& the& inherent& increased& size& for& the& former,& and& increased&
lipophilicity&associated&with&nonKspecificity&for&the&latter.& &Additionally,&peptides&tend&to&be&
more&expensive& to&produce&and&are&often&administered&subcutaneously,&which& limits& their&
usefulness.&The&therapeutic&area&of&biologics,&however,&has&bolstered&the&success&of&peptides&
as& drug& candidates,& and& also& in& some& cases,& small& molecules,& through& the& generation& of&
humanised&monoclonal&antibodyKpeptide&or&monoclonal&antibodyKsmall&molecule&chimeras&
that&act&to&target&the&ligand&to&a&specific&tissue&or&receptor&(Feng&et&al.,&2014).&&The&antibody&
provides& highly& specific& targeting& to& the& desired& site,& increasing& the& specificity& of& the&






for& the& treatment& of& human& epidermal& growth& factor& receptor& 2& (HER2)Kpositive& breast&
cancer&(PiccartKGebhart&et&al.,&2005).&
Despite& the& increased& ingenuity& associated& with& the& delivery& of& therapeutics,&
however,&characterisation&of&therapeutic&targets&and&success&in&validating&these&targets&has&
fallen& dramatically.& Indeed,& it& is& estimated& that& only& 59& of& 370& nonKolfactory& GPCRs& have&
been& utilised& as& successful& drug& targets,& suggesting& that& either& the& remainder& are& either&
unsuitable& or,& perhaps,& that& there& still& remains& great& potential& within& the& ‘GPCRs& as&
therapeutic&targets’&arena&(SamsKDodd,&2005;&Gashaw&et&al.,&2011;&Garland,&2013).&&Calls&for&
more&innovative&techniques&to&expand&the&understanding&of&GPCR&function&have&been&met&
with& considerable& and& significant& milestones:& the& outcome& of& the& genome& sequencing&
project& (International& Human& Genome& Sequencing& Consortium,& 2004)& which& revealed&
putative,&previously&unidentified,&GPCRs&based&on&their&7TM&sequence;&and&crystallisation&of&
the& first&activeKstate&GPCR& (Lander&et&al.,&2001;&Venter&et&al.,&2001;&Abdellah&et&al.,&2004),&






the& ‘classical& pharmacological& approach’& whereby& previously& identified& ligands& were&
associated&with& their& cognate& receptor.& & Two&cases& in&point& are&adrenaline&and&histamine,&
molecules& that& were& well& characterised& in& terms& of& their& physiological& response,& but& the&
identity&of&their&endogenous&receptor&remained&undetermined&for&nearly&a&century&(Branch,&
1939;& Bennett,& 1999),& and& are& now& known& to& activate& the& α1,& α2,& β1,& β2,& and& β3&
adrenoceptors&and&H1&to&H4&histamine&receptors,&respectively&(Wallukat,&2002;&Lomasney&et&
al.,& 1991;& Hough,& 2001).& & During& the& 1970s,& there& existed& approximately& 50& endogenous&
ligands& that& remained& to& be& paired& with& their& cognate& receptors,& however,& advances& in&
molecular&biology&approaches&led&to&a&concerted&effort&during&the&eighties&and&nineties&that&
identified& novel& GPCRs& with& homology& to& previously& identified& sequences& using& the&








identified& based& on& sequences& suggestive& or& predictive& of& a& 7TM& structure& (Levoye& and&
Jockers,& 2008;& Yoshida& et& al.,& 2012).& & However,& many& of& these& GPCRs& shared& limited&
sequence& identity& with& previously& identified& GPCRs,& making& it& difficult& to& decode& their&
physiological& function&and&predict& their&endogenous& ligands.& &Furthermore,& there&began& to&
amass&many&more&GPCRs&than&endogenous&ligands&(Civelli&et&al.,&2013)&and&techniques&such&
as& gene& expression& profiling,& tissue& extraction,& and& pharmacological& screening& assays&
became&widely&used&in&an&effort&to&increase&the&repertoire&of&endogenous&ligands&(Im,&2002;&
Brown& et& al.,& 2003;& Kotarsky& and& Nilsson,& 2004).& & As& a& result,& small& molecule& compound&





Most& recently,& informationKbased& approaches& have& become& available& that& compare& novel&
and& known& GPCRs& based& on& sequence& or& pharmacology& to& infer& function& (Tunaru& et& al.,&
2005;&Kotarsky&et&al.,&2003).&&Together&these&practices&were&collectively&termed&‘the&reverse&
pharmacology&approach’& (Libert&et&al.,&1991;&Civelli&et&al.,&2013),&which& is&a&summary&term&
describing& the& situation& in& which& the& GPCR& sequence& was& identified& first,& followed& by& a&
search&for&the&endogenous&ligand.&&After&an&initial&‘boom’&in&the&late&1990s&and&early&2000s,&
however,& progress& to&associate&newlyKidentified&GPCRs&with& their& endogenous& ligands&had&






ligand,& and& many& of& these& were& identified& from& their& putative& 7TM& structure& identified&










that& had& limited& sequence& identity& but& a& shared& pharmacology,& such& as& the& histamine& H4&
receptor,&which&was&added&to&the&histamine&receptor&family&(Nakamura&et&al.,&2000;&Zhu&et&
al.,&2001;&Morse&et&al.,&2001;&Liu&et&al.,&2001;&Nguyen&et&al.,&2001;&Zampeli&and&Tiligada,&2009)&
or& the& converse,& receptors& that& shared& a& high& degree& of& sequence& identity& but& not&




the& metabolic& intermediates& succinate& and& the& free& fatty& acids,& of& which& succinate& was&
paired& with& GPR91& (which& was& subsequently& renamed& the& succinate& receptor& (He& et& al.,&










Not& all& orphan&GPCRs,& or& GPCRs& in& general,& are& suitable& as& therapeutic& targets.& & A&




the& ghrelin& receptor,& which& was& indicated& for& numerous& applications& but& failed& in& the&









postoperative& ileus,& but& failed& recently& in& phase& III& clinical& trials& due& to& lack& of& efficacy&
(Ejskjaer& et& al.,& 2010;&Hoveyda& et& al.,& 2011).& &However,& a& second& ghrelin& receptor& agonist,&













antagonism& of& the& OX1& and& OX2& receptors& emerged& as& treatment& for& sleep& disorders&
(Riemann& and& Spiegelhalder,& 2014).& & Subsequently,& clinical& candidate& submissions& from&
almost& all& major& pharmaceutical& companies& followed& (Scammell& and& Winrow,& 2011).& & To&
date,&two&dual&orexin&receptor&antagonist&compounds&have&proved&successful&in&clinical&trials&





furthering& research& efforts& without& a& thorough& knowledge& of& the& pharmacology& of& the&
target.&&An&example&an&orphan&receptor&in&clinical&trials&is&the&bombesin&receptor&subtypeK3&
(BRS3)&(Battey&et&al.,&1991),&which&presented&with&reduced&metabolic&rate,&increased&feeding&






trials& (Reitman&et&al.,&2012).& &An&example&of&an&orphan& ligand& is&unacylated&ghrelin& (UAG),&
which&is&a&distinct&form&of&ghrelin&from&that&mentioned&previously,&and&accounts&for&50K90&%&










& With&a&reduction& in& the&rate&of&GPCRs&being&verified&as& therapeutic& targets,&orphan&
GPCRs& have& provided& a& means& by& which& to& expand& this& repertoire& with& initial&
characterisation& efforts& in& some& instances& revealing& novel& pathways,& signalling& molecules&
and&disease&states.&&One&such&orphan&GPCR&that&was&billed&as&a&therapeutic&target&is&GPR35,&
since&it&presented&with&a&therapeutically&relevant&gene&expression&profile&and&was&genetically&
linked& to&a&number&of&disease&states.& &This& included&metabolic&and& inflammatory&diseases,&
such& as& ulcerative& colitis,& irritable& bowel& syndrome& (IBS),& gastric& cancer,& diabetes,& heart&
failure&and&atherosclerosis.& &However,&despite&this&disease&association,& in&the&sixteen&years&
since& its& discovery,& GPR35& remains& poorly& characterised& and& has& been& slow& to& amass&
interest.&&This&has&stemmed&from&a&lack&of&selective&and&potent&tool&compounds&with&which&












in# situ& hybridisation& (FISH)& technology& revealed& that& GPR1& (located& on& chromosome& 15&
q21.6)&crossKhybridised&with&a& locus&on&chromosome&2.& & In&an&effort& to& reveal& the&basis&of&
this& crossKhybridisation,& degenerate& oligonucleotide& primer& sequences& based& on& GPR1#
transmembrane& (TM)2& and& TM7&were& employed& and& subjected& to& PCR& amplification& from&
genomic& DNA& (gDNA)& (O’Dowd& et& al.,& 1998).& & Insertion& of& the& PCR& fragment& into& a&
Bluescript™& plasmid& enabled& screening& of& a& human& genomic& library,& which& led& to& the&
identification&of&a&sequence&predicted&to&encode&a&309&amino&acid&protein,&named&GPR35.&&
GPR35& was& found& to& share& little& homology& with& GPR1,& GPR30,& or& GPR14& (less& than& 26& %&
overall&identity).&&GPR35&does&however&share&sequence&homology&with&GPR23&(renamed&as&
LPA4)&(32&%&overall&identity),&HM74&(subsequently&reclassified&as&the&hydroxycarboxylic&acid&
HCA2&and&HCA3& receptors)& (30&%&overall& identity),&GPR55& (30&%&overall& identity)&and& some&
purinergic&receptors&(approximately&29&%&overall&identity)&(O’Dowd&et&al.,&1998).&
Although& no& data&was& shown& in& the& short& communication,&O’Dowd& and& colleagues&
described& rat& GPR35& messenger& RNA& (mRNA)& transcripts& to& be& expressed& within& the& rat&
intestine,& but&not&within& the&heart,& spleen,& liver,& lung,& ovary,& kidney,& or&whole&brain;&with&
human&GPR35#mRNA& transcripts& not& detected& in& the& caudateKputamen,& thalamus,& frontal&
cortex,&pons,&cortex,&midbrain,&medium&pons,&lung,&or&adrenal,&using&Northern&blot&analysis&
with&poly(A)&RNA& isolated& from&various& tissues& (O’Dowd&et& al.,& 1998).& &More& recently,& and&
with& a& more& sensitive& means& of& mRNA& transcript& detection,& Wang& et& al.,& (2006a)& used&
quantitative& reverse& transcriptase& PCR& (qRTKPCR)& analysis,& presented& relative& to&
glyceraldehydeK3Kphosphate& dehydrogenase& mRNA& levels& on& human& and& mouse& DNase& I&
digested&tissues.&&This&revealed&expression&of&GPR35&in&human&small&intestine,&colon,&spleen,&
foetal&spleen,&peripheral&leukocytes&and&stomach,&with&lower&levels&in&monocytes,&mast&cells,&
T& cells,& neutrophils,& dendric& cells,& eosinophils,& adipose,& thymus,& kidney,& liver,& and& caudate&
nucleus.& Independent& studies& also& identified& upregulation& of& human& GPR35& following&
immunoglobulin&E& (IgE)& stimulation&of&mast& cells& (Yang&et& al.,& 2010)& and&expression&within&
the& lung,& skeletal& muscle& and& pancreas& (Horikawa& et& al.,& 2000).& In& mouse,& Wang& et& al.,&
reported&much& higher&mRNA& levels,& with& the&mouse& spleen& generating& a& signal& over& 100&
times&higher&than&that&of&the&human,&in&addition&to&expression&within&the&lymph&node,&small&





with&GPR35& RNA& probes& directed& against& a& mouse& tissue& array& revealed& that&GPR35& was&
expressed&the&denum,&jejunum,&ileum,&cecum,&colon,&and&rectum,&and&in&various&regions&of&
the& intestine&GPR35&was&primarily&expressed&within&epithelial&cells& located& in& the&crypts&of&
Lieberkhün,&with&lower&levels&in&the&intestinal&villi&(Wang&et&al.,&2006a),&as&well&as&expression&
in& the&dorsal& root&ganglion& (Cosi&et&al.,&2011).&Using&qRTKPCR&analysis& from&rat& total& tissue&
RNA,&GPR35&was&found&in&uterus,&small&intestine,&colon,&dorsal&root&ganglion,&stomach,&and&









FISH& analysis& performed& on& metaphase& chromosomes& prepared& from& lymphocytes&
using&a&biotinylated&phage&probe&in&conjunction&with&DAPI&banding&indicated&that&GPR35&was&






in& the& transformation& process& leading& to& formation& of& gastric& cancer,& two& alternatively&
spliced&GPR35&transcripts&were&identified&from&human&gastric&cancer&tissue:&the&original&309&
amino&acid&transcript&identified&by&O’Dowd&et&al.,&(1998)&and&a&longer&transcript&containing&a&
31&amino&acid&NKterminal&extension& (Okumura&et&al.,&2004).& &As&a&result&of& this& finding&the&
authors& named& the& GPR35& short& variant& GPR35a& and& the& long,& GPR35b& (Okumura& et& al.,&








Figure! 1.2! The! human! GPR35! gene! region! at! chromosome! 2q37.3! produces! two! alternatively!
spliced!transcripts!to!encode!GPR35a!or!GPR35b!The&short&variant&of&GPR35&(GPR35a),&encoded&by&
transcript&variant&1,&produces&a&protein&of&309&amino&acids&from&the&open&reading&frame&in&exon&7&
(exon& 6& is& nonKcoding).& & The& long& variant& (GPR35b)& is& encoded& by& two& transcript& variants.& & Both&























and& two& encoding& GPR35b),& three& transcript& variants& of&Mus#musculus& and& one& of&Rattus#
norvegicus,& of& which& the& rodent& isoforms& encode& only& the& short& version& of& GPR35&
(information&from&the&National&Centre&for&Biotechnology&Information&database).&&GPR35&and&
its& surrounding& region& is& highly& polymorphic,& with& over& 1000& single& nucleotide&






investigated& the&pharmacology& and& function&of&GPR35b,& there&has& been& a& suggestion&of& a&
higher&transforming&capability& in&NIH3T3&cells&with&a&more&prominent&expression&profile&of&
GPR35b& than& GPR35a& in& various& human& gastric& cancers& compared& with& the& healthy,& nonK
tumorous,&surrounding&tissue&(Okumura&et&al.,&2004).& & In&primary&cardiomyocytes&however,&
GPR35a&and&GPR35b&were&found&to&be&expressed&to&similar&levels&and&to&respond&in&a&similar&
manner& to& external& stimuli& (Ronkainen& et& al.,& 2014).& & Previously,& GPR35b& was& found& to&
generate& pharmacological& responses& that& were& similar& but& more& variable& than& those&







& Although& the& gene& expression& profile& described& for& GPR35& mRNA& suggested& an&
expression& that&was& primarily& restricted& to& the& immune& and& gastrointestinal& tissues,& early&





sibships& (Sun& et& al.,& 2008a).& & This& study& identified& a& SNP& within& GPR35& positioned& at&
rs3749172,&which&encoded&a&nonKsynonymous&alteration&from&serine&to&arginine&at&position&
294& (Sun& et& al.,& 2008a).& & Since& this& SNP& encodes& an& amino& acid& located& at& the& CKterminal&




ligand& potency& or& βKarrestinK2& recruitment& to& human& GPR35& in& a& HEK293& cell& system&
(Mackenzie&et&al.,&2014),&perhaps&suggesting&a&system&dependent&effect.&
& More&recently,& in&a&study&aiming&to& identify&novel&therapeutic&targets&for&treatment&
of&the&late&stages&of&heart&failure,&Min&et&al.,&(2010)&isolated&RNA&from&twelve&patients&with&
severe& late& stage& chronic& heart& failure& and& subjected& the& samples& to& global& microarray&
analysis.& &GPR35#was& found& to& be& upregulated& compared& to& two&nonKfailing& heart& disease&
control& samples& and& as& a& result& was& adenovirus& transfected& into& primary& cardiomyocytes&
isolated& from& neonatal& rats& (Min& et& al.,& 2010).& & Assessment& of& cardiomyocyte& cellular&
morphology&revealed&that&upregulation&of&GPR35#decreased&cell&viability&and&presented&with&
a&hypertrophic&cellular&morphology,&while&knockKout&GPR35#mice&revealed,&through&insertion&
of& a& catheter& to& the& right& carotid& artery,& a& leftKventricular& systolic& pressure& that&was& 37.5&
mmHg&higher&than&wild&type&littermates&(Min&et&al.,&2010).&&&&
& Thus,& although& there& is& an& association& between&GPR35& and& cardiovascular& disease,&
the&basic& profile& of&GPR35& and& its& role&within& the&physiology&of& the&heart& remained& to&be&
clarified.&&Researchers&at&the&University&of&Oulu,&Finland,&began&to&elucidate&the&basic&profile&
of&GPR35&function&within&the&cardiovascular&system&with&the&revelation&that&mouse&GPR35&
expression& was& extremely& sensitive& to& hypoxia,& implicating& a& role& of& GPR35& in& the& acute&
phase& of& myocardial& infarction& during& pressureKload& induced& progressive& cardiac&
hypertrophy&(Ronkainen&et&al.,&2014).& &Furthermore,& it&was&revealed&that&hypoxiaKinducible&
factorK1& (HIFK1)& bound& to& and& activated&mouse&GPR35& through& interaction&with& a& hypoxia&
response&element&sequence& in&the&GPR35&promoter&region&that& increased&the&number&and&
density&of&GPR35&at&the&cell&surface&(Ronkainen&et&al.,&2014).&&Furthermore,&overexpression&










chronic& inflammatory& disorders& of& the& gastrointestinal& tract& including& earlyKonset&
inflammatory& bowel& disease& (IBD)& and& ulcerative& colitis.& & This& association& was& primarily&
reported& as& a& result& of& a& genome&wide& association& study& (GWAS)& that& identified& a& SNP& at&
rs4676410,&which&is&an&upstream&intron&variant&of&GPR35&that&is&altered&from&a&cytosine&to&a&
thymine&in&European&and&North&American&suffers&of&earlyKonset&IBD&(Imielinski&et&al.,&2009).&&
This& study& also& found& that& rs4676410& was& associated& with& CAPN10& (Calpain& 10,& a& Ca2+K
regulated& intracellular& cysteine& protease& involved& in& cytoskeletal& remodelling& and& signal&
transduction),&KIF1A#(kinesin&family&member&1A&protein,&an&anterograde&motor&protein&that&
transports& membranous& organelles& along& axonal& microtubules),& and& RNPEPL1& (arginyl&
aminopeptidase&BKlike&1,&a&zinc&metallopeptidase&with&preference&for&methionine,&glutamine&
and&citrulline&residues,& inhibited&by&Ca2+)& in&a& linkage&disequilibrium&block&(Imielinski&et&al.,&
2009).& &While&expression& levels&of&KIF1A&and&RNPEPL1&were&not&significantly&altered& in& the&
GWAS,&CAPN10#was&found&to&be&expressed&at&a&significantly&lower&level&in&ulcerative&colitis&
cases&than&in&genetically&related&nonKIBD&controls&(Imielinski&et&al.,&2009).&&&
CAPN10& and&GPR35,& neighbouring& genes& on& chromosome& 2,& have& previously& been&
associated&and&linked&to&disease&through&GWAS&studies,&respectively&(Horikawa&et&al.,&2000).&&
In&2000,&in&a&GWAS&of&T2D&MexicanKAmericans&native&to&Mexico,&four&nonKsynonymous&SNPs&
were& identified& within& the& coding& region& of& GPR35:& alanine& 25& threonine,& valine& 291&
isoleucine,&threonine&253&methionine,&arginine&125&serine,&and&serine&294&arginine,&of&which&
only&the&latter&was&found&to&be&associated&with&T2D&(Horikawa&et&al.,&2000).&&The&S294R&SNP&
also& associates&GPR35& with& cardiovascular& disease,& but& at& least& within& an& in# vitro& setting,&
none&of&the&aforementioned&GPR35&SNPs&affect&agonistKinduced&βKarrestinK2&recruitment&in&
HEK293&cells&(Mackenzie&et&al.,&2014).&
& Further& links& between& GPR35& and& ulcerative& colitis& were& provided& in& an& effort& to&
identify& risk& factors& for& primary& sclerosing& cholangitis& (PSC),& a& chronic& cholestatic& liver&
disease&of&unknown&etiology&that&is&frequently&presented&with&the&comorbidity&of&ulcerative&





et& al.,& 2013).& & In& a& population& of& German& decent,& two& GPR35# SNPs& (rs3749171& and&
rs4676410)& were& identified& that& showed& association& and& linkage& disequilibrium& with& PSC&
(Ellinghaus& et& al.,& 2013).& & The& rs3749171& SNP& encoded& a& nonKsynonymous& change& in& the&
GPR35& protein& from& methionine& to& threonine& at& position& 108,& located& within& the& third&
intracellular& loop& of& the& receptor,& and& highly& correlated& with& the& rs4676410& SNP& located&






& GPR35& has& been& linked& to& inflammation,& primarily& in& studies& whereby& addition& of&
GPR35& agonists& has& attenuated& inflammatory& processes,& leading& to& the& suggestion& that&
GPR35&can&modulate& inflammatory& conditions.& &Currently,& there& is& considerable& interest& in&





(Thorburn& et& al.,& 2014).& & In& the& gut& kynurenic& acid& can& be& liberated& from& dietary& protein&
through&the&activity&of&Escherichia#coli&and&transported&to&the&extracellular&milieu&and&blood&
where&it&elicits&broadly&antiKinflammatory&effects&(Kuc&et&al.,&2008).&&&
Kynurenic& acid& acts& as& a& glycine& and& allosteric& site& antagonist& of& the& glutamate& NK
methylKdKaspartate& (NMDA)Kreceptor& ion& channel& complex& and& as& a& nonKcompetitive&
antagonist& at& the& α7& nicotinic& acetylcholine& receptor& (Hilmas& et& al.,& 2001;& Stone,& 2001;&




disease& (Forrest& et& al.,& 2002;& Forrest& et& al.,& 2003).& & Levels& of& kynurenic& acid& were& also&






& The& actions& of& the& purported& GPR35& agonist& kynurenic& acid& and& the& surrogate&
reference& agonist& zaprinast& have& also& provided& links& between& GPR35& and& inflammation.&&
Kynurenic& acid& was& found& to& attenuate& lipopolysaccharide& (LPS)Kinduced& tumour& necrosis&
factorKα& (TNFα)& secretion& in& human& peripheral& blood& mononuclear& cells& and& purified&
peripheral&blood&CD14+&(cluster&of&differentiation&14+)&monocytes&(Wang&et&al.,&2006a).& & In&
an&independent&study,&kynurenic&acid&and&zaprinast&were&added&to&human&invariant&natural&
killer& like& T& (iNKT)& cells& preKstimulated& with& the& superKagonist& αKGalKCer& (a& chemically&
synthesised& αKgalactosylceramide)& (Fallarini& et& al.,& 2010).& & Using& an& EnzymeKLinked&
Immunosorbent& assay& (ELISA),& kynurenic& acid& and& zaprinast& were& shown& to& reduce&
interleukinK4&(ILK4)&release&into&the&culture&medium&in&a&doseKresponsive&and&Pertussis&toxin&
sensitive&manner&without&significantly&reducing& levels&of& interferonKγ& (INFγ)& (Fallarini&et&al.,&
2010).&&(Activated&iNKT&cells&are&involved&in&the&maturation&of&dendric&cells&and&can&counterK
regulate&autoimmunity&by&secreting&the&cytokines&ILK4,&ILK5&and&transforming&growth&factorKβ&




toxin& treatment& and& reduced& by& small& hairpinKRNA& delivery& targeting& GPR35,& implicating&
GPR35& as& a& direct&mediator& of& leukocyte& adhesion& (Barth& et& al.,& 2009).& & The& physiological&
functions& reported& for& GPR35& are& therefore& beginning& to& be& unravelled& (Fig! 1.3),& with&








GPCRs&are&named&as&a& result&of& their& function:&originally&described&as&proteins& that&






arrestin91! and!β 9arrestin92& The&majority&of& studies& that&have& revealed& functional& effects& following&
GPR35&activation&have&used&Pertussis&toxin&to&indicate&the&involvement&of&Gαi/o&and&its&corresponding&
βγ&subunits&in&the&transduction&of&GPR35’s&signal&(Ohshiro&et&al.,&2008;&Barth&et&al.,&2009;&Fallarini&et&
al.,& 2010;& Cosi& et& al.,& 2011).& & The& studies& indicating& an& involvement& of& Gα13! are& fewer& in& number&
(Jenkins& et& al.,& 2011;& Jenkins& et& al.,& 2010)& since& there& are& no& specific& inhibitors& of& this& G& protein;&
however&downstream&effectors&can&be&inhibited&to&reveal&signalling&through&this&pathway&(Oka&et&al.,&
2010;&Deng&et&al.,&2012a).&While&there&are&no&functional&studies&indicating&recruitment&of&βKarrestin&





they& interact& with& following& GPR35& activation& are& indicated.& & RhoGEF,& Ras& guanine& nucleotide&

























binding& (G)& proteins.& & G& proteins& contain& α,& β,& and& γ& subunits& that& are& essentially& the&
transducers& of& the& extracellular& stimuli& that& act& upon& receptors,& relaying& signals& to&
intracellular&effector&proteins.&&This&process&is&critical&for&an&organism’s&survival,&as&for&a&cell&
to& adapt& to& its& environment& it& must& be& able& to& receive& extracellular& cues& and& elicit&




through& the& specificity& of& their& sequence,& their& structure& and& their& electrostatic& potential&
(Baltoumas&et&al.,&2013).& &G&protein&and&GPCR& interactions&can&also&be&controlled& spatially&
and&temporally,&through&controlled&expression&levels&and&distribution&profiles,&which&may&be&
distinct&between&cell&types&and&tissues&(Downes&and&Gautam,&1999).&&This&complexity&is&the&
key& to& the&multiplicity& of&GPCR& signals.& & Additional& control& is& provided& by& the& rate& of&GTP&
hydrolysis&occurring&upon&Gα&dissociation&that&dictates&the&length&of&time&that&the&G&protein&
is&active.& &This&can&be&accelerated&by& the&effector& target&or&by& the&Regulators&of&G&protein&
Signalling&(RGS)&proteins,&which&serve&as&GTPaseKactivating&proteins&(GAPs)&for&some&classes&
of&Gα&subunits&(McCudden&et&al.,&2005).&&&
G& proteins& are& activated& following& ligand&binding& and& receptor& activation,& but& they&
can&also&be&constitutively&recruited&to&receptors&that&are&active&in&the&absence&of&ligand.&&The&
classical& model& of& G& protein& recruitment& is& that& the& activated& GPCR& recruits& the& GαGDP&
subunit,&which& forms& part& of& an& inert&membraneKbound& heterotrimeric& complex&with&Gβγ&
(Lambright&et&al.,&1996;&Wall&et&al.,&1995).&&Since&the&GPCR&is&as&guanine&nucleotide&exchange&
factor& (GEF)& and& the& GαGDP& subunit& is& a& substrate& for& the& activated& GPCR,& a& catalytic&
exchange&process&occurs&upon&their&interaction&that&replaces&GαGDP&with&GαGTP&(Rasmussen&
et&al.,&2011).&&Upon&binding&of&GαGTP,&a&conformational&change&occurs&within&the&Gα&subunit&
that& enables& the& release&of&Gα& from&both& the&GPCR&and& the&Gβγ& subunit& (Coleman&et& al.,&
1994;&Lambright&et&al.,&1994).&&The&Gα&and&Gβγ&subunits&are&then&free&to&modulate&specific&
downstream& processes& (Hamm& et& al.,& 1998;& CabreraKVera& et& al.,& 2003).& & Gα& is& a& guanine&
nucleotide& triphosphatase& (GTPase)&and&so& it& slowly&hydrolyses&back& to&GαGDP& in&a&process&







Hewavitharana& and&Wedegaertner,& 2012),& and& are& grouped& into& four& distinct& subKfamilies&





leads& to& the& attenuation& of& the& initiation& of& signalling.& & Activated& GPCRs& must& be& rapidly&






ubiquitously& expressed& in&mammals)& (Kang& et& al.,& 2014).& & Interaction& between& an& arrestin&
molecule&and&the&phosphorylated&GPCR&occludes&the&heterotrimeric&G&protein&binding&site,&
which&prevents&further&G&protein&coupling&and&terminates&G&proteinKdependent&signalling&at&
the&cellKsurface&(Shukla&et&al.,&2013).& &Additionally,& the&arrestins& facilitate& internalisation&of&
GPCRs&by&acting&as&scaffolding&proteins&for&clathrin&and&the&clathrin&adaptor&protein&APK2&to&
promote&clathrinKmediated&receptor&endocytosis,&which&mechanically&removes&the&receptor&
from& the& cell& surface& (Tian& et& al.,& 2014).& & In& some& cases& the& arrestins& are& also& involved& in&
signalling& processes& independent& of& G& protein& coupling.& & This& finding& has& led& to& the&
observation&that&certain&ligands&can&‘bias’&a&receptor&to&signal&via&a&G&protein&or&a&βKarrestin&




























Gαz 41 platlets,3brain,3neurons,3neurosensory3cells Inhibit3adenylate3cyclase
Gαt1 40 retinal3rods,3taste3buds
Gαt2 40 retinal3cones











































metazoan& phyla,& GPCRs& have& evolved&within& five& structurally& distinct& protein& families:& the&
glutamate& (G),& rhodopsin& (R),& adhesion& (A),& frizzled/taste2& (F)&or& secretin& (S)&GPCRs,&which&
are& clustered&using& the&GRAFS&phylogenetic& classification& system& (Fredriksson&et& al.,& 2003;&
Fredriksson&and&Schioth,&2005;&Josefsson,&1999),&(Fig!1.4).&&&
GPR35& is& placed& within& the& rhodopsin& ‘class& A’& family,& which& is& the& largest,& most&
studied,&and&therapeutically&targeted&family&of&GPCRs.&&Although&the&extracellular&sequences&
of& these& GPCRs& are& inherently& diverse& and& receptors& typically& only& share& 25& %& sequence&
identity& in& their& TM& helices,& there& are& some& sequence& motifs& that& are& highly& conserved.&&
These&motifs&have&been&used&to&generate&a&system&of&amino&acid&nomenclature&for&GPCRs,&
known& as& the& Ballesteros& and& Weinstein& numbering& system& (Ballesteros& and& Weinstein,&
1995).&&This&system&numbers&the&most&highly&conserved&amino&acid&in&each&TM&domain&with&
the&number&50,&which&decreases&(i.e.&49)&or&increases&(i.e.&51)&toward&the&N&or&C&terminus,&
respectively.& & Incorporation&of& the&TM& in&question&gives& rise& to& the& format& for&TM1&amino&
acid&50&as&‘1.50’.& &Accordingly,&the&most&highly&conserved&amino&acids&and&motifs&are&N1.50,&
LxxxD2.50,&E/DR3.50Y,&W4.50,&P5.50,&CWxP6.50&and&N/DP7.50xxY.&&&
Other&conserved& features& include&a&disulphide&bridge&between&ECL2&and&the& top&of&
TM3& that& tethers& ELC2& to& the& helical& bundle& and& provides& conformational& constraint,&
sculpting& the& topography& of& ligand& entry& to& the& binding& pocket& (Wheatley& et& al.,& 2012;&
Venkatakrishnan&et&al.,&2013).&&Although&the&ligand&binding&pockets&of&GPCRs&are&inherently&
diverse,& for&most& small& molecule& ligands& the& binding& pocket& is& situated&within& the& helical&
bundle,&while&for&peptide&ligands&the&NKterminus&and&extracellular&loops&of&the&receptor&play&
a&more&prominent&role&in& ligand&binding.& &Despite&the&inherent&differences&of&GPCR&ligands&
and& their& mode& of& binding& however,& a& recent& bioinformatics& study& indicated& that& while&
distinct& ligands& penetrate& to& different& extents&within& the& ligandKbinding& pocket,& all& class&A&










































the& lipid& environment,& and& despite& being& ubiquitously& expressed,& exist& in& relatively& low&
abundance& within& cell& membranes.& & This& adds& to& the& difficulty& associated& with& obtaining&




successful& crystallisation& efforts,& which& were& achieved& by& recent& advances& in& protein&






of& rhodopsin,&which&eased& the& isolation&process.& &Other&GPCRs&however,& are&expressed&at&





Recent& crystallisation& studies& of& rhodopsin,& the& β2KAR,& and& the& adenosine& A2A&
receptor& in& their& inactive& and& active& states& revealed& that& a& conserved& series& of&
conformational& changes& ensues& following& receptor& activation.& & Ligand& binding,& whether&
initiated& by& interaction& with& the& extracellular& loops& or& within& the& ligand& binding& pockets,&
must& form& contacts& with& TM3& and& TM6& to& initiate& the& structural& movements& involved& in&
GPCR&activation&(Rosenkilde&et&al.,&2010;&Doré&et&al.,&2011),&as&TM3&and&TM6&directly&contact&
all&other&helices&in&the&TM&bundle&with&the&exception&of&TM1&(Doré&et&al.,&2011).&&The&largest&
structural& change& that& occurs& during& receptor& activation& is& the&movement& and& rotation& of&
TM6&between&7K14&Å,&accompanied&by&movement&of&TM5&as&part&of&the&previously&proposed&
global&toggleKswitch&mechanism&(Schwartz&et&al.,&2006;&Lebon,&et&al.,&2011;&Rasmussen&et&al.,&






interaction& occurring& between& the& arginine& of& DR3.50Y& motif& and& E6.30& that& connects& the&
intracellular&ends&of&these&TMs&in&the&inactive&state,&although&this&is&not&conserved&in&all&class&




2011;& Lebon& et& al.,& 2011).& & Like& the& DRY& motif,& which& is& conserved& in& 96& %& of& class& A&
receptors,&the&NPxxY&motif,&conserved&in&97&%&of&such&receptors,&serves&as&a&microswitch&for&
GPCR& activation,&whereby& Y7.53& is& altered& from& its& inactive& position,& pointing& toward& TM1,&
TM2&or&the&aliphatic&intracellular&helix&8,&to&form&interactions&with&side&chains&of&amino&acids&
in& TM6& and& TM3.& & This& subsequently& enables& Y7.53& to& point& toward& the&middle& of& the& TM&
bundle&(Katritch&et&al.,&2013).&&Overall,&therefore,&ligand&binding&and&receptor&activation&act&
to& open& a& cleft& in& the& intracellular& surface& of& the&GPCR& that& enables& G& proteins& (or& other&
effectors)&to&bind&to&the&receptor.&
Despite&sharing&conserved&sequence&motifs,&the&biophysical&studies&of&rhodopsin&and&
the& β2KAR& have& provided& evidence& for& the& existence& of& two& distinct& receptor& activation&
models.& & Rhodopsin,& which& is& unique& in& that& it& exists& in& a& stable& twoKstate& conformation&
(inactive&or&active)&with&a&series&of&transient&intermediates,&does&not&require&the&binding&of&a&
Gα&protein&to&stabilise&the&active&state,&which&is&already&preKformed&once&11KcisKretinal&has&
isomerised& to&allKtransKretinal.& & In& contrast,& the&β2KAR,&which&exists& in&an&ensemble&of& low&
energy& conformations&with&different& functional& properties& is& not& fully& activated&by& agonist&





It& is& important& to& point& out& that& the& majority& of& crystallisation& efforts& have& been&
focussed&on&rhodopsin&and&the&β2KAR&and&that&these&receptors&bear&little&similarity&to&GPR35&
in& terms& of& their& shared& sequence& identity& or& ligand& binding& properties.& & A& sequence&
comparison& between& GPR35& and& rhodopsin& reveals& that& these& receptors& share& only& 20& %&
sequence& homology,& and& this& includes&many& of& the& highly& conserved& residues& and&motifs&




within& TM1& and& TM2,& in&which& GPR35& lacks& a& proline& at& position& 1.48& (and& has& a& leucine&
instead)& and& contains& an& additional& proline& residue& at& 2.58& (a& serine& in& rhodopsin).&&
Moreover,&GPR35&and&the&β2KAR&share&even&less&sequence&identity&(14&%),&but&they&do&share&
key& conserved& residues& at& positions& N1.50,& D2.50,& R3.50,& W4.50,& P5.50& and& P6.50.& & Importantly,&
GPR35&lacks&a&proline&within&the&highly&conserved&NPxxY&motif&of&TM7,&and&instead&presents&
with&a&‘DAICY’&series&of&residues.&&Since&proline&residues&can&cause&kinks&and&bends&in&the&TM&









binding& pocket,&with& the&GPR35& residues& projected& toward& this& space& being& buried& in& the&
TM2KTM3&interface&of&the&β2KAR&(Zhao&et&al.,&2014).&&Further&to&this,&the&lack&of&a&conserved&
proline&residue&at&position&4.60&may&cause&a&conformational&change& in& the&TM4&of&GPR35,&

































contrast& to& the& canonical& twoKstate& receptor&model,& which& states& that& GPCRs& exist& either&
inactive&(R)&or&active&(R*)&states,&and&that&all&ligands&with&functional&capabilities&would&share&
a& common& receptor& conformation& (Wisler& et& al.,& 2014).& & In& fact,& the& conformational&
complexity& and& downstream& signalling& processes& emanating& from& receptor& activation& are&
inherently&more&complicated&than&originally&surmised&(Deupi&and&Standfuss,&2011;&Kenakin,&
2013).& & Indeed,& recent& mass& spectrometry& approaches& applied& to& monitor& the&
conformational& changes& of& the& β2KAR& indicated& that& functionally& distinct& ligands& evoke&
distinct&receptor&conformations&once&bound&(Kahsai&et&al.,&2011;&West&et&al.,&2011)&and&that&
pharmacologically&distinct& ligands& regulate& receptor& activity&by& shifting& the& conformational&
equilibrium& and& shape& of& the& energy& landscape& associated& with& the& receptor& towards& a&
specific& state& (Deupi&and&Kobilka,&2010;&Nygaard&et&al.,& 2013).& &Moreover,& it& emerged& that&






& The& concept& of& ligand& efficacy,& therefore,& has& changed& completely& from& its& original&
description&as&a&property&of& agonists& that& cause& tissue&activation,& and&now& represents& the&
property&of&a&ligand&to&change&the&behaviour&of&a&receptor&towards&the&cell&(Kenakin,&2013).&&
Efficacy& is&a&term&used&to&define&the&properties&of&a& ligand&alongside& ligand&affinity& for&the&
biological&target,&and&the&ability&of&the&ligand&to&bind&for&a&period&of&time&sufficient&to&affect&
target& behaviour& (dissociation& rate,& target& coverage).& & Unlike& affinity,& efficacy& is& a& system&
dependent&parameter&and&is&a&reflection&of&both&receptor&density&and&coupling&efficiency&in&
a& given& system.& & Further& to& this,& not& all& ligands& need& to& activate& all& receptors& in& a& given&





Agonist&molecules& preferentially& bind& to& and& stabilise& the& active& (R*)& population&of&
receptors& to& generate& a& system& response& or& efficacy& that& is& attributed& to& the& chemical&
properties&of&the&ligand.&&For&example,&a&full&agonist&will&act&to&generate&a&system&maximum&
response,&while&a&partial&agonist&will&produce&a&submaximal&response&(Kenakin,&2001).&&Using&
the& β2KAR& as& an& example,& it& was& observed& that& binding& of& functionally& diverse& agonist&
molecules&generated&distinct&efficacy&profiles&that&could&be&attributed&to&the&conformational&





intrinsic& activity& that& may& show& agonist& or& antagonist& properties& depending& on& receptor&
density,&how&well&coupled&the&system&is,&or&whether&the&endogenous&ligand&is&present&(Burris&






own& emerged& in& 1989& following& the& observations& of& Costa& and& Herz.& & Costa& and& Herz&
revealed& that& the& basal& activity& of& the& δKopioid& receptor& could& be& diminished& with& the&
application& of& the& inverse& agonist& ICI174864.& & Moreover,& the& inverse& agonism& nature& of&
ICI174864& could& itself& be& blocked& by& the& presence& of& the& antagonist& MR2266,& revealing&
(importantly)&that&inverse&agonists&and&neutral&antagonists&were&distinct&entities&(Costa&and&
Hertz,&1989;&Kenakin,&2013).&&Although&initially&inverse&agonists&were&thought&to&be&purely&of&
academic& interest,& many& have& been& found& to& act& with& considerable& clinical& benefit.& & This&
includes& some& of& the& atypical& antipsychotic& drugs& (such& as& clozapine),& that& are& inverse&
agonists&of& the&constitutively&active&5Khydroxyryptamine&5KHT2C& receptors& (HerrickKDavis&et&
al.,&2000;&Meltzer&and&Massey,&2011),&or&the&histamine&receptor&H1&class&of&antihistamines,&
for&example&(Leurs&et&al.,&2002).&
Neutral& antagonists& impart& their& function& through& acting& in& a& competitive& or& nonK






were& subsequently& reKclassified& as& inverse& agonists& following& characterisation& of& these&
compounds&in&constitutively&active&cell&systems&(Khilnani&and&Khilnani,&2011;&Kenakin,&2013).&&
Despite&this&reKclassification,&there&remain&compounds&that&display&neutral&antagonism,&even&
in& constitutively& active& systems& (Sally& et& al.,& 2010;& Millan& et& al.,& 2011).& & Competitive&
antagonists&typically&interact&and&compete&with&endogenous&agonist&for&binding,&and&can&be&
of& use& to& identify& ligand& binding& to& the& orthosteric& (endogenous& ligand& binding)& site.&&
Conversely,& nonKcompetitive&but& reversible& ligands& typically& bind& to& a& site&on& the& receptor&
distinct&from&this,&named&an&allosteric&site.&&Allosteric&ligands&alter&the&conformation&of&the&
GPCR,& resulting& in& a& change& in& the& nature& of& its& interaction& with& an& orthosteric& ligand&
(Langmead& and& Christopoulos,& 2014).& & Allosteric& ligands& can& possess& intrinsic& efficacy& or&
impart&effects&only&when&in&the&presence&of&an&orthosteric&ligand.&&In&the&case&of&the&former,&
agoKallosteric& ligands& act& on& their& own,& but& they& can& also& potentiate& the& affinity& and/or&
efficacy&of&the&endogenous&ligand&if&both&ligands&are&present&together,&such&as&in&the&case&of&
the&FFA2&agoKallosteric& ligand&4KCMTB&(Smith&et&al.,&2011).& & In&the&case&of& the& latter,&other&









& A&number&of& endogenous&molecules&have&now&been& reported& to& act& as& agonists& at&




acyl& chain,& a& glycerol& backbone& and& a& phosphate& head& group,& and& is& the& smallest& and&




produced& through& enzymatic& cleavage& of& lysophosphatidylcholine& (LPC)& in& the& serum& or&
plasma&through&the&enzyme&autotaxin’s&lysophospholipase&D&activity&(Nakanaga&et&al.,&2010;&
Nishimasu& et& al.,& 2011).& & LPA& exerts& its& effects& through& a& number& of& cellular& proteins& that&
form& a& specific& subKfamily& of& GPCRs,& named& LPA1K6,& and& LPA& has& been& associated& with&
numerous& pathological& conditions& including& atherosclerosis& (Schober& and& Siess,& 2012),&
cancer& (Gotoh&et&al.,&2012),&obesity,& impaired&glucose&homeostasis& (Rancoule&et&al.,&2014),&
and&pain&(Ueda&et&al.,&2013).&&
& In&the&study&by&Oka&et&al.,&that&identified&LPA&as&a&GPR35&agonist,&HEK293&cells&stably&
expressing& human& GPR35& incubated& with& 2Koleoyl& LPA& or& 2Klinoleoyl& LPA& were& found& to&
stimulate& intracellular& calcium& mobilisation& above& the& level& of& [Ca2+]i& produced& by&
endogenously&expressed&LPA&receptors&(Oka&et&al.,&2010).&&Since&GPR35&has&not&been&found&
to& couple& to& the&Gαq& pathway& (Jenkins&et& al.,& 2011;&Mackenzie&et& al.,& 2011;& Jenkins&et& al.,&
2012),&this&study&could&suggest&a&novel&route&for&GPR35&stimulated&signalling.& &The& level&of&
zaprinast& stimulated& [Ca2+]i& in& GPR35& expressing& cells& was& almost& undetectable,& and& no&
response& to& kynurenic& acid& was& detected& (Oka& et& al.,& 2010),& indicating& that& the& mode& of&
action&of& LPA& (if& at&GPR35)&must&be&distinct& from& the&previously&described&agonists.& &Also,&
these& [Ca2+]i& responses&were& not& assessed&with& a&GPR35& antagonist& as& there&was& not& one&
available&at&that&time&and,&therefore,&have&not&been&intrinsically&linked&with&GPR35&activity.&&
Lastly,&it&is&important&that&to&note&that&no&other&study&has&reported&any&effect&of&LPA&as&an&




& The& first&endogenouslyKgenerated& ligand&associated&with&GPR35& is& the&LKkynurenine&
metabolite& kynurenic& acid& (4KoxoK1HKquinolineK2Kcarboxylic& acid),& which& acts& as& a&
neuroprotective&modulator&through&its&antagonist&action&at&the&AMPA&(αKaminoK3KhydroxyK
5KmethylK4Kisoxazole& propionic& acid),& Kainate,&NMDA& and&α7& nicotinc& receptors& and& as& an&
agonist& of& the& aryl& hydrocarbon& receptor& (Hilmas& et& al.,& 2001;& Stone,& 2001;&Marchi& et& al.,&
2002;&Prescott&et&al.,&2006;&DiNatale&et&al.,&2010).&&Importantly&however,&it&remains&unclear&
whether& any& of& the& ion& channels& are& actually& blocked& by& kynurenic& acid& under& normal&
physiological&conditions,&as& levels&of&kynurenic&acid& in&the&brain&have&been&reported&under&










Name! Structure! Action! Potency!(EC50)!
Comments! References!









































DHICA! ! Partial&agonist& Human:&&22!μM&&&&&&&&&&&&&&&&&&&&&&&&&(DMR&24&μM)& Intermediate&in&the biosynthesis&of&melanin& Deng&et&al.,&2012c&
Reverse!














































Wu&et&al.,& 2007),&while&micromolar& concentrations&of& kynurenic&acid&are& required& to&block&








wish& to& consider& GPR35& as& a& contributor& to& the& effects& of& kynurenic& acid& in& the& CNS&
(Mackenzie&et&al.,&2015).&
Although&the&early&studies&did&not& focus&on&a&role&of&GPR35& in&the&CNS,&GPR35&has&
begun& to& receive& attention& as& a& potential& modulator& of& kynurenic& acid’s& effects& in& the&
periphery& since&GPR35& was& found& to& be& highly& expressed&within& the& gastrointestinal& tract&




the& CNS,& the& level& of& kynurenic& acid& reported& to& occur& and& the& concentration& required& to&
activate&GPR35& in& the& periphery& also& do& not& appear& to& overlap,& at& least& in& humans& under&
normal&physiological& conditions& (Jenkins& et& al.,& 2011;&Milligan,& 2011).& &Although& this& is& the&
case,& a& number& of& researchers& believe& the& concentration& of& kynurenic& acid& reported& is&
artificially& low& (Moroni& et& al.,& 2012)& since& estimates& of& this& molecule& are& limited&
technologically,&and&there&is&reason&to&believe&that&the&actual&level&of&kynurenic&acid&is&much&









Wu& et& al.,& 2010).& & Changes& to& the& levels& of& kynurenic& acid& have& been& associated& with& a&
number& of& disease& states& including& Huntington’s& disease& (Beal& et& al.,& 1990),& Alzheimer’s&













CKterminally& manipulated& forms& of& GPR35& and& βKarrestinK2,& which& recorded& half& maximal&
effects& using& a& Bioluminescence& Resonance& Energy& Transfer& (BRET)& assay& of& 66& µM& rat&
GPR35KeYFP&and&>&100&µM&at&human&(Jenkins&et&al.,&2010).&&&
More&recently,&the&second&messenger&cyclic&guanosine&3’&5’&monophosphate&(cGMP)&
was& identified& as& a& putative& endogenous& ligand& of& human& GPR35& (Southern& et& al.,& 2013).&&
cGMP& and& derivatives& MANT& cGMP& (2}KOK(NKmethylanthraniloyl)KcGMP)& and& dbKcGMP&
(dibutyrylKcGMP)& were& identified& from& a& concerted& effort& to& deorphanise& a& panel& of& 82&
orphan& GPCRs& by& screening& 10,500& candidate& endogenous& ligands& using& the& DiscoveRx&
PathHunterTM&βKarrestinK2& recruitment&assay& (Southern&et& al.,& 2013).& &MANTKcGMP& (EC50&2&
µM)&was&the&most&potent&while&cGMP&was&the&least&potent&(EC50&130&µM)&(Southern&et&al.,&
2013).&&Despite&this&discovery,&the&functional&relevance&of&these&ligands&at&GPR35&remains&to&
be&demonstrated,& including&whether&concentrations&of& these& ligands&present# in#vivo&would&
be&sufficient&to&activate&GPR35.&&Notwithstanding,&it&is&interesting&to&note&that&cGMP&and&its&
associated& signalling& pathways& have& received& considerable& attention& recently& for& the&









dihydroxyindoleK2Kcarboxylic& acid)& and& thyroid& hormone& synthesis& intermediates& T3& (3,5,3’&
triiodothyronine)& and& reverse& T3& (3,3’,5’Ktriiodothyronine)& promoted& dynamic& mass&
redistribution& (DMR)& in& the& human& colorectal& adenocarcinoma& cell& line& HTK29,& which&
endogenously& expresses& GPR35& (Deng& et& al.,& 2012c).& & Application& of& the& synthetic& GPR35&
antagonist&CIDK2745687& (methylK5K[(tertKbutylcarbamothioylhydrazinylidene)methyl]K1K(2,4K
difluorophenyl)pyrazoleK4& carboxylate)& at& a& fixed& concentration& of& 64& µM& reduced& the&
wavelength& shift&of&each&of& the&aforementioned&agonists& to&almost&basal& levels,& indicating&









and& 513& ±& 61& µM& in& the& Tango™& assay& (Deng& et& al.,& 2012c).& & As& with& the& previously&








Thus,&although& there&have&been&advances& in& the&number&of&endogenous&molecules&
activating&GPR35,&because&of&the&low&potency&of&many&of&these&compounds&and&the&fact&that&














display& moderateKtoKhigh& potency& at& GPR35,& and& indeed& there& now& exists& a& reasonable&
number&of&tool&compounds&with&which&to&probe&the&basic&physiology&and&pathophysiology&of&
this& receptor.& Notably,& however,& as& observed& for& kynurenic& acid,&many& of& these& synthetic&
compounds&display&marked&species&selectivity.&&&
& One& of& the& first& ligands& documented& for& GPR35& was& the& cyclic& guanosine&
monophosphate& (cGMP)Kphosphodiesterase& (PDE)& 5/6& inhibitor& zaprinast& (2K(2K
propyloxyphenyl)K8KazapurinK6Kone)& (Taniguchi& et& al.,& 2006),& which& was& originally&
synthesised&during&the&creation&of&xanthines&for&the&treatment&of&allergy&(Broughton&et&al.,&
1974).& Due& to& zaprinast’s& success& in& increasing& the& amplitude/duration& of& nitrergic&
responses,& it& became& a& lead& compound& for& the& rational& drug& design& of& sildenafil& (Gibson,&
2001).& &However,& although& zaprinast& is& an& analogue&of& cGMP&and& is& structurally& similar& to&
sildenafil,&cGMP&acts&only&with&weak&activity&at&GPR35&(Southern&et&al.,&2013)&while&sildenafil&
is& inactive& (unpublished& observations).& & Zaprinast& tends& to& be& employed& as& a& reference&
agonist&for&GPR35&since&it&displays&moderateKtoKhigh&potency&at&each&of&the&human,&mouse,&
and&rat&species&orthologs&(Taniguchi&et&al.,&2006;&Yang&et&al.,&2010;&Jenkins&et&al.,&2012),&and&
zaprinast’s& GPR35Kmediated& effects& can& be& dissected& from& those& exerted& through& its&
inhibition&of&phosphodiesterases&(Taniguchi&et&al.,&2006;&Yoon&et&al.,&2005;&Choi&et&al.,&2007).&&&
& Because&zaprinast& is& the&only&phosphodiesterase&blocker& to&specifically& inhibit&PDE6&
over&PDE5&(Zhang&et&al.,&2005),& in&a&study&aiming&to&elucidate&the&effects&of&PDE6&in&retinal&
photoreceptors& on& lightKdependent& signal& transduction,& Du& et& al.,& used& zaprinast.& & These&
authors& unexpectedly& found& that& zaprinast& altered& the&metabolic& profile& of&mitochondrial&



























































































































































































































































































function& at& the& mouse& orthologue& of& GPR35& (Jenkins& et& al.,& 2012)& and& as& such& these&
conclusions&must&be&viewed&with&caution.&&In&a&separate&study&zaprinast&was&found&to&inhibit&
hydrogen& peroxideKinduced& lysosomal& destabilisation,& a& step& that& precedes& mitochondrial&
apoptotic&changes&and&oxidative&cell&death&in&cultured&astrocytes&in&a&manner&independent&
from&cGMP&activity&(Choi&et&al.,&2007).&&Further&studies&have&linked&zaprinast&activity&to&antiK
nociception,& with& spinal& application& of& zaprinast& following& formalinKinduced& nociception&
doseKdependently& reducing& the& sum& of& flinches& in&male& SpragueKDawley& rats& (Yoon& et& al.,&




& Indeed,& ligands& that& acted& with& potencies& higher& than& zaprinast& at& the& human&
ortholog&were& subsequently& identified& (Table! 1.3).& This& includes&pamoic& acid& (5KnitroK2K(3K
phenylproplyamino)& benzoic& acid),& which& was& identified& independently& by& two& groups&
following&screens&of&the&Prestwick&Chemical&Library®&(Zhao&et&al.,&2010;&Jenkins&et&al.,&2010).&&
Pamoic& acid& is& a& substance& that& is& added& as& a& counter& ion& to& stabilise& drug& formulations,&
including& the& antihelminthics& oxantel& pamoate& and& pyrantel& pamoate,& the& psychoactive&
compounds& hydroxyzine& pamoate& (Vistaril®)& and& imipramine& pamoate& (TofranilKPM®)& and&
the& peptide& hormones& triptorelin& pamoate& (Trelstar®)& and&octreotide& pamoate& (OncoLar®)&
(Zhao&et&al.,&2010;&Neubig,&2010).&&Crucially,&pamoic&acid&was&added&to&these&formulations&as&
an& ‘inert’& substance,&as& classified&by& the&US&Food&and&Drug&Administration& (FDA),& and&was&
believed&to&act&only&to&prolong&the&activity&of&the&active&components&before&it&was&identified&
as&a&GPR35&agonist& (Neubig&2010;&Zhao&et&al.,&2010;& Jenkins&et&al.,&2010).& &This,& therefore,&
since&pamoic&acid&is&present&in&the&therapeutic&formulation,&could&link&GPR35&to&the&disease&
states& treated& by& these& formulations& (Citrome,& 2009;& Xu& et& al.,& 2013b;& McCarthy,& 2014).&&
Specifically,&pyrvinium&pamoate&was&found&to&inhibit&the&NADHKfumarate&reductase&system&
in& mitochondria& of& a& PancK1& (human& pancreatic& cancer)& cell& line,& a& system& involved& in&




al.,& 2012).& & Pyrvinium&pamoate&was& also& found& to&disable& survival& of& cardiac& fibroblasts& to&
















1.3)& (Yang& et& al.,& 2010;& Jenkins& et& al.,& 2012).& & Cromolyn& has& been& used& clinically& for& the&
treatment& of& asthma& since& 1967.& & Although& the&mechanism& of& cromolyn’s& action& has& not&
been& elucidated,& inhalation& of& cromolyn& in& patients& with& allergic& asthma& blocks& allergenK
induced&bronchospasm,&thought&to&be&through&inhibition&of&mast&cell&degranulation&(Oka&et&
al.,& 2012),& which& was& supported& by& cromolyn’s& ability& to& inhibit& the& degranulation& of& rat&
peritoneal&mast&cells& in&response&to&challenge&with& IgE&(Shin&et&al.,&2004).& & In&keeping&with&
the&ligandKassociated&functions&of&zaprinast&and&pamoic&acid,&cromolyn&has&been&associated&




discovered& for& GPR35,& including& ‘compound& 1’& (4K{(Z)K[(2Z)K2K(2Kfluorobenzylidene)K4KoxoK
1,3KthiazolidinK5Kylidene]methyl}benzoic&acid)&(NeetooKIsseljee&et&al.,&2013),&and&PSBK13253&












The& study& by& Funke& and& colleagues& also& presented& the& first& comprehensive&
assessment& of& the& structureKactivity& relationship& between& various& chemical& structures& at&
human,&mouse,&and&rat&orthologs&of&GPR35.&&Although&noted&previously&for&individual&ligands&
(NeetooKIsseljee&et&al.,&2013),&this&study&provided&collective&evidence&that&GPR35&ligands&act&
with& either& humanKselective,& humanKandKmouseKselective,& humanKandKratKselective& or&
rodentKselective&properties,&with&no&ligands&found&to&act&with&high&and&equal&potency&at&all&
three&orthologs& (Funke&et&al.,&2013).& &However,&shortly&after&this&study&was&published,& two&
mast&cell&stabilisers&were&found&to&activate&human&and&rat&in&a&high&and&equipotent&manner,&
becoming& the& first& tool& compounds& reported&at&GPR35& that&could& feasibly&be&employed& to&
translate& the& findings& obtained& for& the& human& receptor& in# vitro& into& in# vivo& physiological&
studies&in&rat&models&of&physiology&and&disease&(Mackenzie&et&al.,&2014).&&In&the&BRETKbased&
βKarrestinK2& recruitment& assay,& lodoxamide& (2,2'K[(2KchloroK5KcyanoK1,3K
phenylene)diimino]bis[2Koxoacetic& acid])& and& bufrolin& (6KbutylK4,10KdioxoK1,7KdihydroK1,7K
phenanthrolineK2,8Kdicarboxylic&acid)&activated&human&and&rat&GPR35&with&EC50s&of&3.6&nM&
and&12.5&nM&at&human&and&12.5&nM&and&10&nM&at&rat,&respectively&(Table!1.3)&(Mackenzie&et&
al.,& 2014).& & This& study& also& identified& a& number& of& mast& cell& stabilisers& that& act& with& ratK








The& lack& of& consensus& surrounding& the& endogenous& ligand& of& GPR35& has& limited&
efforts&to&understand&and&dissect&the&basic&physiologic&function&of&the&receptor.&&Indeed,&as&
mentioned& previously,& the& majority& of& reports& that& suggest& GRP35& to& be& a& notable&
therapeutic& target& stem& from&GWAS& and& gene& knockKout& studies.& & In& an& effort& to& provide&
potent&tool&compounds&to&elucidate&the&pharmacology&and&function&of&GPR35,& I&embarked&
upon&a&drug&discovery&effort&through&a&collaborative&project&with&Medical&Research&Council&
Technology& (MRCT)& (NeetooKIsseljee& et& al.,& 2013),& and,& independently,& with& Novartis&
(Mackenzie&et&al.,&2014).&&The&efforts&from&such&studies&are&presented&herein&(Chapter!Four),&
following&optimisation&of&assay&formats&for&drug&screening&efforts&at&GPR35&(Chapter!Three).&&
Finally,& in& an& effort& to& understand& how& these& ligands& interact& with& GPR35,& and& why& they&
display&marked& species& selectivity& profiles,& a&mutagenesis& effort&was& carried&out& to& switch&
key& residues& from&the&human&and& rat&orthologue& ligand&binding&pockets& to&ascertain& their&
role& in& ligand&binding&(Chapter! Five).& &At&the&time&of&completing&this&project&my&efforts,&as&
part& of& the& two& aforementioned& collaborations,& had& reported& three& of& the& most& potent&

















Chemical& substances& were& supplied& either& by& SigmaKAldrich& (Gillingham,& UK)& or&
Thermo&Fisher&Scientific&(Waltham,&MA)&at&the&highest&possible&analytical&grade.&&Cell&culture&
reagents&were& supplied&by& Life& Technologies& Ltd,& (Paisley,&UK),& unless& specified&otherwise.&&










1,3KthiazolidinK3Kyl]butanoylamino]benzoic& acid)& were& purchased& from& Tocris& Bioscience&
(Bristol,& UK).& & Amlexanox& (2KAminoK7K(1Kmethylethyl)K5KoxoK5HK[1]Benzopyrano[2,3K
b]pyridineK3Kcarboxylic& acid),& compound! 48/80& (2K(4Kmethoxyphenyl)KNK
methylethanamine),& cromolyn! disodium& (disodium;5K[3K(2KcarboxylatoK4KoxochromenK5K
yl)oxyK2Khydroxypropoxy]K4KoxochromeneK2Kcarboxylate),& doxantrazole! (3K(1HKtetrazolK5K
yl)K9HKthioxanthenK9Kone& 10,10Kdioxide& monohydrate),& ketotifen! fumarate& 4K(1K
methylpiperidinK4Kylidene)K4,9KdihydroK10HKbenzo[4,5]cyclohepta[1,2Kb]thiophenK10Kone),&
kynurenic! acid! (4KHydroxyquinolineK2Kcarboxylic& acid),& pamoic! acid! disodium! salt! (4,4}K
Methylenebis(3KhydroxyK2Knaphthoic&acid),!pemirolast!potassium& (9KMethylK3K(1HKtetrazolK
5Kyl)K4HKpyrido[1,2Ka]pyrimidinK4Kone& potassium& salt),& tranilast& (2K[[3K(3,4K
Dimethoxyphenyl)K1KoxoK2Kpropenyl]amino]& benzoic& acid)& were& purchased& from& SigmaK
Aldrich& (Gillingham,& Dorset).& & Bufrolin! (6KbutylK4,10KdioxoK1,7KdihydroK1,7KphenanthrolineK
2,8Kdicarboxylic& acid)& was& synthesised& in& collaboration& with& Novartis,& Horsham& UK.&&
Lodoxamide&(2K[2KchloroK5KcyanoK3K(oxaloamino)anilino]K2Koxoacetic&acid),&compound!1&(4K
{(Z)K[(2Z)K2K(2Kfluorobenzylidene)K4KoxoK1,3KthiazolidinK5Kylidene]methyl}benzoic& acid),&
compound! 2& (2,2’KbithiopheneK5,59Kdicarboxylic& acid),& compound! 3! (4KchloroK3K(2,5K
dimethylK1HKpyrrolK1Kyl)benzoic& acid),& compound! 4& (4HKthieno[3,2Kb]pyrroleK2Kcarboxylic&
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acid),& and& compound! 5& (9KbenzylK5KmethylK3K(4Kmethylphenyl)K5,9KdihydroK6HK
[1,2,4]triazolo[4,3Ke]purineK6,8(7H)Kdione)&were&synthesised&in&collaboration&with&the&MRCT,&
London,&U.K.&&
With& the& exception& of& compound& 48/80,& ketotifen& fumarate,& and& pemirolast&
potassium,& which& were& soluble& in& dH2O,& all& other& powdered& test& compounds& were& reK






Human,& rat& and& mouse& GPR35& receptor& cDNAs& were& NKterminally& fused& with& the&
FLAG&epitope&tag&(sequence&DYKDDDDK),&with&removal&of&the&stop&codon&and&addition&of&the&




As&part&of& this&project& the&FLAGKhuman&GPR35aKEcoRVKGα13EE& fusion& construct&was&
generated&by&PCR&cloning&(Section!2.4.9)&using&oligonucleotide&primers.&&This&enabled&the&3’&
NheI& sequence& to& be& adjoined& to& the& KOZAKKFLAGKhuman& GPR35a& construct& NKterminus&
(forward& 5’& TGGAGCTAGCACCATGGATGGACTACAAAGACGATGACGACAAGCTGAGTGG&
TTCCCGGGC& 3’)& and& an& EcoRV& site& to& be& added& immediately& following& the& CKterminal&
sequence& of& GPR35,& removing& the& stop& codon& (reverse& 5’&
TTAAGATATCGGCGAGGGTCACGCACAG&3’).&&&To&allow&a&subsequent&ligation&between&GPR35&
and&Gα13EE&using&the&EcoRV&site,&an&EcoRV&sequence&was&added&to&the&NKterminus&of&Gα13EE&
(forward:& 5’& TTAAGATATCGCGGACTTCCTGCCGTC& 3’)& in& addition& to& a& stop& codon& and&NotI&
sequence& at& the& CKterminal& end& of& Gα13EE& (reverse& 5’& TCCAGCGGCCGCTGACTGT&
AGCATAAGCTGCTT& 3’).& The& Gα13EE& construct& was& purchased& from& the&Missouri& S&T& cDNA&
Resource&centre&(Rolla,&Missouri&#&GNA130EI00)&and&contained&an&internal&‘GlaKGlu’&epitope&
























































































& Bovine& βKarrestinK1KRenilla& luciferase& and& βKarrestinK2KRenilla& luciferase& were&
generated&previously&by&PCR&amplification&of&Renilla&luciferaseKcontaining&plasmid&pRLKCMV&
(Promega,& Southampton,& UK,&#& E2261),&which&was& digested&with& 5’&XbaI& and& 3’&NhoI& and&
subcloned& into& the& respective& βEarrestin& pcDNA™3.1& vector& to& create& βEarrestinERenillaK
luciferaseKpcDNA™3.1&(Jenkins&et&al.,&2011).&&Chimeric&Gαq&subunits&were&previously&created&
by& the& replacement& of& last& five& carboxyl& terminal& amino& acids& of& Gαq& (EYNLV)&with& those&
from& Gαi& (DCGLF)& to& create& Gαqi1/2& or& Gα13& (QLMLQ)& to& create& Gαq13& expressed& in&
pcDNA™3.1& (Molecular&Devices,& Life& Technologies,& Paisley,&UK).& & These& constructs& allowed&
reKrouting&of&human,&mouse,&and&rat&Gαi1/2&and&Gα13&coupled&receptors&through&the&Gαq/11&
pathway.& & pcDNA™& vectors& contained& the& immediateKearly& Cytomegalovirus& (CMV)&
promoter,&and&included&CAAT&and&TATA&boxes.& &Additionally,& inserted&constructs&contained&
the&KOZAK&enhancer& sequence& surrounding& the&ATG& initiation&codon,&which&ensured&highK
level&mRNA&expression&was&obtained.&&In&HEK293T&cells,&which&expressed&the&Simian&Virus&40&
large& T& antigen,& replication& from& pcDNA™& plasmids& was& initiated& from& the& SV40& early&
promoter& sequence,& and& terminated& at& the& SV40KPolyA& sequence.& & Each& pcDNA& vector&
contained&a&pUC&origin&of&replication&and&ampicillin&resistance&gene&to&enable&growth&in&and&
selection&in&bacterial&cultures.&The&p426&glyceraldehydeK3Kphosphate&dehydrogenase&(GPD)&
vector& (ATCC®,& Middlesex,& UK,& #& 87361™)& was& used& for& yeast& expression& of& FLAGKtagged&
GPR35&constructs,&which&were&inserted&within&the&polyKlinker&site&using&the&5’&BamHI&and&3’&
PaeR71& restriction& sequences,& as& described& in& Jenkins& et& al.,& 2010.& & The& p426GPD& vector&
contained&the&GPD&promoter&for&gene&expression&initiation,&with&replication&controlled&by&a&







Luria& Bertani& medium& (LB)& or& Luria& Bertani& agar& (LB& agar)& were& prepared& by&
reconstitution&of&LB&Broth&or&LB&Agar& (Merck&Millipore& International,&Darmstadt,&Germany,&





an& autoclave& (Prestige& Medical,& Coventry,& UK,& 2100& series& model),& with& 11& min& cycle& at&
126°C.&&For&LB&agar,&autoclaved&bottles&were&sealed&and&placed&in&an&incubator&set&at&50°C&to&
cool.&&By&use&of&sterile&technique,&the&plastic&pouring&ring&was&flamed&using&a&Bunsen&burner&
and& approximately& 20& mL& LB& agar& poured& into& sterile& 10& cm2& Sterilin®& single& use& dishes&
(Thermo& Fisher& Scientific,&Waltham,&MA).& & Lids& were& replaced& on& plates& and& set& at& room&
temperature,&before&storage&overnight&at&4°C.&&LB&was&stored&at&room&temperature&for&up&to&







& Escherichia# coli& laboratory& strain# XLK1& Blue& contain& recA1,& endA1,# gyrA96,& thiE1,&
hsdR17,& supE44,& relA1,& lac& [F’& proAB# lacIqZΔM15,& Tn10& (Tetr)]& mutations& to& improve& the&





was& inverted& at& incubated& at& 37°C& for& 16& h.& & Using& sterile& technique,& a& single& colony&was&
isolated&and& inoculated& into&a&30&mL&Universal&containing&5&mL&freshly&prepared&LB&(in&the&
absence&of&antibiotic).&&Each&5&mL&starter&culture&was&incubated&overnight&(16&h)&at&37°C,&250&
RPM.& & To&a&1& L&PYREX®&Erlenmeyer& flask& containing&100&mL&LB,&100&µl& starter& culture&was&
added& and& incubated& at& 37°C,& 220& RPM.& &Once& an& optical& density& of& 0.48& at& 600& nm&was&
obtained,& growth& was& stalled& by& incubation& of& cultures& on& ice& for& 20& min,& before&
centrifugation&in&preKchilled&sterile&50&mL&centrifuge&tubes&(2000&x&g,&10&min&at&4°C).&&&
To&gently&reKsuspend&the&bacterial&pellet&in&freshly&prepared&solution&1&[CH3CO2K&(30&
















! Under& the& same& principle& for& LB& and& LBKAgar& as& described& in& Section! 2.4.1,& yeast&
peptone& dextrose& (YPD)&media& and& agar& were& prepared.& & Briefly,& 1& %& (w/v)& yeast& extract&
powder& (ForMedium™,& Norfolk,& UK,& #& YEA02),& 2& %& (w/v)& peptone& (Duchefa& Biochemie,&
Haarlem,&Netherlands,&#& P1328)& and& 2&%& (w/v)& DKglucose&were& reconstituted&with&MilliKQ&
dH2O.&&For&YPDKAgar,&2&%&micro&agar&(Duchefa&Biochemie,&Haarlem,&Netherlands,&#&M1002)&
was& added,& and& autoclaved& as& described& previously& (Section! 2.4.1).& & By& use& of& sterile&

















in& a& designated& orbital& yeast& incubator.& & To& a& sterilised& 2& L& PYREX®& Erlenmeyer& flask&
containing& 200&mL& YPD,& 2&mL& saturated& overnight& starter& culture&was& added,& using& sterile&
technique,& and& incubated& at& 30°C,& 220& RPM.& & Absorbance&was& recorded& regularly& using& a&
disposable&plastic& cuvette&and&UV&absorbance&quantified&at&an&optical&density& (OD)&of&600&
nm& using& an& Eppendorf®& BioPhotometer.& & Following& doubling& for& a& minimum& of& two&
generations&(approximately&2.2&h&each),&with&growth&in&midKlogarithmic&growth&phase&(OD600&
between&0.8&–&1.0),&the&flask&was&placed&on&ice.&&S.#cerevisiae&cells&were&isolated&by&transfer&




LiTESorb& and& placed& in& a& shaking& incubator& at& 30°C,& 220& RPM,& for& 1& h.& & Centrifuge& tubes&
containing& S.# cerevisiae& cultures& were& then& placed& in& a& metal& rack,& housed& within& a&











(PEG)K3350& (Sigma&Aldrich,&Gillingham,&UK)&was& added& to& cells& and& incubated& in& a& shaking&
yeast&designated&incubator&at&30°C,&220&RPM,&for&45&min.&&Cells&were&then&heatKshocked&for&
20&min& at& 42°C& in& a& temperatureKcontrolled& waterbath,& and& isolated& by& centrifugation& at&














& To& isolate& cellular& RNA& from& mammalian& cell& lines,& cultures& were& grown& to& subK
confluence&in&10&cm2&dishes,&prior&to&trypsinisation&as&described&in&(Section!2.5.3).&&The&cell&




and& plastic& tube& racks&were& also& decontaminated& prior& to& use& and& allowed& to& air& dry.& & To&
prevent&aerosol& contamination,& sterile,&RNaseK&and&DNaseKfree& filter& tips& (TipOne®,&Starlab&
Group,& Milton& Keynes,& UK)& were& used& throughout& the& RNA& isolation& procedure.& & Nitrile&
gloves&were&worn&and&changed&frequently&throughout.&&All&centrifugation&steps&were&carried&
out&on&a&benchtop&centrifuge&at&room&temperature.&
To& the& isolated& cell& pellet,& 600&µl& Buffer& RLT& (containing& guanidinium& thiocyanate)&
was& added& and& sample& vortexed& briefly& to& ensure& protein& denaturation,& cell& lysis,& and&
immediate& inactivation&of&RNases.& & The& cell& lysate&was&homogenised&by&passing& five& times&
through& a& 20Kgauge& needle& (BD& Microlance™)& fitted& to& an& RNaseKfree& syringe& (BD&
Plastipack™),&before&the&addition&of&600&µl&70&%&ethanol&to&prepare&the&sample&for&the&silicaK
based&membrane.& & The& sample& (600&µl)&was& transferred& to&an&RNeasy& spin& column&placed&














µl& RNaseKfree& water& (supplied)& was& added& directly& to& the& spin& column&membrane.& & After&
standing&for&1&min,&the&sample&was&centrifuged&at&8000&x&g,&for&1&min,&with&the&eluted&RNA&
collected&and&spun&once&more&through&the&spin&column&to&increase&the&RNA&concentration.&&




Ltd.,& Paisley,& UK,& #& 18068K015)& as& per& manufacturer’s& instructions.& & Briefly,& samples&
containing& or& lacking& reverse& transcriptase&were& prepared& on& ice,& in& sterile,& nucleaseKfree&
microcentrifuge& tubes& to& provide& a& positive& and&negative& sample& for& reverse& transcriptase&





& Complimentary& DNA& (cDNA)& was& generated& from& DNase& treated& mRNA& using&
SuperScript™&II&Reverse&Transcriptase&(Life&Technologies&Ltd.,&Paisley,&UK,&#&18064K014),&100&




were& then& centrifuged& briefly& in& a& benchtop& centrifuge& before& addition& of& 5X& firstKstrand&
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in&a& temperatureKcontrolled&waterbath&at&42°C& for&50&min&prior& to&enzyme& inactivation&by&
heating&at&70°C&for&15&min.&&
& The& RTKPCR& reaction& was& carried& out& using& GoTaq®& DNA& polymerase& assay& kit&
(Promega,& Southampton,& UK,& #& M3005).& & To& a& sterile,& nucleaseKfree,& thermostable&
microcentrifuge&tube,&5X&Green&GoTaq®&Reaction&Buffer&(containing&blue&and&yellow&dye&for&
gel& electrophoresis)& (10& µl),& 10& mM& dNTP& mix& (1& µl),& 10& µM& human& GPR35& forward& (5’&
GATCAAGCTGGGCTTCTACG& 3’)& and& reverse& primers& (5’& CAGGCTGATGCTCATGTACC& 3’)& (0.5&
µl),&GoTaq®&DNA&polymerase&(0.25&µl&=&1&unit),&template&cDNA&(1&µl&single&stranded&cDNA&=&
5&ng),&and&DEPCKtreated&water&(to&50&µl)&was&added,&on&ice.&&Tubes&were&centrifuged&briefly&
(30& sec),& vortexed& gently,& and& placed& immediately& into& a& MultiGene™& Gradient& Thermal&
Cycler&containing&a&heated&lid&(MultigeneKLabnet&International&Inc.,&Edison,&NJ).&&The&RTKPCR&
reaction&was&carried&out&in&the&following&steps:&&preheat&95°C,&2&min;&denature,&95°C,&30&sec;&





& To& determine& gene& expression& in& native& and& overexpressing& cell& lines,& mRNA& was&
isolated,& cDNA&prepared,& and&RTKPCR& carried&out& as&described& in&Section! 2.4.6.& & Since& the&
amplified&RTKPCR&fragments&were&between&200&to&250&bp&in&length,&a&2&%&(w/v)&agarose&gel&
was& prepared& by& adding& 1& g& multiKpurpose& agarose& (Roche,& Applied& Science,& Penzberg,&































primer& sequences& were& designed& using& the& online& software& programme& PrimerX&
(http://www.bioinformatics.org/primerx),& and&were&between&21K25&bases& in& length,&with&a&
GC& content& below& 60& %& (when& possible),& and& a& Tm& of& approximately& 80°C.& & Primer& selfK
complimentary& and& primer& dimer& formation& was& assessed& using& the& online& software&
programme& (http://www.biocompute.bmi.ac.cn/CZlab/MFEprimerK
2.0/index.cgi/check_dimer).& & Primer& sequences& were& synthesised& via& the& custom& DNA& deK
salted& oligonucleotide& facility& provided& by& ThermoKFischer& Scientific& (Leicestershire,& UK),&
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with&dried&primer& sequences& reconstituted& in& sterile&MilliKQ&dH2O& to&100&µM&and&working&
stock&aliquots&(10&µM)&diluted&in&sterile&MilliKQ&dH2O&and&stored&at&K20°C.&&
Site& directed&mutagenesis&was& carried& out& using& the&QuickChange®&method& as& per&
manufacturer’s&instructions&(Stratgene,&La&Jolla,&CA,&#&200518).&&Mutations&were&induced&by&
thermo& cycling& using& Pfu& DNA& polymerase& isolated& from& Pyrococcus# furiosus& (Promega,&
Southampton,& UK,& #&M774A),& pcDNA™3.1& vectors& containing& FLAGEhGPR35EeYFP& or& FLAGE
rGPR35EeYFP&DNA&constructs,&and&the&oligonucleotide&primers&containing&the&mutations&of&
interest.& &A&master&mix,& prepared&on& ice&using&a& sterile&nucleaseKfree&PCR&microcentrifuge&
tube,&contained&deoxynucleotide&triphosphates&(dNTPs)&dATP,&dTTP,&dCTP,&dGTP&(Promega,&
Southampton,& UK,& #& U120A,& U123A,& U122A,& U121A,& respectively)& diluted& to& 10& µM& final&
concentration;& Pfu& DNA& polymerase& reaction& buffer& containing& MgSO4& (10x& stock,& 5& µl&
addition/reaction)& (Promega,& Southampton,& UK,&#&M776A);& DMSO& to& reduce& formation& of&
secondary& structure& (2&µl/reaction);& and& Pfu#DNA& 5’→3’& polymerase& (1.25& units/reaction)&
(Promega,&Southampton,&UK,&#&M7741),&which&was&added&last.&&All&reagents&were&added&to&
sterile& iceKcold&MilliKQ&dH2O&to&generate&an& individual& reaction&volume&of&50&µl.& &Template&




















& To&clone&by&PCR,& the& following&was&assembled&on& ice& in&a& sterile&nucleaseKfree&PCR&
microcentrifuge&tube:&Pfu&DNA&polymerase&reaction&buffer&containing&MgSO4&(10x&stock,&5&µl&
addition/reaction)&(Promega,&Southampton,&UK,&#&M776A),&Pfu#DNA&5’→3’&polymerase&(1.25&
units/reaction)& (Promega,& Southampton,& UK,& #& M7741),& 10& mM& dNTP& mix& (200& µM& final&
concentration),& oligonucleotide& primers& (200& ng& final& concentration),& template& cDNA& (100&





& To& confirm& that& sufficient& amplification&of& the&PCR&product& had& taken&place,& a& 1&%&
(w/v)&analytical&agarose&gel&was&generated,& (as&described& in&Section!2.4.7)&by&adding&0.3&g&
multiKpurpose&agarose&to&30&mL&TBE.&&Before&restriction&digests&were&initiated,&a&PCR&cleanK
up& step& was& performed& to& remove& PCR& buffers& and& enzyme& using& the& QIAquick& PCR&





using& the& KpnIEHF®# and& NotIEHF®& enzymes& (1& µl& each)& with& the& CutSmart™& buffer.& & All&
samples&were&incubated&at&37°C&for&six&hours&in&a&50&µl&volume.&
& Once& digested,& each& sample& was& loaded& and& run& on& a& 1& %& (w/v)& agarose& gel& to&
separate&the&digested&vector& from& its& insert& (performed&as&described& in&Section!2.4.7).& &To&
isolate& DNA& from& the& agarose,& the& QIAGEN& QIAquick& Gel& Extraction& kit& (#& 28706)& was&
employed& and& used& as& per& manufacturer’s& instructions.& & To& determine& the& relative&
concentration&of&each&fragment,&a&second&1&%&(w/v)&agarose&gel&was&set&up&and&loaded&using&
4&µl&DNA&and&1&µl&5X&dye&alongside&a&1&kb&HyperLadder™&molecular&weight&marker&(BIOLINE,&





& Ligation& of& the& KpnIKFLAGKGPR35a& and& pcDNA™5/FRT/TO& was& carried& out& in& a& 1:4&





EcoRVKGα13EEKNotI.& & Following& ligation,& the& fusion& construct&was& transformed& according& to&






Chemically& competent& Escherichia# coli& laboratory& strain& XLK1& Blue& prepared& as&
described&in&Section!2.4.2&were&defrosted&on&ice.&&Using&sterile&technique,&DNA&(between&1K
10&ng&or&1&μl&of&restriction&digested&PCR&sample),&and&XLK1&Blue&(50&μl/tube)&were&added&to&a&
preKchilled& sterile& microcentrifuge& tube& and& incubated& for& 20& min& on& ice.& & Samples& were&
carefully& placed& in& a& floating& foam& tube& rack& and& heatKshocked& at& 42°C& for& 90& sec,& then&
immediately&transferred&to&ice&and&cooled&for&2&min.&&After&addition&of&450&μl&LBKAmp&using&
sterile& technique,& samples&were& incubated&at&37°C& for&1&h&at&250&RPM&to& induce&Bla& gene&
expression.& & This& confers& ampicillin& resistance& to& XLK1& Blue& cells& successfully& transformed&
with&pcDNA™3.1&or&pcDNA5/FRT/TO&vectors.& &To& isolate&cells,&samples&were&centrifuged&at&
5900& x& g& for& 2& min.& & After& removal& of& supernatant,& the& bacterial& pellet& was& gently& reK
suspended&by&pipetting&to&a&volume&of&100&μl,&added&to&a&freshly&prepared,&preKwarmed&LBK
Amp&plate&and&spread&using&an&70&%&ethanolKflamed&metal&spreader&using&sterile&technique.&&









using& the& Wizard®& Plus& SV& Miniprep& DNA& Purification& System,& as& per& the& manufacturer’s&
instructions& (Promega,& Southampton,& UK& #& A1460).& & Bacterial& cells& were& isolated& by&
centrifugation& at& 3184& x& g& for& 5& min& at& room& temperature& using& a& benchtop& centrifuge.&&
Supernatant&was& removed&by&pouring,&and&30&mL&Universal& tubes&were& inverted&on& tissue&
paper& to& remove& excess& media.& & Cells& were& reKsuspended& via& the& addition& of& 250&µl& Cell&
Suspension& Solution& [TrisKHCL& (50& mM,& pH& 7.5),& EDTA& (10& mM),& RNase& A& (100& µg/mL)],&
homogenised& by& pipetting,& and& vortexed& briefly& before& transfer& to& a& sterile& 1.5& mL&
microcentrifuge& tube.& & Post& addition&of& 250&μl& Cell& Lysis& Buffer,& [NaOH& (200&mM),& sodium&
dodecyl&sulphate&(SDS;&1&%&(w/v)]&each&tube&was&inverted&four&times&and&incubated&for&4.5&
min& at& room& temperature.& & Cellular& proteins& were& inactivated& by& the& addition& of& Alkaline&
Protease&Solution&(10&μl)&[isolated&from&Bacillus#licheniformis],&mixed&by&inversion&four&times&
and&incubated&for&5&min&at&room&temperature.&&This&reaction&was&deactivated&by&the&addition&
of&350&μl&Neutralisation&Solution,& [guanidine&hydrochloride& (409&mM),&CH3CO2K& (759&mM),&
glacial&acetic&acid&(212&mM),&pH&4.2]&with&each&tube&inverted&four&times&and&centrifuged&to&
remove&cellular&debris&(16,100&x&g,&10&min,&room&temperature).&&&
Cleared& lysate& (approximately& 750& μl)& was& carefully& transferred& to& a& Spin& Column&
inserted& into& a& 2& mL& Collection& Tube& and& centrifuged& at& 14,000& x& g& for& 1& min& at& room&
temperature.& & Column& flowKthrough& was& discarded& by& pouring& into& a& waste& beaker& and&













Isolated& DNA& or& RNA& was& assessed& for& concentration& and& purity& by& UV&
spectrophotometry&using&an&Eppendorf®&BioPhotometer,&via&the&addition&of&5&µl&sample&to&














DNA& samples&were& diluted& to& a& concentration& of& 500& ng/30&µl& using& sterile&MilliKQ&
dH2O,& added& to&1.5&mL&microcentrifuge& tubes& and&packaged& in& a&padded&envelope&before&
being&sent& for&DNA&sequencing&under& standard&postal& conditions.& & Sequencing&was&carried&
out&by&DNA&Sequencing&and&Services™&(Dundee&University,&Dundee,&UK)&using&an&automated&
ABI& PRISM®& capillary& DNA& sequencer& (Applied& Biosystems®,& Life& Technologies& Ltd,& Paisley,&
UK,& #& 3730),& and& BigKDye®& terminator& cycle& sequencing& kit& (Applied& Biosystems®,& Life&
Technologies&Ltd,&Paisley,&#&3.1)&to&analyse&fluorescently&labelled&DNA&fragments&by&capillary&
electrophoresis.&&Forward&sequencing&reactions&were&primed&using&the&CMV&oligonucleotide&
sequence& provided& by& DNA& Sequencing& and& Services™,& while& the& reverse& eYFP&
oligonucleotide&primer&was&designed& inKhouse&and&provided&at&3.2&pm/µl& in& sterile&MilliKQ&
dH2O&in&a&volume&of&10&µl.&&The&presence&of&the&desired&sequence&alteration&from&processed&























preKchilled& Buffer& P3& [CH3CO2K,& (3& M)& pH& 5.5].& & This& was& mixed& by& inversion& four& times,&
poured& immediately& into& the& barrel& of& a& QIAfilter& Cartridge,& and& incubated& for& 10&min& at&
room&temperature.&
During& this& incubation& time,& a& QIAGENKtip& coated&with& a& DEAE& (diethylaminoethyl)&
anionKexchange&resin&was&calibrated&by&addition&of&10&mL&Buffer&QBT&[NaCl&(750&mM),&MOPS&
(50&mM),& isopropanol& (15&%& (v/v))&pH&7.0],&which& travelled& through& the& column&by&gravity&
flow.&&After&10&min,&a&plunger&was&inserted&into&the&QIAfilter&Cartridge&and&approximately&25&
mL&bacterial&solution&gently&pushed&through&the&QIAGENKtip.&&&
In& order& to& remove& any& residual& cellular& protein,& RNA& or& DNA& contaminants,& the&
QIAGENKtip&was&rinsed&twice&using&the&mediumKsalt&wash&of&30&mL&Buffer&QC&[NaCl& (1&M),&






centrifuged& at& 5000& x&g& for& 60&min& at& 4°C.& & Supernatant&was& carefully& removed& and& clear&
pellets&washed&with&70&%&ethanol,&vortexed,&and&centrifuged&at&3110&x&g,&30&min,&4°C.&&Upon&
ethanol& removal,& the&pellet&was&airKdried&at& room& temperature& for&30&min,& reKdissolved& in&







Prior& to& use,& all& cell& culture& reagents& were& preKwarmed& to& 37°C& by& heating& in& a&
temperatureKcontrolled& waterbath& for& approximately& 30& min.& & All& cell& cultures& were&
maintained& in& vented& cell& culture& treated& T752& flasks& with& canted& necks& (Corning™,&
Tewksbury,& MA,& #& 10K126K31)& containing& 10K15& mL& medium& with& phenol& red& and& heat&
inactivated&foetal&bovine&serum&(FBS)&(GE&Healthcare,&Fairfield,&CT,&EU&Approved,&#&A15K101).&&
Cells&were& incubated& a& designated& cell& culture& facility& in& an& inCu& saFe®& SANYO&humidified&
incubator&supplied&with&5&%&CO2&and&maintained&at&37°C.&&Media&was&replaced&by&aspiration&





Adherent& HEK293T& cells& constitutively& expressing& the& large& simian& virus& 40& large& T&
antigen& clone& 17& were& purchased& from& ATCC®& (Middlesex,& UK,& #& CRLK11268™)& and& were&
maintained& in& Dulbecco’s& modification& of& Eagle’s& medium& (DMEM)& (SigmaKAldrich,&











(v/v)& FBS,& 15& µg/mL& blasticidin& (Life& Technologies& Ltd,& Paisley,& UK& #& A1113903)& and& 200&
µg/mL& hygromycin& B& (Roche& Applied& Science,& Penzberg,& Germany,&#& 10843555),& passaged&
routinely&at&85K90&%&confluence,&and&dissociated&by&use&of&0.25&%&trypsin•EDTA.&
Human& colorectal& adenocarcinoma& cell& line& HTK29& was& purchased& from& ATCC®&
(Middlesex,& UK,& #& HTBK38™),& maintained& in& McCoy’s& 5A& (Modified)& Medium& (Life&
Technologies& Ltd,& Paisley,& UK& #& 26600K023)& supplemented& with& 10& %& (v/v)& FBS& and& 1X&
penicillin/streptomycin&mixture.&&HTK29&cells&were&supplemented&with&fresh&media&every&two&






& Upon& reaching& the& desired& confluence,& medium& was& aspirated& under& sterile&
conditions&inside&a&laminar&flow&cabinet&by&use&of&a&Corning®&5&mL&pipette&connected&to&an&

























at& room& temperature,& the& DNA/PEI& mixture& was& added,& dropKwise,& to& a& freshly&
supplemented& 10& cm2& transfection& dish& containing& 8& mL& preKwarmed& complete& medium.&&
Transfection& plates& were& returned& to& the& cell& culture& incubator& and& maintained& for& a&








contains& the& hygromycin& resistance& gene& and& a& flippase& recognition& target& (FRT)& site& that&
enables& selection& of& transformants& that& are& inserted& via& DNA& recombination& by& Flp&
recombinase& at& the& FRTKsite.& & The& Flp& recombinase& is& constitutively& expressed& from& the&
pOG44&plasmid&under&control&of&the&human&CMV&promoter.&&Prior&to&transfection,&FlpKIn™&TK
REx™&HEK293&cells&were&maintained&in&DMEM&(Life&Technologies&Ltd,&Paisley,&UK,&#&41965)&






fusion& gene& and& an& FRT& site& that& serves& as& the& binding& and& cleavage& site& for& the& Flp&
recombinase.&
Two&days&prior&to&transfection&Zeocin™&must&be&removed&from&the&medium&to&allow&
recombination& and& stable& insertion& of& the& pcDNA™5/FRT/TO& construct& into& the& HEK293&
genome&at& the&FRT&site.& & Insertion&of&pcDNA™5/FRT/TO&at& the&pFRT/lacZeo&site&brings& the&
SV40& promoter& and& the& ATG& initiation& codon& from& pFRT/lacZeo& into& frame& with& the&
hygromycin& resistance& gene& on& the& pcDNA™5/FRT/TO&plasmid,&which& inactivates& the& lacZK
Zeocin™& gene& and& induces& hygromycin& resistance.& & To& begin& the& stable& insertion& of& FLAGK




transfection& the& cells& were& subcultured& in& 1:10,& 1:5,& 1:3& ratios& to& ensure& that& the& cell&
confluence& would& be& low& enough& to& allow& hygromycin& to& kill& the& nonKtransfected& cells.&&
TwentyKfour& hours& later,& the& media& containing& 200& µg/mL& hygromycin& B& was& added& and&
replaced& every& threeKtoKfour& days& to& remove& dying& cells.& & Once& cell& death& was& complete,&
resistant& colonies& were& identified& and& subKcultured& together& to& generate& a& homologously&
expressing&FLAGKhumanGPR35aKEcoRVKGα13EE& cell& line.& &To&determine& the&concentration&of&
doxycycline& required& to& induce& maximal& expression& of& the& FLAGKhumanGPR35aKEcoRVK
Gα13EE& construct,& unlike&with& previous&GPR35& stable& cell& lines& that&were& tagged&with& eYFP&
and& doxycycline& concentration& determined& by& quantifying& maximal& eYFP& expression,& the&
FLAGKhumanGPR35aKEcoRVKGα13EE& construct& expression& was& assessed& via& Western& blot&










& TwentyKfour& h& post& transfection& or& doxycycline& induction,& cells& were& harvested& by&
aspiration&of&medium&and& replacement&with& 10&mL& iceKcold& sterile& PBS& (1X).& &On& ice,& cells&
were&dislodged&from&plasticware&by&scraping.&&Cell&suspensions&were&added&to&iceKcold&50&mL&
Corning®&tubes&and&pellets& isolated&by&centrifugation&(3110&x&g,&5&min,&4°C).& &Following&reK






& Cells& were& harvested& as& described& in& Section! 2.6.1.& & Isolated& cell& pellets& were& reK
suspended&in&500&µl&1x&radioimmunoprecipitation&(RIPA)&buffer,&which&was&diluted&from&a&2X&
RIPA&stock&(HEPES&(10&mM),&NaCl&(300&mM),&Triton&XK100&(2&%&(v/v)),&sodium&deoxycholate&(1&
%& (w/v)),& SDS& (0.2& %& (w/v)),& pH& 7.4)& on& the& day& of& use,& and& supplemented& with& sodium&
fluoride&(0.5&M),&EDTA&(0.5&M),&NaPO4&(0.2&M),&ethylene&glycol&(5&%&(v/v)),&and&1&EDTAKfree&
cOmplete™& protease& cocktail& inhibitor& tablet& per& 50& mL& buffer& (Roche& Applied& Science,&
Penzberg,& Germany,& #& 11873580001).& & Lysates& were& placed& within& a& rotating& wheel& and&
rotated&for&1&h&at&4°C,&before&centrifugation&at&14,000&x&g&at&4°C&for&30&min&to&pellet&cellular&
debris.&&Supernatants&were&isolated,&and&protein&concentration&quantified&by&the&bicinchonic&










(Life& Technologies& Ltd,& Paisley,& UK& #& NP0321BOX),& stored& at& 4°C&were& removed& from& the&
plastic&casing,&the&well&separator&removed,&rinsed&with&MilliKQ&dH2O&and&inserted&into&a&XCell&
SureLock™&miniKcell& electrophoresis& gel& tank& system& (Life& Technologies& Ltd.,& Paisley,&UK,&#&
EI0001).&&If&only&one&preKcast&gel&was&to&be&used,&then&an&empty&cassette&was&inserted&into&
the&other&side&of&the&gel&tank,&with&wells&facing& inward,&and&the&gel&tension&wedge&locked.&&





warmed& 2X& concentrated& Laemmli& buffer& [SDS& (4& %& (v/v)),& glycerol& (20& %& (v/v)),& 2K
mercaptoethanol& (10&%& (v/v)),& bromophenol&blue& (0.0004&%& (v/v)),& TrisKHCL& (0.125&M),&pH&
6.8]&was&added&to&each&sample.&&To&allow&estimation&of&protein&size,&a&preKstained&full&range&
molecular& weight& Rainbow™&marker& was& added& (10&µl)& (GE& Healthcare,& Buckinghamshire,&
UK,&#&RPN800E)&to&the&first&well,&followed&by&each&sample&to&be&analysed.&&Any&empty&wells&












filled&with&1X& transfer&buffer.& &A& fixed&voltage&of&30&volts&was&applied& for&90&min& to&allow&









at& room& temperature.& & Horseradish& peroxidase& (HRP)& conjugated& secondary& antibody,&
diluted&in&PBST&containing&5&%&(w/v)&lowKfat&milk&was&added&to&the&membrane&and&incubated&
at&room&temperature&for&60&min&under&gentile&agitation.& &Antibodies&used&herein&were&the&
monoclonal& antiKFLAG®& M2& antibody& (SigmaKAldrich,& Gillingham,& UK,& #& F1084),& and&
monoclonal& antiKGα13EE& (raised& inKhouse),& which& were& detected& with& antiKmouse& IgG&
secondary&antibody&conjugated&to&HRP& (Cell&Signalling,!Danvers,&MA,&#&7076).& &Sheep&antiK












plastic& coating& inside& a& developing& cassette.& & All& air& pockets& were& smoothed& out& and& the&
plastic& coating& taped& in& place.& & Once& inside& a& dark& room,& under& red& light,& a& sheet& of&










passing& through& a& 19Kgauge& needle& (BD& Microlance™)& fitted& to& a& sterile& syringe& (BD&
Plastipack™),&followed&by&passing&through&a&25Kgauge&sterile&needle&(BD&Microlance™).&&The&
membrane&buffer&consisted&of&iceKcold&1X&TrisKEDTA&(pH&8.0)&and&protease&inhibitor&cocktail&
(1X& cOmplete& EDTAKfree& tablet& per& 50& mL& buffer).& & Dependent& upon& the& volume& of& the&
membrane&preparation,&either&the&cell&suspension&was&passed&manually&50&times&through&a&
TeflonKinKglass& homogeniser,& or& sheered& mechanically& (while& on& ice)& using& an& electronic&
Janke&and&Kunkel&Ultra&T45&Turax®&homogeniser&for&approximately&2&min.&&&
Unbroken&cells,&nuclei&and&larger&organelles&were&removed&by&centrifugation&at&3110&
x& g,& 5& min,& 4°C& followed& by& the& careful& removal& of& supernatant& and& addition& to& an&
ultracentrifuge& tube& (Beckman& Coulter,& Palo& Alto,& CA).& & Each& tube&weight&was& normalised&
using&a& Satorius& fine&balance& to& three&decimal&places&by& the&addition&of&membrane&buffer&
prior& to& being& secured& in& an& evenly& balanced& Optima& TLX& Ultracentrifuge& rotor& (Beckam&
Coulter,& Palo&Alto,&CA).& & Post&ultracentrifugation&at& 20,000& x&g& for& 1&h& at& 4°C,& the& isolated&
pellet&was&reKsuspended&in&TrisKEDTA&membrane&buffer,&passed&10&times&through&a&19Kgauge&
needle& and& 10& times& through& a& 25Kgauge& needle& on& ice,& until& homogeneous.& & Generally&








The&bicinchoninic&acid& (BCA)&method&utilised& two&chemical& reactions& (the&reduction&
of& cupric& ions&by&peptide&bonds& in&alkaline& solution&and&chelation&of& the& resulting&cuprous&
ions& by& BCA& reagent)& in& order& to& estimate& protein& concentration.& & First,& bovine& serum&
albumin&standards&at&set&concentrations&(0.2,&0.4,&0.6,&0.8,&1.0,&1.2,&1.4,&1.6,&1.8,&2.0,&and&2.2&
mg/mL,&diluted&in&MilliKQ&dH2O,&and&stored&at&4°C)&were&added&to&a&clear&96&well,&nonKsterile,&
flat&bottom&polystyrene&plate& in& triplicate& (10&µl& volume)& (SigmaKAldrich,&Gillingham,&UK,&#&




briefly& and& immediately& added& (200& µl)& using& an& Eppendorf& Repeater®& manual& handheld&
dispenser& (Eppendorf,& Hauppauge,& NY,& #& 022260201)& to& each& sample.& & Test& plate& was&
covered&using&a&disposable&plate&seal&(PerkinKElmer,&Norwalk,&CT,&TopSeal™&#&6050195)&and&
incubated& at& 37°C& for& 10& min.& & Absorbance& values& generated& at& 560& nm& for& each& BSA&
standard& were& determined& using& a& POLARstar& Omega& microplate& reader& (BMG& Labtech,&













MgCl2& (6&mM),& BSA& (0.1%& (w/v)),& pH& 7.4],& was& added& to& 1&mL& GTPγS& Filtration& buffer,& 10&
µg/tube&cellular&membrane,&10&µM&GDP,&0.1&nM&[35S]GTPγS&and&incubated&for&1&h&at&25°C&in&
a&temperatureKcontrolled&waterbath&covered&with&foil&to&minimise&evaporation.&
The& [35S]GTPγS& reaction& was& terminated& by& rapid& filtration& through& GF/C& filters&
(Brandel,&Brandel,&Gaithersburg,&MA,&#&800K948K6506)&preKsoaked&in&iceKcold&1X&PBS&using&a&
cell&harvester& (Brandel,&Gaithersburg,&MA)&and&washed& three& times&before&being&airKdried.&&
Filter&areas&containing&test&sample&were&isolated&using&and&placed&into&a&plastic&scintillation&








To& detect& G& protein& activation& via& the&Gα13& pathway,& FlpKIn™& TKREx™&HEK293& cells&
were&transiently&transfected&with&an&internal&‘EE’&(EYMPME)&epitopeKtagged&Gα13EE&construct&
as&described&in&Section!2.5.4.&&As&a&modification&to&standard&[35S]GTPγS&binding&assay,&Gα13EE&
incorporation&was& isolated&using& an& immunoprecipitation& step& (Jenkins& et& al.,& 2010).& & To& a&




followed& by& isolated& cellular& membrane& (25& µg/point),& prepared& as& described& in& Section!
2.6.1.&&All&tubes&were&placed&in&a&plastic&tube&rack&in&a&temperatureKcontrolled&waterbath&at&
25°C&for&1&h,&covered&with&foil&to&minimise&evaporation,&before&the&reaction&was&terminated&
by& addition& of& 500& µl& iceKcold& GTPγS& assay& buffer& containing& an& EDTAKfree& cOmplete&
protease&inhibitor&cocktail.&






















& Haploid& MATa& S.# cerevisiae& strain& W303K1A& stably& expressing& chimeric& Gpa1KGαx&
subunits& at& the&TRP1& locus&were& generated& by&GlaxoSmithKline,& as& described& (Dowell& and&
Brown,&2009).& & To& assess& functional& coupling&between&agonist& induced& receptor& activation&
and&functional&response,&the&pheromone&response&pathway&of&S.#cerevisiae&was&manipulated&
by& removal& of& FAR1& to& prevent& cell& cycle& arrest,& forcing& pathway& responses& toward& the&
mating&pathway&through&activation&of&the&FUS1&promoter.& &Subsequent&activation&of&FUS1E
lacZ&produced&reporterKgene&readout,&measurable&through&βKgalactosidase&activity.&
& An& individual& colony& from& a& freshly& transfected& S.# cerevisiae& strain& transiently&
expressing&FLAGKGPCRKp426GPD&and&stably&expressing&Gpa1KGαx&subunit&was&isolated&from&
agar& containing& selective& media& (SD& –Ura& –Met)& and& inoculated& into& a& 30& mL& Universal&











• Fluorescein& DiKβKDKGalactopyranoside& (FDG),& (50& µl)& (Molecular& Probes®,& Life&
Technologies&Ltd.,&Paisley,&UK,&#&FK1179),&reconstituted& in&sterile&MilliKQ&dH2O&to&20&
mM,&protected&from&light&
Reconstituted& yeast& cells& were& distributed& into& sterile& 96& well& deep& block& plates& and&
thoroughly&reKsuspended&before&addition&to&assay&plate.&&Ligand,&prepared&at&10x&final&assay&
concentration,& was& diluted& in& Assay& Medium& with& DMSO& concentration& (below& 1& %)&
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Following& a& 16& h& incubation,& fluorescence,& occurring& upon& sequential& hydrolysis& of&
FDG&to&fluorescein&monogalactosidase&and&fluorescein&by&βKgalactosidase,&was&gain&adjusted&
using& the& well& with& the& highest& treatment& of& ligand& concentration,& and& subsequently&
quantified&using&a&top&reading&function&using&a&2x2&grid&with&an&excitation&of&490&nm&and&an&
emission& of& 514& nm& using& a& PHERAstar& FS& plate& reader& (BMG& Labtech,& Durham,& NC).&&





In& order& investigate& G& protein& signalling,& GPR35& was& coupled& through& the& Gαq/11&
pathway& and& agonist& induced& response& quantified& using& the& IPKOne& HTRF®& Tb& assay,&
according& to&manufacturer’s& instructions& (Cisbio& Assays,& Codolet,& France&#& 62IPAPEC).& & IPK
One,& a& competitive& immunoassay,& used& HTRF& (homogeneous& time& resolved& fluorescence&
resonance& energy& transfer)& between& a& (donor)& terbium& cryptate& labelled&monoclonal& anti&
myoKinositol& 1& phosphate& (IP1)& antibody& and& d2& (acceptor& dye)& labelled& IP1.& & To& begin,&
HEK293T&cells&were&transiently&transfected&under&sterile&conditions&as&described&in&(Section!
2.5.3).&
Post& 24& h& incubation& HEK293T& cells& transfected& with& 2.5& µg& FLAGKGPR35KeYFPK
pcDNA3.1& and& 2.5& µg& G& protein& chimera& (Gαqi1/2& or& Gαq13)& were& visually& assessed& by&
microscopic&analysis&using&a&Nikon&inverted&microscope&to&confirm&cell&surface&receptorKeYFP&
expression.&&Under&sterile&conditions,&in&a&category&II&laminar&flow&biosafety&cabinet,&medium&
was& aspirated& from& each& 10cm2& dish& and&mechanically& dislodged& by& pipetting.& & Following&




was& either& commercially& supplied& or& generated& inKhouse.& & To& reduce& constitutive& activity,&
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Ltd,& Paisley,& UK).& & The& concentration& of& cells& was& adjusted& to& 10,000& cells/7&µl& in& IPKOne&
Stimulation&Buffer.& &Agonist,& prepared& fresh&on& the&day&of& assay,&was&diluted& to& twice& the&
final& assay& concentration& in& IPKOne& Stimulation&Buffer,&DMSO&normalised& throughout,& and&
added&at&7&µl/well&using&a& lowKvolume&multichannel&pipette& to&a&white,& solid&bottom,& low&
volume& OptiPlate™K384& microplate& (PerkinKElmer,& Norwalk,& CT,& #& 6007299).& & A& series& of&
internal&assay&standards&were&also&prepared& in& IPKOne&Stimulation&Buffer&and&added&at&14&
µl/well.&&This&included&a&positive&control,&a&negative&control,&and&a&standard&curve&that&was&
used& to& calibrate& the&assay.& &Upon&addition&of& test& compound&and&control,& the&microplate&
was&centrifuged&briefly&(900&x&g,&30&sec)&at&room&temperature&to&ensure&compound&settled&at&
the&bottom&of&each&well.&&This&was&followed&by&the&addition&of&diluted&cells&(7&µl/well)&using&
an& Eppendorf& Repeater®& manual& handheld& dispenser& to& wells& containing& test& compound&
only.& & The& plate& was& centrifuged& briefly,& wells& covered& using& a& TopSeal™& to& prevent&
evaporation,&and&cells&incubated&for&2&h&at&37°C.&&&
For& antagonist& assays,& test& compound& was& prepared& at& four& times& final& assay&
concentration,&added&at&3.5&µl/well&using&a&low&volume&multichannel&pipette&and&centrifuged&




concentration,& was& added& at& 3.5& µl/well& and& incubated& for& 2& h& at& 37°C& as& described&
previously.&
To& detect& IP1& accumulation,& the& HTRF®& reagents& IP1Kd2& and& antiKIP1& Lumi4™KTb&
cryptate&were&diluted& (1/20&or&1/5&dependent&upon& the&assay&kit)& in&Cell& Lysis&Buffer,& and&









d2& was& quantified& using& the& fluorescence& ratio& of& acceptor& emission& at& 665& nm/& donor&
emission&at&620&nm,&following&excitation&at&337&nm.&&Emission&was&measured&following&a&50&
µs&delay&with&an&integration&time&of&400&µs,&with&the&number&of&flashes&totalling&53.&&The&665&
nm& and& 620& nm& reads&were&measured& simultaneously& using& a& PHERAstar& FS& plate& reader&
(BMGKLabtech,& Germany).& & IP1& accumulation& (nM)& was& generated& by& calculation& of& the&
fluorescence& ratio,& which&was& calibrated& by& plotting& a& fourKparameter& curve& fit& through& a&












were&warmed& to& room& temperature.& & Following& a& 24&h& incubation&between&HEK293T& cells&
and& PEI& transfected& constructs& (total& 5& µg& DNA& in& a& ratio& of& 4:1& FLAGKGPR35KeFYP& to& βK
arrestinKRenilla& luciferase),& cells& were& visually& assessed& to& determine& confluence& and& cell&
surface&receptorKeYFP&expression&by&microscopic&analysis&using&a&Nikon&inverted&microscope.&&
Under& sterile& conditions,& in& a& category& II& laminar& flow& biosafety& cabinet,& medium& was&




media& (Section! 2.5.1)&and&added&at&100&µl/well& to&polyKDKlysine&coated&plates.& &Cells&were&
settled& at& room& temperature& for& 30& min& before& 24& h& incubation& at& 37°C& +& 5& %& CO2& in& a&
humidified&incubator.&
Test& compounds& were& prepared& on& the& day& of& use,& diluted& to& 10x& final& assay&




twice& with& room& temperature& HBSS& (100& µl/well).& & Transfected& HEK293T& wells& were&
incubated& in& a& final& volume& of& 80& µl/well& HBSS& (agonist& assay)& or& 70& µl/well& (antagonist&
assay)&and&incubated&at&37°C&for&30&min.&
& A&quantitative&measure&of&eYFP&was&gathered&by&measurement&of&eYFP&fluorescence&
(excitation& 500K10& nm,& emission& 530K10)& using& the& POLARstar& Omega& (BMG& Labtech& Ltd.,&
Alyesbury,& UK)& to& ensure& receptor& expression.& & For& antagonist& assay& only,& antagonist&
compound&was&added&(10&µl/well)&and&plates&incubated&for&5&min&at&37°C.&&Next,&and&initially&
for& the& agonist& assay& format,& luciferase& substrate& coelenterazineKh,& diluted& to& a&
concentration&of&25&μM&in&HBSS&and&protected&from&light,&was&added&(10&µl/well)&using&an&
Eppendorf& Repeater®&manual& handheld& dispenser.& & To& allow& oxidation& to& coelenteramide,&
plates& were& covered& with& aluminium& foil& and& incubated& for& 10&min& at& 37°C.& & Agonist& (10&
µl/well)& was& then& added& using& a& 2K20& µl& multichannel& pipette& and& cells& incubated& for& a&
further&5&min&at&37°C&in&the&absence&of&light.&&&
Subsequently,& after& a& 10& min& incubation& with& substrate,& luminescence& was& read&
simultaneously&for&the&acceptor&at&535&nm&(with&an&optical&bandpass&of&10&nm)&and&donor&at&




535& nm& divided& by& luciferase& donor& emission& at& 475& nm.& The& net& BRET& ratio& was& then&
calculated&as& the&ratio&of&cells&coKexpressing&Renilla& luciferase&and&eYFP&minus&the&ratio&of&









! To& assess& the& temporal& kinetics& of& βKarrestinK1KRenilla& luciferase& or& βKarrestinK2K
Renilla& luciferase,& the& BRET& system& of& protein/protein& interaction&was& employed.& & Briefly,&










& To&quantify&cell& surface& receptor&expression,&an&ELISA&assay&was&performed&using&a&
cell& impermeable& horseradish& peroxidase& (HRP)& substrate& TMB& (3,3’,5,5’K
tetramethylbenzidine)&(Thermo&Fisher&Scientific,&Waltham,&MA,&#&34018)&and&a&monoclonal&
antibody& (mouse& antiKFLAG®&M2,& SigmaKAldrich,&Gillingham,&UK,&#& F1804)& directed& toward&
the&NKterminal& region& of& the& tagged&GPCR.& & Typically,& cells& that&were& prepared& for& the&βK
arrestinK2& recruitment& assay& as& described& in& Section! 2.7.3!were& used& for& the& cell& surface&
ELISA& to&provide&a&quantification&of& cell& surface& receptor&expression& level.& & From&a&10&cm2&
dish&containing&HEK293T&cells& transiently&coKtransfected&with&FLAGKGPR35KeYFP& (4&µg)&and&
βKarrestinK2& (1& µg),& cells& were& trypsinised,& centrifuged& at& 3110& x& g& for& 5& min& at& room&
temperature,&and&reKsuspended&in&20K22&mL&complete&media&before&addition&at&100&µl/well&









(Cell& Signalling,!Danvers,&MA,&#& 7076,& 1:2500& dilution)& and& the& cell& permeant& nucleic& acid&
stain& Hoechst& 33342& trihydrochloride& (100& ng/mL)& (Molecular& Probes®,& Life& Technologies,&
Paisley,&UK&#&H1399).&&Cells&were&incubated&for&30&min&+&5&%&CO2,&washed&twice&with&100&µl&
preKwarmed&PBS,& and&Hoechst& fluorescence&quantified&using& the& ratio&of&excitation&at&355&
nm& /emission& at& 460& nm& using& 100& flashes& per& well& on& a& POLARstar& Omega& plate& reader&
(BMG&Labtech,&Durham,&NC).&&PBS&was&completely&aspirated&and&replaced&with&100&µl&room&
temperature&TMB,&which&acted&as&a&hydrogen&donor&for&HRP&reduction&of&hydrogen&peroxide&
to& water.& & After& incubation& at& room& temperature& for& 10& min,& protected& from& light,&
absorbance&was&measured&at&650&nm&using&20&flashes&per&well&on&the&POLARstar&Omega.&&&
Cell& surface& expression&was& quantified& per& cell& by& Hoechst/absorbance,& which& had&
nonKspecific& binding,& calculated& from& empty& wells& containing& pcDNA™3.1& or& TMB& only,&
deducted,& and& data& normalised& accordingly.& & Each& experiment& was& carried& out& in&




















Ltd,& Paisley,& UK,&#& 41965),& before& a& final& addition& of& 90&µl& serum& free&media.& & Cells&were&
incubated& for& a& minimum& of& 30& min& before& test& compound,& prepared& at& 10X& final& assay&
concentration& in& serum&free&media,&was&added&at&10&µl/well&using&a&multichannel&pipette.&&
After&a&45&min& incubation&at&37°C&+&5&%&CO2,&medium&was& completely&aspirated&and&cells&
fixed&via& the&addition&of&4&%&paraformaldehyde& in&1X&PBS& (100&µl)&and&subsequent&40&min&
incubation& at& room& temperature.& & Paraformaldehyde&was& removed&by& aspiration& and& cells&
washed&3&times&with&100&µl&1X&PBS.& &Plates&were&then&wrapped&in&Saran&wrap&to&minimise&
evaporation&and&stored&at&4°C&overnight.&
& To& assay,& cells& were& incubated& with& Hoechst& 33342& trihydrochloride& nuclear& stain,&
diluted& to&500&nM& in&1X&PBS& (100&µl/well)&and& incubated& for&30&min&at& room&temperature&
protected& from& light.& & Hoechst& 33342&was& removed& by& aspiration& and& cells& washed& three&
times& with& 100& µl& 1X& PBS& before& assessment& of& receptor& internalisation& using& the&
ArrayScan™&II&High&Content&Analyser& (Cellomics,&Boston,&MA),&Receptor& Internalisation&and&
Trafficking&application.&&Cell&nuclei&(measured&using&Hoechst&nuclear&stain)&were&detected&as&
a& surrogate& measure& of& cell& number,& while& fluorescence& intensity& was& used& to& monitor&
internalised&receptor.& &Cells&were&automatically&detected&using&a&10X&objective&lens,&before&













were& then& carefully& rotated& incubated& for& 2& h& at& 37°C& +& 5& %& CO2.& & To& induce& receptor&
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expression,& each& well& was& flooded& with& 2& mL& complete& media& containing& 100& ng/mL&
doxycycline&and&incubated&overnight&at&37°C&+&5&%&CO2.&&The&next&day,&media&was&carefully&
aspirated&and&replaced&with&500&µl&HBSS&containing&10&mM&DKglucose.&&&
Coverslips& were& placed& into& a& microscope& chamber& containing& physiological& saline&
solution&[NaCl&(130&mM),&KCl&(5&mM),&CaCl2&(1&mM),&MgCl2&(1&mM),&HEPES&(20&mM),&and&DK
glucose& (10& mM),& pH& 7.4].& & Ligand& (2X& final& assay& concentration)& was& added& to& the&
microscope& chamber& and& fluorescent& images& were& acquired& at& 15& min& intervals& using& a&
spinning& disk& structured& illumination& Viva& Tome& device& attached& to& the& bottom& port& of& a&
ZEISS& Axio& Observer.Z1& invert& microscope& (Carl& Zeiss& Ltd,& Cambridge,& UK).& & Narrow& band&
490/20& nm& excitation& light& was& reflected& through& a& 63X,& oil& immersion& PlanKApochromat&
objective& lens& to&excite&eYFP&and&the&resulting&emitted& light&was&detected&at&536&nm/&540&





HTK29& cells&were& plated& in& complete&medium&McCoy’s& 5A& (Modified)&Medium& (Life&
Technologies& Ltd,& Paisley,& UK,& #& 26600K023)& at& a& density& of& 30,000& cells/well& into& black,&
fibronectin&coated,&glass&bottomed&Epic®&384&well&plates&(Corning®,&Tewksbury,&MA&#&5042),&
at& a& volume& of& 50& µl/well& using& an& electronic& multichannel& pipette.& & Each& plate& was&
centrifuged&at&3110&x&g,&for&30&sec&and&plates&kept&at&room&temperature&for&30&min&to&allow&
cells&to&settle&prior&to&incubation&for&24&h&at&37°C&in&a&humidified&atmosphere&containing&5&%&





temperature& (26°C)& in& the&Epic®&Bench&Top& (BT)& system&(Corning,&Tewksbury,&MA,&#&5053)&
followed&by&the&acquisition&of&basal&data& for&2&min&using&the&whole&cell& scanning& function.&&
Plates&were&then&removed&from&the&Epic®BT&system&and&agonist,&five&times&concentrated&in&




returned& to& the& Epic®BT& system.& & Change& in& refractive& index& upon& dynamic& mass&







µl/well).& DMR&data&was& gathered& for& a& further& 60&min.& & DMR& values& obtained& 5&min& post&
ligand& addition& (agonist)& or& 35& min& (antagonist)& were& baseline& corrected& by& deducting&
control&wells& (DMSO&only& treated& cells),&which&were& distributed& across& the&middle& row&of&












vehicleKonly& control& and&was& plotted& one& log& unit& lower& than& the& lowest& concentration& of&


















! To&determine& antagonist& activity,& agonist& responses&were&measured& at& a& fixed& EC80&
concentration& of& the& reference& agonist& (zaprinast)& in& the& presence& of& a& series& of&
concentrations&of&antagonist.& &An&agonistKonly&response&was&also&performed.& &Analysis&was&
performed& using& the& equation& described& in& Section! 2.8.1,& except& that& the& IC50& (the&
concentration&whereby&50&%&of& the&agonist& response&was& inhibited)&was& calculated& rather&
than&the&EC50.&&Such&that:&
&!"#$%&#" = !"##"$! (!"# − !"##"$)1+ 10!"#$%!"!! &
&
The& pIC50& values& were& obtained& from& the& ‘best& fit’& curveKfit& from& each& individual&





& To& determine& if& the& interaction& between& newly& discovered& GPR35& agonists& and&



















the& steepness& of& the& family& of& curves& (with& a&Hill& Slope& of& 1.0& being& standard);& the& Schild&
Slope& (S)# quantifies& if& the& shift& in& the& agonist’s& response& with& increasing& antagonist&





only& control& curve&were& set& to& 0& and& 100&%,& respectively,& such& that& any& reduction& in& the&
maxima&of& the&antagonist& competitions&were&not&artificially& constrained& to&100&%.& & For& IPK
One& assays,&where& the& basal& values& decreased&with& increasing& antagonist/& inverse& agonist&
concentration,& basal& and&maximal& values& had& to& be& constrained& to& 0& and& 100&%& for& each&
concentration& of& antagonist& assessed,& which& negated& the& Schild& analysis& but& allowed&







All& equations& and& analytical& procedures& outlined& below& were& performed& in&
accordance& with& those& described& previously& (Kenakin& and& Christopoulos,& 2013),& and& the&
GraphPad& Prism& file& containing& the& formulae& was& kindly& provided& by& Prof.& Arthur&
Christopoulos,&University&of&Monash,&Australia.&&To&quantify&ligand&bias,&agonist&activity&was&
measured& in& two&or&more&pathways& (such&as&βKarrestinK2&recruitment&or& IP1&accumulation)&
with&functional&concentrationKresponse&data&analysed&using&a&modified&version&of&the&Black&
and&Leff&operational&model&of&agonism&(detailed&in&Kenakin&et&al.,&2012):&
&!"#$%&#" = !"#"$ + ! !! − !"#"$ [!]!!![!]!!! + ( ! + !!)!&
&
Where&[A]& is&the&agonist&concentration;&Em&is&the&maximal&possible&response&of&the&system&
and& basal& is& the& vehicleKonly& response;& KA& is& the& equilibrium& dissociation& constant& of& the&
agonist;&τ&is&the&operational&agonist&efficacy&of&the&agonist&(and&is&defined&as&RT/KE&(where&RT&
is&the&receptor&density&and&KE&is&the&intrinsic&efficacy&of&the&agonist&in&a&particular&signalling&
pathway);& n& is& the& transducer& slope& for& the& function& between& agonist& occupancy& and&
measured&responses.&&Em&and&n#are&cellKtype&specific&and&are&shared&by&all&agonists&that&act&
on& the& same& receptor& in& the& same& pathway.& & Log(τ/KA)& is& defined& as& the& transduction&
coefficient&for&a&particular&agonist&in&a&particular&signalling&pathway.&
To&determine&the&difference&between&pathways,&Δlog(τ/KA)&values&are&calculated&by&
subtracting& the& log(τ/KA)&value&of& the& test&compound& from&the&Δlog(τ/KA)&of& the& reference&
agonist& (usually& the& endogenous& agonist& but& in& this& case,& zaprinast).& & For& each& agonist,&
ΔΔlog(τ/KA)& values& are& calculated& by& subtracting& the& Δlog(τ/KA)& value& from& pathway& one&
from&the&corresponding&Δlog(τ/KA)&value&from&the&second&pathway.&&Bias&is&then&quantified&









Step&2:& The& transduction& coefficient&difference&Δlog(τ/KA)& between&different& ligands&
in&the&same&pathway&were&calculated&by&subtracting&transduction&coefficient&
of&the&test&sample&from&the&reference&compound&(zaprinast):&
&Δ!"# !!! = !"#! !!! !!"!!"#$%& − !"#! !!! !!"!!"#"!"$%"&
&
Step&3:& The&difference&between&transduction&coefficients&ΔΔlog(τ/KA)&were&calculated&
between& different& pathways& for& the& same& test& ligand& by& subtracting& the&
Δlog(τ/KA)&for&pathway&one&from&that&of&pathway&two:&&
&ΔΔ!"# !!! = !Δ!"#! !!!!! − !Δ!"#! !!!!! &
&
Step&4:&& The&bias&factor&was&calculated&as:&




& Statistical& analysis& was& performed& using& a& oneKway& analysis& of& variance& (ANOVA)&




















& At& the& beginning& of& 2011,& when& this& project& commenced,& there& were& few& ligands&
available&for&assessing&the&pharmacology&of&GPR35.&&Of&those&that&were&available,&most&were&




2006a)& and& the& phospholipid& derivative& lysophosphatidic& acid& (Oka& et& al.,& 2010),& suffered&
from&the&above&issues,&with&kynurenic&acid&acting&with&low&potency&at&the&human&orthologue&
(Jenkins& et& al.,& 2011)& and& with& lysophosphatidic& acid& responses& being& irreproducible& by&
independent&investigators&(Southern&et&al.,&2013;&my&unpublished&findings).&
In& this& first& results& chapter,& five& synthetic& ligands& were& used& to& characterise& assay&




GPR35&agonist&with&mast& cell& stabiliser&properties& (Yang&et& al.,& 2010;& Jenkins&et& al.,& 2010);&
and&two&novel&GPR35&antagonist&molecules,&MLK145&and&CIDK2745687&(HeynenKGenel&et&al.,&
2010;&HeynenKGenel&et&al.,&2011).&
In& addition& to&drug&discovery,& at& the&beginning&of& this&project,& a&number&of& groups&




al.,&2010).& &Subsequently,& it&emerged&that&GPR35&also&selectively&coupled& to& the&RhoA&and&
Src&family&kinase&activator&Gα13&but&not&to&the&closely&related&Gα12&G&protein&subunit&(Jenkins&
et&al.,&2011).&&This&presented&GPR35&as&a&Gα13&and&Gαi/o&selective&GPCR.&
Herein,& I& began& my& research& efforts& through& identification& of& assay& formats& that&
would&be&suitable&for&subsequent&GPR35&drug&discovery&and&characterisation&efforts.&&To&this&
end,& the& heterologous& Saccharomyces# cerevisiae# yeast& system& that& employed& yeastK





















































coupling& profile.& & Subsequently,& distinct& [35S]GTPγS& incorporation,& second& messenger,& βK
arrestin&recruitment,&and&receptor&internalisation&assays&were&investigated&as&drug&screening&
formats.& & To&characterise&GPR35& responses& in&an&endogenous&cell& line,&a& labelKfree& system&
was& employed& to& assess& cellular& dynamic& mass& redistribution& (DMR).& & Finally,& species&
orthologue& responses& were& assessed& where& appropriate& in& order& to& characterise& ligand&
responses& but& also& to& identify& any& species& selectivity& issues& that& could& hinder& future& drug&
development&efforts.&
&
3.1.1# Investigating# zaprinastEinduced# G# protein# coupling# at# human# and# rat# GPR35# in# the#
yeast#assay#
&
& In& order& to& reassess& the& published& G& protein& coupling& preference& of& GPR35,& I&
employed&a&previously&described&S.# cerevisiae& yeast& system& (Dowell& and&Brown,&2009).& & In&
this& system& a&W303K1A& strain& is& manipulated& to& chromosomally& express& the& endogenous&
yeast& Gα& subunit,& Gpa1,& or& a& yeastKmammalian& chimeric& G& protein& from& the& trp& locus&
(Dowell& and& Brown,& 2009).& & YeastKmammalian& G& protein& chimeras& were& generated& by&
replacement&of&the&last&five&carboxyl&terminal&amino&acids&of&Gpa1&with&the&corresponding&
mammalian&G& protein& sequence& to& couple&mammalian&GPCR& responses& through& the& yeast&
mating& response& pathway& (Dowell& and& Brown,& 2009).& & In& cases&where& the& carboxyl& amino&
acid& sequences& were& identical& between& different& G& proteins& (such& as& for& Gαi1/Gαi2& and&
GαoA/GαoB)&the&emanating&responses&were&nonKdistinguishable&and&were&thus&presented&as&
a& single& incorporated& response.& & Stimulation& of& this& pathway& resulted& in& the& induced&
production&of&βKgalactosidase,&which&cleaved&the&cell&permeable&substrate&fluoresceinKdiKβK
galactopyranoside& (FDG)& to& fluorescein& and& generated& a& fluorescent& readout& for& agonist&
stimulation&(Section!2.7.1).&&&
This& yeast& assay& has& previously& been& employed& to& characterise& Gα13& responses& at&
human& and& rat& GPR35& (Jenkins& et& al.,& 2011)& and& had& been& optimised& for& this& purpose.&&
Nonetheless,& negative& control& strains& were& employed& to& ensure& selectivity& following&
overnight& treatment&with&varying&concentrations&of&zaprinast& (Fig! 3.2).& &These&were&empty&
p426GPD&vector&strains& lacking&GPR35&but&containing&each&G&protein&chimera&to&assess&for&
receptorKindependent& activity,& or& Gpa1& only& with& p426GPD& vector,& human& GPR35,& or& rat&
Chapter&Three:&Identification&of&drug&screening&formats&for&GPR35!
88&
Figure! 3.2! Yeast! control! strains! are! not! stimulated! following! overnight! zaprinast! treatment! S.#
cerevisiae& cells& stably& expressing& empty& yeast& expression& vector& p426GPD& or& p426GPD& vectors&
containing&human&(h)&or&rat&(r)&FLAGKGPR35&were&grown&to&confluence&in&the&absence&or&presence&of&
zaprinast&overnight&at&30&°C&(see&Section!2.7.1&for&details).&&Each&receptor&strain&also&stably&expressed&
a& yeastKmammalian& chimera& that,& if& activated& following& zaprinast& treatment,&would& signal& through&
the&Gpa1&pathway&to& induce&βKgalactosidase&expression&and&generate& fluorescence&proportional& to&


















































































selective& for&Gpa1KGα13,& since&Gpa1KGα12& failed& to& generate& an& increase& in& AFU& via& either&
human&or&rat&GPR35&(Fig!3.3B).&&Meanwhile,&zaprinast&acted&at&the&Gpa1KGαi1/2&strains&with&
significantly&higher&potency&at&rat&than&at&human&GPR35&(P&≤&0.05)&(Fig!3.3C).&&At&the&Gpa1K




families& of& G& proteins& (Table! 3.1).& & For& the& Gpa1KGα16& strain& various& concentrations& of&
zaprinast& induced& a& response& at& human& but& not& rat& GPR35,& for& which& only& the& highest&
concentration&(100&µM)&elicited&a&response&(Fig!3.3F;&Table!3.1).&&There&was&not&an&increase&
in&AFU&following&zaprinast&stimulation&of&Gpa1KGαs,&Gpa1KGαq,&and&Gpa1KGα14&human&or&rat&







yeast& system& translated& into&a&mammalian&assay& format,& and& to&establish& a&mammalian&G&
protein&drug&screening&system,&distinct&[35S]guanosineK5’KOK(3Kthio)triphosphate&([35S]GTPγS)&
assays& were& employed.& & The& premise& of& the& [35S]GTPγS& assay& is& to& monitor& receptor&
activation&at&the& level&of&the&exchange&process&occurring&between&GDP&and&GTP&at&the&Gα&
protein& subunit,& which& relies& on& the& slower& dissociation& properties& of& GTPγS,& a& poorly&
hydrolysable&analogue&of&GTP& that& is& radiolabelled& for&detection&purposes&using& [35S].& &The&
[35S]GTPγS&assay&format&is& ideally&suited&to&assessment&of&Gαi/o&responses&as&Gαi/o&proteins&





or& presence& of& zaprinast& overnight& at& 30°C.& & Signalling& through& the& Gpa1& pathway& induced& βK































































































































































































to&express&Gαi/o&proteins& that& contained& the&C351I&mutation& (Section! 2.6.7).& &Application&of&
PTX& to& cells& results& in& ADP& ribosylation& of& all& endogenously& expressed& Gαi/o& G& proteins&
present& within& the& cell& but& not& the& mutant& Gαi/o& proteins& containing& C351I,& which& would&
remain&active&and&able&to&incorporate&[35S]GTPγS.&&Systematic&assessment&of&each&Gαi/oKC351I&
protein& in& the& presence& of& PTX& therefore& provides& a& means& to& dissect& Gαi/o& G& protein&




in& the&presence&or&absence&of&GPR35.& &Quantification&of& [35S]GTPγS& incorporation&by& liquid&
scintillation& spectrometry& revealed& that& there& was& a& difference& in& the& relative& amount& of&





To& specifically& assess& induced& Gαi/o& recruitment,& membranes& were& prepared& from&
HEK293T& cells& transiently& coKtransfected& to& overexpress& individual& Gαi/oKC351I& subunits&

















overnight& treatment&with&PTX& (100&ng/mL),& agonist& induced& [35S]GTPγS! incorporation&was&assessed&
relative& to&vehicle&control& in&membranes&containing&human&GPR35&Gαi1KC351I,&Gαi2KC351I,&Gαi3KC351I,&or&

































































































3.1.3# Assessing# Gα13# coupling# to# human# GPR35# using# a# [35S]GTPγS# assay# with# an#
immunoprecipitation#step!
!
Despite& the& inability& to&detect&Gαi/o&G&protein& subunit& recruitment& to&GPR35& in& the&
[35S]GTPγS&assay,& I& continued&with& the& [35S]GTPγS& format&but&moved& to&a& [35S]GTPγS&assay&
that&incorporated&an&immunocapture&step&to&enrich&for&Gα13&(Section!2.6.8),&since&this&had&
previously& been&employed&with& limited& success& to& characterise& ligand& responses& at&GPR35&
(Jenkins& et& al.,& 2010).& & For& this& assay& an& internally& EEKepitope& tagged& form& of& Gα13& was&
overexpressed&that&allowed&for&the&EE&tag&to&be&used&in&the&immunoprecipitation&step.&&FlpK
In™& TKREx™&HEK293& inducible& stable& cells& (Section! 2.3),& were& transiently& transfected&with&
Gα13EE&and&incubated&overnight&in&the&absence&or&presence&of&100&ng/mL&doxycycline,&which&
was&used&to&induce&expression&of&FLAGKGPR35KeYFP.&&Membranes&prepared&from&these&cells&
were& treated&with& zaprinast,& and& [35S]GTPγS& incorporation&was&monitored& after& an& antiKEE&
immunocapture&step&to&enhance&the&Gα13EE&response.&&Membranes&expressing&FLAGKhuman&
GPR35KeYFP& and& Gα13EE& showed& a& clear& increase& in& [35S]GTPγS& incorporation& relative& to&
Gα13EE&alone,&FLAGKhuman&GPR35KeYFP&alone,&or&empty&vector&pcDNA5/FRT/TO&(Fig!3.5A).&&
Zaprinast& induced& [35S]GTPγS& incorporation& via& FLAGKhuman& GPR35KeYFP& with& a& pEC50& of&
7.08&±&0.37&(Fig!3.5A).&
In&an&effort&to&increase&the&signal&window&in&the&[35S]GTPγS&assay&a&fusion&construct&
was& generated.& & Fusion& proteins& between& GPCRs& and& G& proteins& have& been& shown& to&
increase&signalling&efficiency&since&the&two&polypeptides&are&expressed&within&close&proximity&
to&each&other&(Milligan,&2003a).&&The&fusion&was&generated&between&FLAGKhuman&GPR35&and&
Gα13EE& and& contained& an& EcoRV& restriction& site& sequence& between& the& receptor& and& G&
protein& (Section! 2.3).& & This& construct&was& stably& inserted& into& the& genome&of& a& FlpKIn™&TK
REx™&HEK293& cell& line& and&expressed&on&demand& following&overnight& incubation&with&100&
ng/mL&doxycycline&(Section!2.5.5).&&Since&the&antiKEE&antibody&did&not&appear&to&detect&the&
fusion& construct,& as& indicated& in& the& immunoblot& presented& in& Figure! 3.5B,& the&
immunocapture&step&in&the&[35S]GTPγS&assay&was&carried&with&an&antiKFLAG&antibody.&&&
Membranes& prepared& from& FlpKIn™& TKREx™& HEK293& cells& containing& FLAGKhuman&
GPR35KGα13EE& displayed& a& concentration& dependent& increase& in& [35S]GTPγS& incorporation&





Figure! 3.5! Investigating! Gα13! coupling! at! human!GPR35! using! a! [35S]GTPγS! immunoprecipitation!
assay&Gα13EE&or&pcDNA™5/FRT/TO&constructs&were&transiently& transfected& into&FlpKIn™&TKREx™&cells&
that& were& incubated& in& the& presence& (black& symbols)& or& absence& (open& symbols)& of& doxycycline.&&
Overnight& incubation& with& 100& ng/mL& doxycycline& induced& FLAGKhuman& GPR35KeYFP& receptor&
expression.& & Membranes& prepared& from& these& cells& were& treated& with& or& without& zaprinast& and&
assessed&for&their&ability&to&recruit&Gα13EE&using&the&[35S]GTPγS&assay&with&an&antiKEE&immunocapture&
step& (Section! 2.6.8).& & All& reactions&were&performed&at& 25°C& for& 1&h&using&25&µg&protein.& &Negative&
controls&were& assessed& using& a& single& high& concentration& of& zaprinast& only& (100&µM)& (A).& & For& the&
Western&blot,&10&µg&of&membrane&protein&was&added&per&lane.&&Approximate&sizes&of&the&proteins&are&
indicated&on&the&left&of&the&blots&(in&kDa).& &FlpKIn™&TKREx™&membranes&containing&the&FLAGKhuman&
GPR35KGα13EE& fusion& construct& (78& kDa)& was& detected& with& the& antiKFLAG& but& not& the& antiKGα13EE&
































































































construct&was&not& greater& than& that& of& the&previously& described& FLAGKhuman&GPR35KeYFP&
and& Gα13EE& [35S]GTPγS& immunoprecipitation& experiment& (Fig! 3.6A/B).& & Furthermore,& the&
potency& generated&by& zaprinast&was& lower& at& the& fusion& construct& (pEC50& 5.98&±& 0.3)& than&
that& generated&when& the& FLAGKhuman&GPR35KeYFP& and&Gα13EE& proteins&when& individually&
expressed&(pEC50&7.08&±&0.37).&&This&indicated&that&individual&expression&of&GPR35&and&Gα13EE&







! To& obtain& a& higher& throughput& G& protein& output& for& drug& screening& efforts& in& a&











1,4,5& trisphosphate& (IP3),& is& degraded& rapidly& and& difficult& to& quantify.& & However& in& the&
presence& of& lithium& chloride,& the& IP3& metabolite& inositol& monophosphate& (IP1)& can& be&
maintained&and&quantified.&&Thus,&agonist&stimulation&of&the&Gαq&pathway&can&be&measured&
through&accumulation&of& IP1.& &To&monitor&this&process& I&employed&a&commercially&available&
IPKOne&assay&kit&(see&Section!2.7.2).& &The&IPKOne&assay&utilises&homogeneous&time&resolved&
fluorescence& (HTRF®)& to& assess& IP1& accumulation& through& utilisation& of& a& Cryptate& labelled&









To& optimise& the& IPKOne& assay& for& GPR35,& donor& to& acceptor& transfection& ratio,&
seeding& cell& density,& and& incubation& time& was& assessed& using& both& the& Gαqi1/2& and& Gαq13&
chimeras.& & Since& various& transfection& ratios& provided& similar& signal& windows& (data& not&
shown),& a& ratio& of& 1:1& between& GPR35& and& the& Gαq& chimera& was& utilised& throughout.& & A&
density&of&5,000&(Fig!3.6A)&and&10,000&(Fig!3.6B)&cells&per&well&was&used&to&assess&the&effect&
of& cell& number& upon& zaprinast& induced& IP1& accumulation.& Cells& expressing& human& GPR35,&
Gαqi1/2&or&Gαq13&chimeras&were&treated&with&zaprinast&(100&µM)&for&two&hours&and&generated&
an& increase& in& IP1& accumulation& that& was& greater& than& the& response& associated& with& the&
vehicle& control& (DMSO,& 0.1& %).& & Furthermore,& in& cells& expressing& GPR35& and& G& protein&
chimera,&the&magnitude&of&IP1&accumulation&was&substantially&higher&at&10,000&cells&per&well&
than&that&generated&at&5,000&cells&per&well&(Fig!3.6A/B).& &Interestingly,&the&basal&signal&was&










Although& I&had& initially&used&the&maximum&ligand& incubation&time&suggested&by&the&
manufacturer& when& optimising& cell& number& in& the& IPKOne& assay,& I& wanted& to& justify& this&
decision& by& ensuring& that& a& shorter& time& point& did& not& provide& a& similar&magnitude& of& IP1&
accumulation.& & Assessment& of& IP1& accumulation& at& one& (Fig! 3.6C)& or& two& (Fig! 3.6D)& hours&




HEK293T& cells& were& transiently& coKtransfected& to& express& FLAGKhuman& GPR35aKeYFP& and& a& Gαq&
chimeric&G&protein&Gαqi1/2&or&Gαq13.&&The&FLAGKmuscarinic&M3&receptor&was&transfected&as&a&positive&
control.& & The& IPKOne& assay& quantified& IP1& accumulation& through& an& immunoKcompetition& occurring&
between& a& cryptate& labelled& monoclonal& antiKIP1& antibody& (acceptor)& and& a& IP1& labelled& D2& dye&
(donor)& using& HTRF®& technology,& is& presented& as& pM& IP1& accumulation.& & Following& a& twoKhour&
incubation&at&37°C&with&zaprinast,& IP1&accumulation&was&assessed&at&cell&densities&of&5,000& &(A)&and&
10,000& (B)& cells& per& well.& & Using& 10,000& cells& per& well,& ligand& incubation& time& was& assessed& post&
zaprinast&treatment&for&one&(C)&or&two&hours&(D).&&Cells&expressing&the&M3&receptor&were&incubated&in&



































































































































































the&Gαq13& (P&≤& 0.01)&and&Gαqi1/2& (P&≤& 0.05)& chimeras&with&human&GPR35.& & Furthermore,& in&
addition&to&a&higher&maximal&response,&the&difference&between&unstimulated&and&stimulated&
responses&also&increased,&and&generated&a&higher&signal&to&background&ratio&after&two&hours.&&
This& was& observed& for& GPR35& and& the& muscarinic& M3& receptor.& & The& M3& receptor& was&
employed& as& a& positive& control& for& IP1& accumulation& as& M3& couples& to& Gαq& following&









To& determine& which& Gαq& chimera& would& be& best& suited& for& future& drug& discovery&
efforts& (to& be& carried& out& using& both& human& GPR35& and& species& orthologues),& various&
concentrations&of&zaprinast&were&assessed&using&Gαqi1/2&and&Gαq13&chimeras&with&human&and&
rat&GPR35& (Fig! 3.7).& &Both& the&Gαqi1/2& and&Gαq13& chimera&expressing& cells&displayed& similar&
potency& to& zaprinast& at& human& (pEC50& 6.86& ±& 0.19& and& 7.09& ±& 0.06,& respectively)& and& rat&
(pEC50&8.38&±&0.19&and&8.61&±&0.21,&respectively)&GPR35.&&However&for&both&orthologues,&the&
observed& response& of& the& Gαqi1/2& chimera& was& significantly& lower& than& that& of& the& Gαq13&
chimera& (P& ≤& 0.01).& & This& suggested& that& while& either& chimera& would& be& suitable& for&




3.1.8# Assessing# agonistEinduced# responses# at# species# orthologues# of# GPR35# using#Gαq13# in#
the#IPEOne#assay&
&





Figure! 3.7! Zaprinast9induced! coupling! of! Gαqi1/2! and! Gαq13! chimeras! at! human! and! rat! GPR35!
assessed!in!the!IP9One!assay&Concentration&responses&to&zaprinast&were&generated&following&a&twoK
hour& incubation& at& 37°C& using& 10,000& cells& per& well.& & FLAGKhuman& GPR35KeYFP& (A)& or& FLAGKrat&
GPR35KeYFP&(B)&were&transiently&transfected&with&Gαqi1/2&(closed&circles)&or&Gαq13&(open&circles).&&Data&





























































using&Gαq13& at& human& and& rat& GPR35.& & Prior& to& development& of& the& IPKOne& assay& system,&
measures& of& potency& and& efficacy& for& these& agonists& at& species& orthologues& had& been&





human& selective& (P& ≤& 0.001),& and& generated& a& significant& difference& in& efficacy& between&
human&and& rat&GPR35& (P&≤& 0.001)& compared& to& zaprinast& (Fig! 3.8B).& & Cromolyn,&distinctly,&




et& al.,& 2012),& although& the& rank& order& of& potency& and& profiles& of& species& selectivity& were&
maintained&between&the&two&systems.&&As&a&result,&the&IPKOne&assay&format&was&established&



















































































































































IP1&accumulation& response&below&the&vehicle& level& (Fig! 3.9A).& &When&preKequilibrated&with&
GPR35& and& challenged& with& 300& nM& zaprinast,& MLK145& reduced& the& signalling& below& the&
zaprinastKonly&response&to&the&level&associated&with&MLK145&alone,&and&toward&the&level&of&
the& pcDNA3.1/Gαq13& negative& control& (Fig! 3.9A).& & This& suggested& that& MLK145& displayed&
inverse& agonism& to& reduce& basal& and& agonistKinduced& responses& at& human& GPR35.&&
Assessment& of& CIDK2745687& resulted& in& a& similar& profile& of& inverse& agonism,& although&
responses&were&less&potent&than&those&generated&at&MLK145&(Table!3.3)&as&noted&previously&
(Jenkins&et&al.,&2012;&Appendix!A).&&CIDK2745687&acted&to&reduce&IP1&accumulation&below&the&
level&of& the&vehicle& response,&and&also& in&a& concentration&dependent&manner& reduced& the&
300&nM&zaprinast&response&below&the&agonistKonly&level&(Fig!3.9B;&Table!3.3).&&As&presented&
initially& in& the&BRETKbased&βKarrestinK2& assay& (Appendix! A)& however,& the& pharmacology& at&
human&GPR35&did&not&translate&to&the&rat&orthologue,&as&addition&of&10&nM&zaprinast&was&not&
concentration& dependently& reduced& using& either& MLK145& (Fig! 3.9C)& or& CIDK2745687& (Fig!
3.9D).& & Therefore,& these& data& indicated& that& the&GPR35& antagonist& compounds& acted&with&
marked& humanKselectivity& in& both& G& protein& and& βKarrestinK2& recruitment& systems& as&









or& antagonistKonly& (black& squares)& response.& & The& negative& control,& pcDNA3.1/Gαq13,&was& assessed&
with&antagonist&only& (crosses).& &At& rat&GPR35,& zaprinast& (10&nM)&was& incubated&with&MLK145& (C)&or&
CIDK2745687&(D)&(black&circles),&and&is&displayed&alongside&zaprinastKonly&responses&(open&triangles).&&
















































































































































Ligand ML(145 CID(2745687 ML(145 CID(2745687
Zaprinast 6.96$±$0.09 5.51$±$0.08 NA NA
FLAG(Human>GPR35(eYFP FLAG(Rat>GPR35(eYFP
pIC50>Values>(>IP(One>Assay






of& ligand& induced&βKarrestinK2&recruitment&and/or& receptor& internalisation&outputs& (Jenkins&
et& al.,& 2010;& Zhao&et& al.,& 2010;&Deng&et& al.,& 2011a;& 2011b;&Deng& and& Fang&2012a;&NeetooK
Isseljee&et&al.,&2013;&Southern&et&al.,&2013),&which&has&provided&a&robust&measure&of&GPR35&
pharmacology& in# vitro.& & Herein,& agonist& induced& stimulation& at& the& level& of& βKarrestin&
recruitment&(using&BRET&technology)&and&receptor&internalisation&(using&confocal&microscopy&







a& fluorescent& energy& acceptor& (eYFP).& & Given& close& proximity& occurring& between& these&
polypeptides&and&degradation&of&luciferase&substrate&coelenterazine&h,&energy&is&emitted&and&
is& transferred& from& donor& to& acceptor& and& subsequently& reKemitted& at& a& characteristic&
wavelength,& which& can& be& quantified& using& a& luminescenceKreadout& (Section! 2.7.3).& & This&
luminescent&signal&decays&within& the&order&of& tens&of&minutes.& &The&BRETKbased&βKarrestin&
recruitment&assay&employed&herein&has&previously&been&utilised&and&optimised&extensively&




To& ensure& the& optimal& arrestin& subtype& and& timeframe& were& employed& for& drug&
screening& efforts,& a& kinetic& BRET& approach& was& taken& to& assess& zaprinast& stimulated& βK
arrestin& recruitment& to&human&GPR35& (Section! 2.7.4).& & To& this&end,& zaprinast& (10&µM)&was&
added&to&transiently&coKtransfected&HEK293T&cells&expressing&FLAGKhuman&GPR35KeYFP&and&
βKarrestinK1KRluc&or&βKarrestinK2KRluc&proteins& and&BRET&occurring&between& these&proteins&





were& transiently& coKtransfected& with& FLAGKreceptorKeYFP& and& βKarrestinKRenilla& luciferase,& with&
agonist& induced& coupling& monitored& kinetically& using& BRET& technology& (Section! 2.7.3& and& Section!
2.7.4).&&Human&GPR35&and&human&FFA4&recruited&βKarrestinK1&(A/C)&and&βKarrestinK2&(B/D)&following&
treatment&with&agonist,&(black&circles)&but&not&vehicle,&0.01%&DMSO&(grey&circles).&&Zaprinast&(10&µM)&
or& TUGK891& (10& µM)& (Hudson& et& al.,& 2013c)& was& used& to& stimulate& BRET& at& GPR35& or& FFA4,&








































































βKarrestinK2& subtypes& were& recruited& to& GPR35,& the& magnitude& of& the& BRET& signal& was&
greater& for&βKarrestinK2.& &Despite& this,& the& kinetic&profile& at&GPR35&was& similar& for&both&βK
arrestinK1&and&βKarrestinK2& subtypes&with&an& induced&BRET& ratio&peak& that&occurred&5&min&
post& addition& and& subsequently& decreased& over& time.& & Importantly,&βKarrestin& recruitment&
did& not& ensue& following& vehicle& addition& (DMSO,& 0.01& %)& indicating& that& the& BRET& signal&
measured&occurred&as&a&result&of&zaprinast&stimulated&receptor&activation&only&(Fig!3.10A/B).&&&
To& assess& whether& the& gradual& decline& in& BRET& signal& observed& after& 5& min& of&
zaprinast& treatment& was& an& artefact& associated& with& coelenterazine& h& oxidation& or& was&
indeed&a&genuine&occurrence,& the&kinetics&of&βKarrestin& interaction&with& the& free& fatty&acid&
receptor&FFA4&were&assessed&following&stimulation&with&the&synthetic&agonist&TUGK891&(10&
µM)& (Hudson& et& al.,& 2013c)& (Fig! 3.10C/D).& & FFA4& was& chosen& since& previous& results& from&
within&our&laboratory&indicated&that&the&kinetic&profile&of&the&interaction&between&FFA4&and&
βKarrestinK2& are& maintained& over& time& (Butcher& et& al.,& 2014).& & Indeed,& TUGK891& (but& not&
vehicle)& stimulated& FFA4& to& recruit& βKarrestinK1& and& βKarrestinK2& with& a& peak& at&
approximately& 10&min& that&was&maintained& over& the& 45&min& assay& duration.& & These& data,&
therefore,&indicate&that&the&kinetics&of&the&GPR35KβKarrestin&recruitment&interaction&display&
rapid&association&followed&by&a&slow&disassociation,&and&thus&placed&a&greater&emphasis&on&
ensuring& that& the& correct& time& point& was& employed& to& ensure& the& strongest& signal& was&
obtained&for&subsequent&drug&screening,&set&timeKpoint,&BRET&assays.&
&




βKarrestinK1,& agonistKinduced&βKarrestinK2& recruitment&was& quantified& following& incubation&
with&varying&concentrations&of&agonist.& &Zaprinast,&pamoic&acid&and&cromolyn&stimulated&βK
arrestinK2& BRET& has& previously& been& quantified& at& human,& mouse,& and& rat& species&
orthologues& of& GPR35& (Jenkins& et& al.,& 2012),& and& this& data& was& therefore& used& to& ensure&
reproducibility&and&data&quality&prior&to&undertaking&subsequent&drug&screening&efforts.&
Prior& to& commencement& of& the& BRET& assay,& cell& surface& receptor& expression& was&
assessed& visually& using& fluorescence& microscopy& (data& not& shown),& while& total& receptor&
Chapter&Three:&Identification&of&drug&screening&formats&for&GPR35&
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expression& was& quantified& by& measuring& eYFP& fluorescence& (Fig! 3.11A).& & Subsequently,&
agonistKinduced&βKarrestinK2&BRET&was&quantified& following&a&5Kminute&agonist& incubation,&
and& these& studies& replicated& previously& published& findings& (Jenkins& et& al.,& 2012).& & This&
included& zaprinast,& which& was& active& at& all& three& species& orthologues& and& acted& with&
significant& rat& selectivity& (P&≤& 0.001)& (Fig! 3.11B;&Table! 3.4);&pamoic&acid,&which&acted&with&
human&selectivity&(P&≤&0.001)&and&partial&efficacy&at&human&GPR35&(P&≤&0.001),&but&recorded&
weak&or&no&responses&at&rat&and&mouse,&respectively&(Fig!3.11B);&and&cromolyn,&which&acted&
at& all& three& species& orthologues& but& generated& pEC50s& at& human& and& rat& that& were&










often& suffer& from& variability& in& the& cell& surface& expression& level& within& and& between&
transfections&and&are&associated&with&a&higher& level&of& internalised&receptor,&a&doxycycline&
inducible&FlpKIn™&TKREx™&HEK293&cell&line&that&stably&expressed&FLAGKhuman&GPR35KeYFP&on&
demand&was& employed.& & Using& confocal&microscopy,& liveKcell& receptor& internalisation& was&
imaged& following& zaprinast& stimulation& (100& µM)& over& a& 45Kminute& period& (Fig! 3.12A)&
(Section! 2.7.7).& & At& 0& minutes,& prior& to& zaprinast& addition,& the& majority& of& eYFPKtagged&
receptor& appeared& to& localise& to& the& cell& surface.& &Upon& application&of& zaprinast& however,&
definition&of&the&cell&surface&became&less&distinct&and&punctate&clusters&of&receptor&began&to&
form&within& intracellular& vesicles,& indicating& that& the& receptor& internalisation& process& was&
underway.&&
To& quantify& this& process,& and& to& utilise& the& internalisation& output& as& a&measure& of&
agonistKinduced&potency,&an&ArrayScan™&high&content&imager&was&employed&(Section!2.7.6).&&
ArrayScan™&technology&utilises&a&proprietary&algorithm&to&quantify& receptor& internalisation&
by& identifying& fluorescence& present& in& endocytic& compartments,& appearing& as& punctate&
Chapter&Three:&Identification&of&drug&screening&formats&for&GPR35&
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Figure! 3.11! eYFP! expression! and!β 9arrestin92! recruitment! profiles! at! GPR35! species! orthologues&
Before& BRET& analysis& was& carried& out,& cells& transiently& transfected& with& FLAGKGPR35KeYFP& and& βK
arrestinK2KRenilla& luciferase& constructs& were& assessed& for& eYFP& fluorescence& (A),& which& was& gain&
adjusted&on&each&occasion&to&the&human&receptor.& &Zaprinast&(B),&pamoic&acid&(C)&and&cromolyn&(D)&
induced&βKarrestinK2&recruitment&to&human&(red),&mouse&(blue)&or&rat&(green)&GPR35&was&quantified&
using& BRET& responses& 5&min& post& ligand& addition& (Section! 2.7.3).& & Efficacy& was& normalised& to& the&

































































































































































zaprinast& (A)& as&described& (Section! 2.7.7),& and&performed&with&Dr.& John&Pediani.& & For&high& content&
imaging&using&ArrayScan™&technology&(Section!2.7.6),&cells&were&incubated&with&agonist,&fixed&using&4&
%& paraformaldehyde,& and& internalisation& quantified& using& the& ArrayScan™& incorporated& algorithm.&&
An&internalisation&timeKcourse&was&carried&out&using&zaprinast,&100&µM&(black&circles)&or&vehicle,&0.1%&
DMSO&(clear&circles)&over&a&60&min&period&(B)&with&subsequent&concentration&responses&to&zaprinast&
(red),&pamoic&acid& (green)&and&cromolyn& (blue)&quantified& following&a&45&min& ligand& incubation& (C).&&
Panels&A& and& B! are& representative& of& two& independent& experiments,& while& C& is& presented& as& the&
mean&±&SEM&of&three&independent&experiments&carried&out&in&triplicate.&
& &
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‘spots’.& To& optimise& the& ArrayScan™& assay& format,& a& suitable& timeframe& for& agonist&
stimulation& was& identified& through& quantification& of& zaprinast& induced& receptor&




As& a& result,& subsequent& agonistKincubations& were& carried& out& for& 45& minutes.& & To&
perform&a&comparison&of&agonist&potency,& concentration& responses& to& zaprinast,& cromolyn&
and& pamoic& acid& were& quantified& in& their& ability& to& internalise& GPR35& using& ArrayScan™&
technology& (Fig! 3.12C).& & Importantly,& the& profile& of& agonist& potency& and& efficacy& was&
maintained&between& the&BRETKbased&βKarrestinK2& recruitment& and& the&ArrayScan™& system&









The& characterisation& of& GPR35& ligand& responses& in& nonKmanipulated& cell& lines& that&
endogenously&express&GPR35&has&proven&difficult&since&the&basic&biology&surrounding&GPR35&
signalling& downstream& from& its& immediate& effectors& has& not& yet& been& elucidated.& & Thus,&
‘label& free’& technology&may& offer& particular& benefit&with& respect& to&GPR35& as& it& offers& the&
ability& to& simultaneously& incorporate& signalling& from&multiple& pathways& in& an& endogenous&
cell&system&and&removes&the&need&for&knowledge&of&the&signalling&pathways&associated&with&
the& receptor.& Although& a& number& of& different& label& free& technologies& are& available,& the&
dynamic& mass& redistribution& (DMR)& format& was& employed& since& it& had& successfully& been&




to&DMR&occurring&approximately&150&nm&above&the&surface&of& the&sensor.& &Changes& in&cell&
shape,&morphology,&adherence,&binding&events&or&intracellular&protein&movements&occurring&









Before& assessing& agonist& induced& DMR& responses& using& the& Epic& Bench& Top™& (BT)&
system,& confirmation& of& expression& of& human& GPR35& messenger& RNA& in& HTK29& cells& was&
carried& out& using& reverse& transcriptase& (RT)KPCR& analysis& (Section! 2.4.6).& & The& RTKPCR&
approach& was& taken& as& although& antibodies& reported& to& be& directed& against& GPR35& are&
commercially&available,&specific&detection&of&GPR35&was&not&obtained,&despite&antiKFLAG&and&




from& GPR35& at& the& protein& level& have& been& obtained& using& GPR35Kspecific& antagonists& to&
silence&receptorKmediated&agonistKinduced&signalling.&&
All& RTKPCR& samples& were& assessed&with& short& oligonucleotide& forward& and& reverse&









The& DMR& assay& format&was& optimised& for& GPR35& using& the& HTK29& cell& system& at& a&
room& temperature& of& 26& °C,& ±& 1& °C& (Section! 2.7.8).& & Initially,& seeding& cell& density& was&
assessed& through& quantified& outputs& of& maximal& response& (Fig! 3.13B)& and& potency& (Fig!
3.13C)& for& zaprinast& and& pamoic& acid.& & The& result& of& this&was& that& kinetic& DMR& responses&
were& increased& with& increasing& cell& number& without& an& alteration& in& ligand& potency,&




Agonist& compounds& were& added& using& an& automated& Biomek®& FXP& liquid& handling&
system& (Section! 2.7.8)& before& the& plate&was& returned& to& the& Epic& BT™& system.& Reference&
agonists& zaprinast,& pamoic& acid,& and& cromolyn& generated& concentration& responses& with&
similar& kinetic& DMR& traces,& producing& a& peak& that& occurred& immediately& following& agonist&
addition&and&decreased&after&a&number&of&minutes&(Fig!3.13D).&&To&assess&which&timeKpoint&
would&be&most& suitable& for&extrapolation&of&kinetic& responses& into&concentration& response&
format,&potencies&generated&within& the&peak&DMR&response& for&zaprinast&and&pamoic&acid&






Figure!3.13!HT929! cells! endogenously!express!human!GPR35! and! respond! to! ligand! treatment!as!
measured!using! the!DMR!system&RTKPCR&analysis&depicted&expression&of&GPR35&mRNA&transcripts.&




26& °C& following& addition& of& agonist& at& 2&min& (D).& & pEC50s& generated& for& zaprinast& and& pamoic& acid&
within& the& peak& DMR& response& were& compared& over& time& to& determine& a& suitable& time& point& for&
extrapolation&of&kinetic&data& into&concentration& responses& (E).& &Agonist&data&extrapolated&at&5&min&
post& ligand& addition& is& presented& (F)& with& each& concentration& data& point& corresponding& to& an&
independent&kinetic& trace&at&5&min&as&presented& in& (D).& & To&assess&whether& this& response&occurred&
through&agonism&of&GPR35,&zaprinast&was&antagonised&with&increasing&concentrations&of&MLK145,&as&
indicated& (G),& with& data& fitted& to& the& GaddumKSchild& EC50& shift& global& analysis.& & Efficacy& was&
























































































































































































Concentration& response& analysis& emanating& from& the& kinetic& DMR& profiles& of&
zaprinast,& pamoic& acid,& and& cromolyn& indicated& that& the& rank& order& of& potency& was&
maintained& between& the& endogenous& HTK29& cell& system& and& the& manipulated& HEK293&
overexpressing& IPKOne&and&BRET& systems& (Fig! 3.13F;! Table! 3.6).& &With& regards& to& efficacy,&
pamoic&acid&recorded&a&response&that&was&significantly&lower&than&zaprinast&(P&≤&0.05),&and&





Since& the& HTK29& cell& system& was& not& manipulated& to& specifically& monitor& GPR35&















& An& important& aspect& of& the& early& drug& discovery& process& is& the& design& and&








proteins,&βKarrestin& assays,& and&most& recently,& labelKfree& technologies,& can& overcome& this&
problem.& & In& an& effort& to& identify& suitable& assay& systems& for& drug& screening& and&
characterisation& efforts& at& GPR35,& a& number& of& distinct& experimental& outputs& were&












employed& the& FDG& yeast& assay& with& a& series& of& chimeric& yeastKmammalian& G& proteins.&&
Overnight& incubation& with& zaprinast& revealed& a& G& protein& coupling& preference& that& was&














mediating& contact& and& conferring& specificity& with& the& GPCR& (Kostenis& et& al.,& 2005).&&
Therefore,&although&this&system&offers&considerable&potential&as&a&format&to&screen&ligands&
for& pathway& bias,& care& should& be& taken& when& interpreting& data& and& subsequent& steps&
employed&using&fullKlength&G&proteins&to&ensure&equivalence&between&assay&systems.&
&
3.4.2# The# yeast# assay# reveals# a# lack# of# species# selectivity# for#G# protein# coupling# and# hints#
toward#an#important#involvement#for#NElinked#glycosylation#at#GPR35&
&
& Application& of& zaprinast& at& GPR35& is& usually& associated& with& species& selectivity,& as&
zaprinast& is& reportedly& some&25& fold& selective& for& rat&over&human&GPR35& (Taniguchi&et& al.,&
2006;& Yang&et& al.,& 2010;& Jenkins& et& al.,& 2011;& Jenkins& et& al.,& 2012).& & This& phenomenon&also&
extends& to& numerous& other& ligands& acting& at& GPR35,& and& is& not& a& zaprinast& specific& effect&
(Jenkins&et&al.,&2012;&NeetooKIsseljee&et&al.,&2013;&Funke&et&al.,&2013;&Mackenzie&et&al.,&2014).&
Surprisingly,& the& data& arising& from& the& yeast& assay& revealed& that& human& and& rat& GPR35&
coupled& to& Gpa1& KGα13,& KGαi3& KGαoA/B& with& similar& potency& following& zaprinast& treatment,&
with& a& significant& difference& noted& only& for& Gpa1KGαi1/2& (Table! 3.1).& Although& the& exact&
reason& for& this& is& unclear,& and& could& indicate& that& as& yet& unidentified& accessory& proteins&
differentially& regulate& the&human&and& rat& receptors& in&mammalian&systems,& this&difference&
could&also&be&a&result&of&the&composition&of&the&yeast&cell&wall.&&The&cell&wall&of&S.#cerevisiae&
contains&ergosterol&rather&than&cholesterol,&and&recombinant&proteins&expressed&in&yeast&are&
often& glycosylated& with& highKmannose& type& sugars& rather& than& complex& NKlinked&
oligosaccharides&(Bonander&and&Bill,&2012).&















glycosylation,& a& lesser& amount& (approximately& 32& %)& contain& a& potentially& glycosylated&
sequence& within& ECL2,& where& it& is& predicted& that& the& oligosaccharide& chain& could& be&
accommodated&within&the&GPCR&tertiary& fold& (Wheatley&et&al.,&2012).& &Glycosylation& in&this&
region&can&act&to&pull&ECL2&away&from&the&ligandKbinding&pocket,&or&simply&act&to&stabilise&the&
conformation&of& the&ECL2& loop& (Wheatley&et&al.,& 2012).& & If& this& is& the&case&at& rat&GPR35,& it&
would&appear&that&human&and&rat&GPR35&could&have&a&different&topological&structure&in&this&
region.& & This& is& supported& by& recent& modelling& efforts& that& predicted& the& ELC2& of& human&
GPR35&to&partially&form&a&lid&over&the&ligand&binding&pocket&but&with&the&ECL2&of&rat&being&
less& involved& in& ligand& binding& (Mackenzie& et& al.,& 2014).& & Thus,& in& addition& to& providing& a&















as& described& herein,& human& GPR35& did& not& appear& to& couple& to& Gαi/o& following& zaprinast&
stimulation& of& membranes& of& HEK293T& cells,& while& bovine& FFA2,& a& receptor& that&
endogenously& couples& to& the& Gαi/o& family& (Hudson& et& al.,& 2012b),& incorporated& [35S]GTPγS&
following& stimulation& with& its& endogenous& ligand& valeric& acid,& suggesting& that& the& assay&
format&was&functional&(Fig!3.4).&&It&is&important&to&note&that&the&results&presented&herein&only&
assessed&the&ability&of&zaprinast&to&stimulate&[35S]GTPγS&incorporation&at&GPR35,&and&further&
analyses& should& evaluate& the& kynurenic& acid& response& in& GPR35Ktransfected& HEK293T& cell&
membranes&to&ensure&that&the&lack&of&the&zaprinast&response&was&not&a&ligand&specific&effect.&&
However,&as&zaprinast&inducedKsignalling&can&be&abolished&following&PTX&treatment&in&GPR35#
endogenously& expressing& cells& (Wang& et& al.,& 2006a;& Barth& et& al.,& 2009;& Zhao& et& al.,& 2010;&
Fallarini&et&al.,&2010),&it&appears&that&the&lack&of&zaprinastKinduced&[35S]GTPγS&incorporation&
could& be& a& result& of& the& cell& type& used& to& assess& the& responses,& indicating& that& GPR35&
signalling&could&be& influenced&by&the&cellular&background& it& is&expressed&within.& & It&may&be&
relevant& that& Chinese& hamster& ovary& (CHO)KK1& cell& membranes& were& employed& for& the&
kynurenic& acid& study& (Wang& et& al.,& 2006a),& while& HEK293T& cell& membranes& were& utilised&
herein.&&Additionally,&the&kynurenic&acid&[35S]GTPγS&incorporation&assay&utilised&by&Wang&and&
colleagues& did& not& employ& Gαi/o& proteins& that& contained& the& C351I& mutation& (Wang& et& al.,&
2006a).&&Given&the&critical&role&for&the&Gα&CKterminus&in&enabling&GPCR&interaction,&it&is&not&
surprising& that& manipulation& to& this& sequence& can& negatively& impact& potency,& agonist&
mediated&GDP&turnover&(Carr&et&al.,&1998),&and/or&efficacy&(Wise&et&al.,&1999).&&Expression&of&
Gαi/o&proteins& in&an& insect&cell& system& is&a&method&that&would&enable&quantification&of& full&
length&G&proteins&without& interference&or& crossKtalk& from&endogenous&G&protein& subunits,&
since& insect& G& proteins& are& expressed& at& a& level& some& 80& %& lower& than& mammalian& G&
proteins,& in& addition& to& insect& G& proteins& sharing& limited& homology& to& their& mammalian&
counterparts&(Knight&et&al.,&2003).&&&
Lastly,& it& has& been& demonstrated& that& the& glycosylation& profile& of& recombinant&






Wang& and& colleagues& stably& expressed& GPR35,& while& I& carried& out& my& studies& using&
transiently&transfected&HEK293T&cells.& &While&there&is& inherent&variability&in&the&cell&surface&
expression&of&GPCRs&within&and&between&cells& following& transient&expression,& this&was& the&
preferred&option&for&these&studies&since&CHO&cells&are&less&amenable&to&transient&expression,&
and&the&amount&of&recombinant&protein&produced&in&CHO&cells&is&substantially&less&than&that&





& Unlike& the& standard& [35S]GTPγS& incorporation& assay,& zaprinast& has& been& shown& to&






initially& began& by& transiently& transfecting& both& FLAGKhuman& GPR35KeYFP& and& Gα13EE,& but&
came& to& the& same& conclusion:& zaprinast& was& able& to& induce& [35S]GTPγS& incorporation&






protein,& the& level& of& expression& of& each& protein,& and& spatial& proximity& within& cellular&
membranes&(Seifert&et&al.,&1999b),&a&fusion&construct&between&the&CKterminus&of&GPR35&and&
the& NKterminus& of& Gα13EE& was& generated.& & This& was& with& the& expectation& that& the& 1:1&
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stoichiometry,& the&close&proximity&of& the& two&polypeptides,&and& the& tethering&of&Gα13EE& to&
the&cell&membrane&would& increase&the& functional&output&of& the&response& (Milligan,&2003b;&
Milligan&et&al.,&2007).&&This&has&been&successful&for&increasing&[35S]GTPγS&incorporation&at&the&
dopamine&D2/D3&(Lane&et&al.,&2007),&FFA1&(Stoddart&et&al.,&2007)&β2KAR&(Bertin&et&al.,&1994;&




3.5C).& & There& are& a& number& of& factors& that& could& account& for& this:& the&G&protein& could& be&
constrained& by& the& linker& sequence& and/or& not& in& the& correct& orientation& for& maximal&
activation& (Robinson& and& Sauer,& 1998;& Seifert& et& al.,& 1999b)& (this& could& also& explain& the&
inability&to&detect&Gα13EE&in&the&fusion&construct&with&the&antiKEE&antibody&(Fig!3.5B));&the&1:1&
stoichiometry& could& prevent&multiple&G& protein& coupling& and& therefore& reduce& the& overall&
potency&and&efficacy&of&the&response;&the&kinetics&of&the&[35S]GTPγS&incorporation&rate&could&
be&increased&due&to&the&close&proximity&of&the&polypeptides,&leading&to&a&lower&estimation&of&
potency& at& the& time& point& measured;& or& there& could& be& a& mechanical& or& structural&
requirement& for& the&association&of&Gβγ& subunit& for&GDP&turnover& (Iiri&et&al.,&1998;&AdjoboK
Hermans&et&al.,&2011).&
& Future& efforts& to& improve& the& signal& from& the& fusion& protein& could& assess& the&
flexibility&between&GPR35&and&Gα13&that&currently&only&contains&the&EcoRV& linker&sequence&
(GATATC).& & This& translates& to&aspartic& acid& and& isoleucine:&only& two&amino&acids& in& length.&&
Some&studies&have&used&two&restriction&sites&as&a&linker&(Zhang&et&al.,&2006),&while&yet&others&
have&placed&an&epitope&tag&and/or&proteolytic&cleavage&sequence&in&this&region,&significantly&
increasing& the& linker& length& (Siefert& et& al.,& 1999a).& & The& secondary& structure& of& the& linker&
region& must& also& be& considered,& as& sequences& encoding& αKhelical& or& βKstrand& structures&
could&alter&the&conformation&of&the&fusion&protein.&&Distinctly,&expression&of&receptor&and&G&
protein& in& an& insect& cell& line& would& provide& a& cell& system& with& limited& interference& of&
endogenous& mammalian& G& proteins& (Knight& et& al.,& 2003)& allowing& for& GPR35KGα13&
measurement& free& from& competing& Gαi/o& proteins& that& could& ultimately& increase& the&
magnitude&of&Gα13&[35S]GTPγS&&incorporation.&&Nevertheless,&considering&the&aforementioned&












transiently&coKtransfected&with&GPR35&and&GαqoA/B,&measurement&of& [3H]& inositol& stabilised&
with& lithium&chloride& revealed& that& cromolyn&acted&with&a&pEC50&of&7.21&±& 0.14&at&human,&
6.15&±&0.31&at&mouse&and&6.31&±&0.13&at&rat&GPR35&(Yang&et&al.,&2010).& &This& indicated&that&
cromolyn&displayed&human&selectivity.& &However,& in& the&βKarrestinK2&recruitment& (Fig! 3.11)&
and& HTRF®& IP1& accumulation& assay& using& Gαq13& (Fig! 3.8)& the& human& and& rat& cromolyn&





(Table! 3.2)&and& lower& than&those&originally&published& in& the&2010&study& (Yang&et&al.,&2010;&
Yang&et&al.,&2012;&Jenkins&et&al.,&2012).& &Thus,&while&my&studies&using&Gαq1/2&and&Gαq13& (Fig!
3.7)&found&no&difference&in&the&potency&of&zaprinast,&this&does&not&mean&that&there&is&no&G&












with& increased&basal& signalling.& &However,& constitutive&activity& is&not&merely&an&artefact&of&
overexpression,&as&some&receptors&are&constitutively&active&even&in&endogenous&systems&(de&
Ligt& et& al.,& 2000).& & For&GPCRs& such& as& rhodopsin& however,& there& is& a& strict& requirement& to&








and& GPR78& (Levoye& and& Jockers,& 2008;& Milligan,& 2003b)& were& found& to& naturally& display&
constitutive&activity.& &GPR35&appears&to&display&constitutive&activity&when&overexpressed&in&
recombinant&cell&systems&(Fig!3.9),&but&also&in&a&cell&line&endogenously&expressing&GPR35#(my&






2013)& receptors;& and& accessory& proteins& such& as& RAMPs& (Roux& and& Cottrell,& 2014;&
Christopoulos& et& al.,& 2003);& and& homoK& or& heterodimers& (Levoye& et& al.,& 2006)& can& also&
influence&the&basal&activity.&&Although&there&has&been&no&suggestion&of&GPR35&acting&as&part&
of& a& higher& order& oligomer& or& with& accessory& proteins,& it& would& be& of& interest& to& assess&





Herein,& the& IPKOne& assay& facilitated& the& characterisation& of& GPR35& antagonist&
compounds&in&a&constitutively&active&G&protein&system&for&the&first&time.&&This&revealed&that&
MLK145&and&CIDK2745687&acted&as& inverse&agonists&of&human&GPR35& in& systems&exhibiting&
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constitutive& activity& (Fig! 3.9).& & This& is& not& a& novel& phenomenon,& and& many& antagonist&
compounds& originally& identified& in& systems& devoid& of& basal& activity& were& subsequently&
reclassified& as& inverse& agonists& following& assessment& within& constitutively& active& systems&
(Milligan& et& al.,& 1995;& Milligan,& 2003b).& & Inverse& agonism& is& not& solely& an& academic&
phenomenon,& as& inverse& agonists& can&potentially& deliver& therapeutic& benefits& over&neutral&
antagonists&(Tao,&2008)&since&they&reduce&the&activity&of&constitutively&active&receptors&to&a&
greater&extent&than&neutral&antagonists.&&Therapeutically&successful&inverse&agonists&include&
naloxone& (Suboxone®)& for& the& management& of& opioid& overdose& (Sirohi& et& al.,& 2009),& and&
clozapine& as& an& inverse& agonist& of& dopamine& D2& and& serotonin& 5HT2C& receptors& for& the&
treatment& of& psychosis& (HerrickKDavis& et& al.,& 2000).& & Inverse& agonists& displaying& functional&
selectivity&also&offer& therapeutic& advantages,& as&demonstrated&by& the&βKblocker& carvedilol.&&
Carvedilol&is&a&nonKselective&βKblocker&that&at&the&β2KAR&acts&as&an&inverse&agonist&of&Gαs&and&
as& an& agonist& of&βKarrestin& recruitment& and& extracellularKregulated& kinase& (ERK)& activity,& a&




compounds& must& first& be& generated& with& efficacy& at& the& rodent& receptors& to& enable&
investigation&of&this&idea&in&in#vivo&models.&
&
3.4.9# The# BRETEbased# βEarrestin# recruitment# assay# reveals# a# distinct# GPR35EβEarrestin#
trafficking#pattern&
&






can& be& grouped& into& two& distinct& categories:& transient& interactors,& named& ‘class& A& GPCRs’&




the& class& A& group& include& the& β2KAR& (Shenoy& and& Lefkowitz,& 2003a),& the& α1bKadrenergic&
receptor,& µKopioid& receptor,& endothelin& ETA& receptor& and& the& dopamine& D1A& receptor&
(Oakley,&et&al.,&2000),&while&examples&of&class&B&receptors& include&the&vasopressin&receptor&
V2R& (Terrillon& et& al.,& 2004),& angiotensin& II& type& 1A& receptor& (Anborgh& et& al.,& 2000),&
thyrotropinKreleasing& hormone& receptor& (Hinkle& et& al.,& 2012),& neurotensin& 1& receptor& and&
neurokinin&NK1&receptor&(Oakley,&et&al.,&2000).&&When&expressed&at&comparable&levels,&class&




BRET&signal&of&FFA4& is&also&higher&with&βKarrestinK2& than&with&βKarrestinK1,& suggesting& that&
perhaps&the&βKarrestinK1&construct&employed&herein&does&not&express&as&well&as&βKarrestinK2.&&
This& may& be& clarified& using&Western& blot& analysis& using& antiKluciferase& or& arrestinKspecific&
antisera.&&&
The& functional& ramifications& of& the& pattern& of& βKarrestin& recruitment& presented& for&
GPR35& and& FFA4& when& linked& to& either& class& A& or& class& B& GPCRs& are& differential& rates& of&
receptor&dephosphorylation,& recycling,&degradation,&and&desensitisation.& &Class&B&receptors&
contain& clusters& of& phosphate& acceptor& sites& in& their& C& terminal& tails,& defined& as& serine& or&
threonine& residues& occupying& three& consecutive& positions,& or& three& of& four& positions,&
suggested& to& be& responsible& for& the& higher& affinity& interaction& with& βKarrestin& than& that&
associated&with&class&A&GPCRs&(Oakley&et&al.,&2000;&Tohgo&et&al.&2003).& & &As&a&result&of&this,&
class& B& receptors&maintain& association& with& βKarrestins& during& the& internalisation& process,&
and& βKarrestin& is& incorporated& with& the& GPCR& into& endosomes.& βKarrestin’s& scaffolding&
function&subsequently&facilitates&association&with&cytosolic&proteins&within&endosomes&that&
can&lead&to&activation&of&signalling&cascades&such&as&ERK&or&cAMP&accumulation&(Calebiro&et&
al.,& 2010);& further& to& this,& the& association& of& βKarrestin& with& the& GPCR& delays& the&
dephosphorylation& and& recycling& process,& resulting& in& a& longer& period& between& successive&
activation&events,&and&augmenting&the&receptor&desensitisation&process&(Shenoy&et&al.,&2001;&
Oakley& et& al.,& 2001;& Shenoy& and& Lefkowitz,& 2003a).& & Class& A& GPCRs,& on& the& other& hand,&













sst4& do& not& recruit& βKarrestin& and& do& not& internalise& (Tulipano& et& al.,& 2004).& & Receptor&
trafficking& profiles& can& also& be& distinct& depending& on& the& agonist& used& to& stimulate& the&
response,& as& indicated&by& the&µKopioid& receptor,&which& is& phosphorylated&and& internalised&
when& treated& with& etorphine,& weakly& phosphorylated& and& poorly& internalised& following&
morphine& treatment,& and& not& at& all& phosphorylated& nor& internalised& following& herkinorin&
treatment& (Bohn& et& al.,& 2004;& Groer& et& al.,& 2007).& & This& indicates& that& the& conformational&
ensemble& of& the& receptor& is& important& for& receptor& trafficking,& with& the& pattern& of&
constitutive&receptor&internalisation&and&receptor&trafficking&also&being&distinct&from&agonistK
induced&internalisation&(Segura&et&al.,&2013).& &Thus,&there&exists&opportunities&to&selectively&
engineer& ligands& to& minimise& receptor& desensitisation& and& degradation& (Woolf& and&
Linderman,&2003),&a&major&issue&impacting&upon&drug&efficacy&and&tolerance&(Williams&et&al.,&
2013;& Hudson& et& al.,& 2013c).& With& regard& to& GPR35,& therefore,& it& may& be& of& interest& to&
determine&whether&distinct&patterns&of&βKarrestin&trafficking&occur&following&stimulation&with&













distinct,& were& employed& using& the& same& cellular& background& (transiently& transfected&
HEK293T& cells).& & The& data& provide& an& interesting& profile& of& species& selectivity& at& GPR35:&
cromolyn& is& essentially& equipotent& at& human& and& rat&GPR35& in& both& the& BRET& and& IPKOne&









& Pamoic& acid& has& been& shown& to& act& in& an& antiKnociceptive& manner& in& a& mouse&
abdominal& constriction& test& (Zhao& et& al.,& 2010).& & If& acting& through&GPR35& in& this&model,& it&
would&be&of&interest&to&determine&which&pathway&pamoic&acid&utilises&to&this&end,&as&unlike&
rat&GPR35&which& gains& efficacy& and& potency& in& the& IPKOne& assay& using& the&Gαq13& chimera,&
mouse&GPR35&does&not&gain&function&to&the&same&extent,&and&only&begins&to&display&efficacy&
at&10&µM&(with& further& increases& in&concentration& limited&by& the&solubility&of&pamoic&acid)&
(Jenkins& et& al.,& 2012).& & However,& it& is& possible& that& mouse& GPR35& could& be& activated& by&
pamoic& acid& at&GPR35& in# vivo& perhaps& even& in& a&Gαi/o& dependent&manner& (which&was& not&
investigated&herein& in& an& in# vitro& format),& and& implications&of& this&would&be& interesting& to&
dissect& in& further&detail.& &At&human&GPR35,&pamoic&acid& increases& in&efficacy&between& the&
BRET&and&IPKOne&systems,&from&a&partial&to&a&full&agonist&(Fig!3.8;&Fig!3.11).&&This&difference&is&
investigated& in& further& detail& in& Chapter! Four,& and& will& not& be& discussed& fully& here.&&
Nevertheless,&the&implications&of&this&appear&to&be&due&to&the&accumulative&nature&of&the&IPK





3.4.11# The# label# free# DMR# system# provides# a# platform# to# assess# ligand# responses# in# an#
endogenous#cell#system#without#the#requirement#for#manipulated#receptor#constructs&
&
& Many& of& the& drug& discovery& campaigns& at& GPR35& have& utilised& βKarrestinK2&
recruitment& assays& including& the& BRETKbased&method& utilised& herein& (Jenkins& et& al.,& 2010,&
2011,&2012;&NeetooKIsseljee&et&al.,&2013;&Mackenzie&et&al.,&2014),&or&reporterKbased&formats&
such&as&DiscoveRx’s&PathHunter®&(Southern&et&al.,&2013;&NeetooKIsseljee&et&al.,&2013)&or&Life&
Technologies’& Tango™& (Deng& et& al.,& 2011a;& 2011b;& 2012b;& 2012c;& 2012d).& & These& assays,&
particularly&for&GPR35,&provide&a&robust&means&of&assessing&ligand&responses,&but&they&also&
potentially& limit& the& selection& of& ligands& to& those& that&may& bias& the& receptor& toward& a&βK
arrestinK2& pathway.& & Since& there& are& very& limited& G& proteinKbased& outlets& for& assessing&
activation&of&GPR35&during&drug&discovery&efforts,&the&extent&of&βKarrestin&bias&had&perhaps&
not&been&realised&until&DMR&assays&were&employed&as&a&nonKbiased&outlet&to&identify&ligands&
of& GPR35.& & Recent& efforts& to& this& end& have& been& reported& by& Corning& researchers& who,&
utilising& the& DMR& platform& with& the& human& colorectal& adenocarcinoma& HTK29& cells&
endogenously& expressing&GPR35,& revealed& ligands& that& induce& DMR& in& HTK29& cells,& which&
could&be& at& least&partially& blocked&by& addition&of& the&GPR35&antagonist&CIDK2745687& (also&
known& as& SPB05142),& but& failed& to& recruit& βKarrestinK2& in& the& Tango™& assay& (Deng& et& al.,&
2011a;&2011b;&2012c;&2012d;&Deng&and&Fang&2012b).&&These&findings&generate&considerable&
excitement& given& the& current& interest& surrounding& biased& agonism.& & However,& the& DMR&
format& is& essentially& a& ‘black&box’&with& regard& to& ligand& responses& (Fang&et& al.,& 2007),& and&




that& there& are& at& least& two& widely& accepted& humanKselective& GPR35& antagonists,& it& is&
concerning& that& CIDK2745687& (the& less& potent& of& the& two)& is& primarily& utilised& for& this&
purpose,& as& it& does&not& act& in& a& competitive&manner&with& all&GPR35&agonists,& for& example&
pamoic& acid& (Jenkins& et& al.,& 2012).& & Thus,& important& agonist& responses& may& not& be&










ablated& following& MLK145& treatment,& suggesting& that& the& zaprinast& DMR& response& was&
indeed&a&result&of&GPR35&activation&(Fig!3.12G).&These&traces&however,&also&appeared&similar&





two& GαsKcoupled& receptors:& the& β2KAR& (expressed& in& CHO& cells)& and& the& prostaglandin& E1&
receptor&(expressed&in&HEK293&cells)&displayed&negative&or&positive&DMR&traces,&respectively&
(Schröder&et&al.,&2010).&&This&indicates&that&a&‘one&fits&all’&kinetic&response&for&each&family&of&












be& useful& and& suitable& to& assess& and& characterise& ligand& responses& emanating& from& drug&
discovery&efforts&at&GPR35.& &This& includes,& the& IPKOne&assay&using&chimeric&G&proteins,& the&


























Upon& commencement& of& this& project,& in& the& absence& of& a& potent& and& selective&
endogenous&agonist,&the&identification&of&novel&chemical&compounds&was&required&in&order&
to& probe& the& pharmacology& and& (patho)physiology& of& GPR35.& & Initial& efforts& undertaken&




chimeric& G& protein& based& and& DMR& assays,& have& been& employed& for& virtually& all& drug&





et& al.,& 2013),& lodoxamide,& and& bufrolin& (Mackenzie& et& al.,& 2014).& & From& highKthroughput&
screening& (HTS)& efforts,& the& identification& of& the& novel& human& selective& GPR35& agonist,&
compound& 1& ((4K{(Z)K[(2Z)K2K(2Kfluorobenzylidene)K4KoxoK1,3KthiazolidinK5Kylidene]methyl}&
benzoic&acid)),&is&described&(NeetooKIsseljee&et&al.,&2013).&&Profiling&of&GPR35&hit&compounds&
generated& from& HTS& efforts& revealed& that& the& antiKasthma& medication& cromolyn,& the&
flavonoids& luteolin,& ellagic& acid& and& quercetin& (Jenkins& et& al.,& 2010),& and& the& antiKallergy&
treatment&amlexanox&(NeetooKIsseljee&et&al.,&2013),&shared&function&as&mast&cell&stabilisers.&&






As&an&extension& to&previous& screening& campaigns&of& the&Prestwick®& small&molecule&
chemical& library& that& identified& pamoic& acid& as& an& agonist& of& GPR35& (Jenkins& et& al.,& 2010;&





(NeetooKIsseljee& et& al.,& 2013).& & Including& zaprinast,& which& was& used& as& a& positive& control,&
previous& GPR35& agonists& from& the& aforementioned& Prestwick®& chemical& library& were&
identified,&such&as&pamoic&acid,&cromolyn,&dicoumarol,&furosemide,&and&NPPB&(5KnitroK2K(3K
phenylpropylamino)benzoic& acid).& & Novel& hits& for& human& GPR35& included& the& mast& cell&
stabiliser& amlexanox,& the& anthraquinone& derivatives& emodic& acid& and& purpurin,& and& the&
kynurenic& acid& derivative& 5KfluoroindoleK2Kcarboxylic& acid& (NeetooKIsseljee& et& al.,& 2013).&&




the& MRCT’s& private& compound& collection& were& screened& using& DiscoveRx’s& βKarrestinK2&
enzyme& complementation& assay& (NeetooKIsseljee& et& al.,& 2013).& & From& these& efforts,& the&
majority& of& hit& compounds& (39%)& generated& pEC50s& between& 4.5& and& 5.3;& some& (11.5%)&











FLAGKGPR35KeYFP& and& βKarrestinK2KRenilla& luciferase,& which& interacted& following& agonist&
stimulation& to&enable&BRET&between&the&CKterminal& tags&of&each&construct& (Section! 2.7.3).&&









T&cells&were& transiently&cotransfected&with&human& (red),&mouse& (blue),&or& rat& (green)&FLAGKGPR35K
eYFP& and& βKarrestinK2KRenilla& luciferase,& with& agonistKinduced& receptor& activation& assessed& via& βK
arrestinK2& recruitment& using& BRET.& & The& species& selectivity& of& zaprinast& (A),& compound& 1& (B),&
compound&2&(C),&compound&3&(D),&compound&4&(E),&and&compound&5&(F)&is&presented.&&Each&dataset&






















































































































































































































































5.51-±-0.04 Inactive Inactive 3 3 3
100.8$±$1.8 NR NR 0 0 0
5.48-±-0.04 Inactive Inactive 3 3 3















4.70-±-0.04 <4 4.86-±-0.04 ≤-0.7 +-0.16-±-
0.08
≤-0.86










































































GPR35& does& not& couple& to& Gαq& (Fig! 3.6).& & The& Gαq13& chimera& consists& of& the& fullKlength&
sequence&of&Gαq& but&with& the& last& five& carboxyl& residues& replaced&with& the& corresponding&
sequence& of& Gα13.& & This& enabled&GPR35& to& couple& to&Gα13& and& to& signal& through& the&Gαq&
pathway,&with&agonistKinduced&IP1&accumulation&monitored&using&HTRF®&technology&(Section!
2.7.2).& & In&the&IPKOne&assay,&zaprinast&maintained&rat&selectivity&(P&≤&0.001)&and&acted&with&
moderate& potency& at& human,&mouse,& and& rat& GPR35& (Fig! 4.2A;& Table! 4.2).& & Compound& 1&
however,& acted& with& 355Kfold& selectivity& (P& ≤& 0.001)& toward& human& GPR35,& but,& in&
comparison&with& the&BRET&assay,& the&difference& in&potency& relative& to&mouse&and& rat&was&
reduced&(Fig!4.2B).&&Compound&1&also&acted&at&mouse&and&rat&with&full&agonism&in&the&IPKOne&
assay,&while&the&efficacy&at&human&GPR35&was&not&significantly&different&from&that&generated&















experiments& carried& out& in& duplicate& ±& SEM.& Efficacy& is& presented& relative& to& the&maximum&of& the&
reference&compound&zaprinast,&which&served&as&an&internal&control&between&experiments.& &
FLAG-GPR35-eYFP






































































































































































































































6.80-±-0.07 <4 <4 3 3 3








96.8$±$5.6 107.3$±$3.8 92.9$±$5.8 +$10.5$±$9.6 2$3.9$±$11.4 2$14.4$±$9.8



































































To& determine& whether& the& gain& in& potency& and& efficacy& associated& with& full& and&
partial&agonists&(respectively)&in&the&IPKOne&assay&was&indicative&of&pathway&bias,&a&reflection&
of& a&better& coupled& cell& signalling& system& (system&bias),& or& an&artefact&of& a&more& sensitive&
assay& system& (observational& bias),& Log(τ/KA)& values& were& calculated.& & Using& a& modified&
equation&of&the&Black&and&Leff&operational&model&of&agonism&(see&Section!2.8.4),&Log(τ/KA)&
values& were& generated& to& calculate& pathway& bias& using& the& transduction& coefficient&
parameter& τ/KA,& which& assessed& the& operational& affinity& and& efficacy& of& each& agonist& to&
remove&cell&system&and&observational&bias&(Kenakin&et&al.,&2012;&Kenakin&and&Christopoulos,&
2013).& & Tau& (τ)& represented& agonist& efficacy,& receptor& density,& and& coupling& within& the&
system,&while& the& dissociation& constant& (KA)& represented& the& reciprocal& of& the& conditional&
affinity&of&the&full&agonist&in&the&functional&system!(Kenakin&and&Christopoulos,&2013).&&
& The&first&column&of&Table!4.3&presents&the&transduction&coefficient&(Log(τ/KA))&values&
for& each& agonist& in& the& BRETKbased& βKarrestinK2& or& IPKOne& assays.& & The& second& column,&
ΔLog(τ/KA),& compares& each& agonist’s& transduction& coefficient& value& with& zaprinast,& with& a&
value&<1&or&>1&representing&an&agonist&with&a& transduction&coefficient& less& than&or&greater&
than&zaprinast,&respectively.&&The&third&column,&ΔΔLog(τ/KA),&compared&the&ΔLog(τ/KA)&ratios&
generated& from&the& IPKOne&assay&with& the&BRET&system&to&generate&a& single&parameter&of&
pathway&bias,&with&ratios&<1&or&>1&indicating&a&βKarrestinK2&recruitment&or&IP1&accumulation&
pathway&bias,&respectively&(Table!4.3).&
The&ΔΔLog(τ/KA)& values& for& compound&1& indicated& that& although& a& strong&bias&was&
displayed& toward& the& βKarrestinK2& recruitment& pathway& at& human& GPR35,& mouse& and& rat&

















Compound BRET, IP/One BRET, IP/One
Zaprinast 5.56 7.05 1 1 1
1 7.53 7.95 93.3 7.94 0.09
2 5.46 6.59 0.79 0.35 0.44
3 5.7 6.67 1.38 0.42 0.3
4 4.98 5.64 0.26 0.04 0.15
5 4.88 5.87 0.21 0.66 3.14
Compound BRET, IP/One BRET, IP/One
Zaprinast 6.18 7.78 1 1 1
1 5.43 6 0.18 0.66 3.67
2 NA 5.06 / 0.006 ,
3 NA NA / , ,
4 4.62 6.12 0.03 0.02 0.67
5 NA 4.93 / 0.001 ,
Compound BRET, IP/One BRET, IP/One
Zaprinast 7 8.61 1 1 1
1 4.84 5.66 0.007 0.05 7.14
2 NA 5 / 0.0002 ,
3 NA NA / , ,
4 4.35 5.6 0.002 0.001 0.5













To& assess& whether& the& potent& GPR35& antagonist& MLK145& acted& in& a& competitive&
manner&with&MRCT&compounds&1K3,&as&has&been&previously& indicated& for&GPR35&reference&
agonists& zaprinast,& pamoic& acid,& and& cromolyn& (Jenkins& et& al.,& 2010;& Jenkins& et& al.,& 2012),&
Schild&analysis&was&carried&out&using&the&global&Gaddum/&Schild&EC50&shift&analysis& (Section!
2.8.3).& & This& was& carried& out& by& an& assessment& of& the& competition& for& receptor& binding&
between& antagonist& and& agonist.& & Seven& concentrations& of& agonist& were& assessed& in& the&
presence& or& absence& of& fixed,& increasing,& antagonist& concentrations& that& had& been& preK
equilibrated&with&the&receptor&prior&to&application&of&agonist&(Section!2.8.3).&&If&the&mode&of&
action& of& the& antagonist& was& competitive,& and& these& compounds& shared& one& overlapping&
ligand& binding& site,& the& analysis& would& produce& a& Schild& slope& of& 1.& & This& calculation& also&
provided&an&estimate&of&antagonist&potency&by&generation&of&the&pA2&value.&&The&pA2&is&the&
negative& logarithm& of& the& concentration& of& antagonist& that& produces& a& 2Kfold& shift& in& the&
concentration&response&curve&of&the&agonist.&&Since&the&endogenous&ligand&of&GPR35&has&not&




MLK145&was& associated&with& an& increase& in& the& concentration& of& compound& 1& required& to&
achieve&halfKmaximal&effect& (Table! 4.4);& this&was&achieved& in&a& fully& surmountable&manner&
(Fig!4.3A).&&MLK145&displayed&similar&properties,&indicative&of&competitive&antagonism&(Table!
4.4),&when& coKincubated&with& compound&2& (Fig! 4.3B)& or& compound&3& (Fig! 4.3C);& however,&
due&to&limitation&in&the&potency&of&each&of&the&agonists,&it&was&not&possible&to&state&whether&
MLK145&was&fully&surmountable.&&In&the&IPKOne&assay,&as&demonstrated&previously&(Fig!3.9),&
increasing&MLK145& concentration& was& associated& with& a& decrease& to& the& basal& signal& as& a&
result&of&GPR35’s&constitutive&activity.& &This& inverse&agonism&invalidated&the&Schild&analysis&
and& the& values&derived& from& such& analysis;& yet& the&data& is& provided& for& completeness& (Fig!
4.4D9F).& & In& order& to& clearly& present& the& rightward& shifts& caused& by&MLK145& in& the& IPKOne&
system,& the& basal& and& maximal& values& were& constrained& at& each& set& of& concentration&





As& a& result& of& this& analysis,& it& is& apparent& that& the& MRCT& agonist& compounds& 1K3&
interact& with& human& GPR35& in& a& manner& similar& to& that& described& previously& for& wellK
characterised& GPR35& agonists& zaprinast,& pamoic& acid,& and& cromolyn& (Appendix! A).& & In&
summary,&herein&I&have&reported&the&activity&of&novel&chemical&compounds&1K5&in&the&BRET&
based&βKarrestinK2&recruitment&assay&and&the&IP1&accumulation&assay&for&human,&mouse&and&
rat&GPR35.& & These& ligands&were& found& to&act&with& species& selectivity,&which& in& some&cases&
was& conditional& upon& the& signalling& pathway& assessed.& & This& data& forms& part& a&








ConcentrationKresponse& curves&of& compound&1& (A/B)& compound&2& (C/D),& and& compound&3& (E/F)& in&
the& presence& and& absence& of& increasing&MLK145& concentrations&were& assessed& using& global& Schild&
analysis&of&agonistKinduced&BRET&(A,&C,&E)&or&Gαq13Kmediated&accumulation&of&IP1&(B,&D,&F).&&BRET&data&
are&normalised& to& the&maximum&agonist&only& response,&whilst& IPKOne&data&are&normalised& to&both&






























































































































































































































Antagonist Agonist Schild.Slope pA2 Schild.Slope pA2
Compound(1 1.09(±(0.09( 7.76(±(0.07( 1.19(±(0.08( 8.14(±(0.11
Compound(2 1.24(±(0.08( 7.79(±(0.05( 0.91(±(0.14( 7.96(±(0.25















are& currently& commercially& available,& but& were& synthesised& by& the& MRCT& and& Novartis,&
respectively,& Section! 2.1),& tranilast,& doxantrazole,& pemirolast,& and& ketotifen& fumarate& (Fig!
4.4).& & The& mast& cell& activator& compound& 48/80& was& also& assessed& as& a& compound& with&
distinct& function& (Fig! 4.4).& & Additionally,& the&mast& cell& stabilisers& and& previously& identified&







the&mast& cell& stabilisers& to& activate& human,&mouse& and& rat& GPR35.& & As& reference& agonist,&
zaprinast&generated&a&species&selectivity&profile&of&r>m>h&(Fig!4.5A;&Table!4.5)&as&described&
previously.& & Despite& a& 3Kfold& difference& in& potency& (P& ≤& 0.001)& between& human& and& rat,&
lodoxamide& became& the& first& agonist& identified& at& GPR35& to& act&with& high& nM& potency& at&
both& the& human& and& rat& orthologues& (Fig! 4.5B).& & However,& at&mouse& GPR35,& lodoxamide&
acted&with&457Kfold&(P&≤&0.001)&and&151Kfold&(P&≤&0.001)&less&potency&than&at&human&or&rat,&
respectively& (Table! 4.5).& & Bufrolin& generated& a& similar& trend& in& species& selectivity& to&
lodoxamide,& although& the& potency& of& human& and& rat&was& not& statistically& distinct& and& the&
potency&at&mouse&was&only&10&to&15Kfold&less&potent&(P&≤&0.001)&than&human&or&rat&GPR35&
(Fig! 4.5C;&Table! 4.5).& Cromolyn&also&displayed& the&h=r>m&profile&of& species& selectivity& and&





The& chemical& structures& of& quercetin,& luteolin,& cromolyn,& amlexanox,& ellagic& acid,& and& zaprinast,&
reported&mast&cell&stabilisers&and&also&GPR35&agonists&(A).&&Mast&cell&stabilisers&lodoxamide,&bufrolin,&














































































































of& zaprinast& (A),& lodoxamide& (B),& bufrolin& (C),& cromolyn& (D),& amlexanox& (E),& doxantrazole& (F),&
pemirolast& (G),&and&tranilast& (H),& to&recruit&βKarrestinK2&to&GPR35&species&orthologues& is&presented.&&
Each&dataset& represents& the&mean&of&a&minimum&of& three& independent&experiments& carried&out& in&
duplicate&±&SEM.&&Efficacy&is&normalised&as&a&percentage&of&the&maximal&zaprinast&response.&



































































































































































































































































































Ligand Human Mouse Rat M0H R0H R0M Selectivity
5.599±90.01 6.189±90.01 7.019±90.02 +90.599±90.02*** +91.429±90.03*** +90.839±90.03***
99.8$±$0.7 99.8$±$1.0 99.3$±$0.9 NA NA NA
5.389±90.05*** 6.759±90.06*** 7.639±90.07*** +91.379±90.11*** +92.259±90.12*** +90.889±90.11***
59.4$±$1.5*** 76.9$±$1.5*** 55.3$±$0.1*** +$17.5$±$3.0*** 1$4.1$±$2.1 1$21.6$±$2.1***
5.209±90.03*** 4.719±90.03*** 5.399±90.03*** 090.499±90.06*** +90.199±90.06* +90.689±90.06***














8.009±90.02*** 091.029±90.06*** +90.179±90.049 +91.199±90.06***
99.5$±$0.9 91.8$±$1.9** 100.6$±$0.1 1$7.7$±$3.0** +$1.1$±$1.3 +$8.8$±$2.7***
8.389±90.02*** 5.729±90.03*** 7.909±90.02*** 092.669±90.05*** 090.489±90.04*** +92.189±90.05***
102$±$1.0 103.2$±$1.7 102.3$±$0.8 +$1.2$±$2.8 +$0.2$±$1.8 1$0.9$±$2.7
5.479±90.07* 6.119±90.03 6.519±90.02*** +90.649±90.11*** +91.049±90.1*** +90.409±90.05***
36.5$±$1.2*** 96$±$1.2 96.2$±$1.0 +$59.5$±$2.4*** +$59.7$±$2.2*** +$0.2$±$2.2
Inactive 6.199±90.02 7.029±90.03 0 0 +90.839±90.05***
NA 111.5$±$1.0*** 100.5$±$1.1 1 1 1$11.0$±$2.1***
Inactive Inactive Inactive 0 0 0
NA NA NA 1 1 1
Inactive Inactive Inactive 0 0 0
NA NA NA 1 1 1
Inactive Inactive Inactive 0 0 0






















at& human& (P&≤& 0.05),&mouse& (P&≤& 0.01)& or& rat& (P&≤& 0.001)&GPR35& (Table! 4.5).& & Amlexanox&
displayed&partial& agonism&at&all& three& species&orthologues& (P&≤& 0.001),&with&potency&at& rat&
GPR35&being&significantly&greater&than&that&at&human&(P&≤&0.001)&or&mouse&(P&≤&0.001)&(Fig!
4.5E;& Table! 4.5).& & Meanwhile,& doxantrazole& displayed& rat& and& mouse& selectivity,& with&









& The& IPKOne& assay& was& carried& out& with& human& GPR35& only,& and& this& time& in& the&






4.6A/B).& & Amlexanox& generated& full& agonism& in& the& IPKOne& system& with& a& nonKsignificant&
difference&in&potency&between&the&two&assay&systems&(Fig!4.6C),&while&cromolyn&generated&a&
15.5Kfold&increase&in&potency&(P&≤&0.001)&between&BRET&and&IPKOne&assays&(Fig!4.6D).&&Akin&






Figure! 4.6!Mast! cell! stabilisers! generate! various! responses! in! the! IP9One! assay! IP1& accumulation&
mediated& by& the& Gαq13& chimera& and& stimulation&with& lodoxamide& (A),& bufrolin& (B),& amlexanox& (C),&

























































































































































































































Doxantrazole 5.83%±%0.19* 104.9%±%14.1 5.47%±%0.07* 36.5%±%1.2*** +%0.36%±%0.29



























































were& calculated& for& the&GPR35&agonist/mast& cell& stabilisers& to&determine& if& they&displayed&
pathway&bias.&&A&ΔΔLog(τ/KA)&ratio&<1&was&indicative&of&bias&toward&βKarrestinK2&recruitment,&
while& >1& indicated& bias& toward& IP1& accumulation& (Table! 4.7).& & All& of& the& compounds&
generated&ΔΔLog(τ/KA)& ratios& that&were& close& to& 1,& indicating& that& there&was& not& a& strong&
bias&towards&either&pathway.&&Nonetheless,&the&data&indicated&that&there&was&at&least&some&
preference&of&bufrolin& toward&G&protein&signalling&and& IP1&accumulation,&while& lodoxamide&
displayed&the&opposite&profile,&toward&βKarrestinK2&recruitment&(Table!4.7).&&Amlexanox&and&





& To& assess&whether&MLK145&behaved& in& a& competitive&manner&with& lodoxamide&and&
bufrolin,& Schild& analysis& was& carried& out& using& various& concentrations& of& agonist& in& the&
presence& and& absence& of& fixed& antagonist& concentration& as& described& previously& (Section!
4.1.5).& & In& the& βKarrestinK2& recruitment& assay,&MLK145& acted& in& a& manner& consistent& with&
competitive& antagonism& when& assessed& alongside& zaprinast& (Fig! 4.7A/B),& with& increasing&





failed& to& achieve& receptor& occupancy& at& high& antagonist& concentrations& (Fig! 4.7E).& & In&
contrast& to& the& competition& observed& between& MLK145& and& zaprinast,& the& global&




is& linear,& indicating& that& these& compounds& are&not& acting& at& distinct& sites& on& the& receptor.&
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BRET;& a& value& >1& indicates& bias& toward& the& IP1& accumulation& pathway,& and& <1& a& bias& toward& βKarrestinK2&
recruitment&pathway&
NA,&not&applicable,&K,&not&calculated&
Compound BRET, IP/One BRET, IP/One
Zaprinast 5.56 6.40 1.00 1.00 1.00
Amlexanox 5.12 6.18 0.36 0.60 1.67
Bufrolin 7.80 8.79 173.80 245.50 1.41
Cromolyn 5.14 6.22 0.38 0.66 1.74
Doxantrazole 5.01 5.82 0.28 0.26 0.93
Lodoxamide 8.40 9.05 691.80 446.70 0.65









were& assessed& in& the& absence& and& presence& of& increasing& MLK145& concentrations& using& the&
Gaddum/Schild& EC50& shift& global& analysis& in& the& βKarrestinK2& recruitment& assay.& & To& determine&
whether& the& antagonist& competition& was& linear,& the& reciprocal& of& the& log& doseKratio& was& plotted&
against& the& molar& MLK145& concentration& for& zaprinast& (B),& lodoxamide& (D)& or& bufrolin& (F).& & Each&
dataset& represents& the& mean& of& three& independent& experiments& carried& out& in& duplicate& ±& SEM,&
normalised&to&the&maximum&agonist&only&response.& &
FLAG-Human GPR35-eYFP


























































































































































































4.3! A! pharmacological! characterisation! of! GPR35! agonist! responses! in! a! cell! system!
endogenously!expressing!GPR35!&
&
& As& the& physiological& function& and& associated& signalling& pathways& have& yet& to& be&
elucidated& for& GPR35,& the& labelKfree& DMR& platform& provided& a& format& for& ligandKinduced&
responses&to&be&monitored&in&cell& lines&endogenously&expressing&GPR35.& &Since&the&pattern&
of& ligandKinduced&DMR&traces& is& reported&to&be&deterministic&of& the&G&proteins& involved& in&
receptor& coupling& (Schröder& et& al.,& 2010)& responses& generated& in& DMR& assays& were&






















Figure! 4.8! Different! GPR35! agonists! display! similar! kinetic! traces! in! the! DMR! assay& Kinetic&DMR&
traces&were&monitored&every&2&sec&for&30&min,&with&agonist&added&following&a&2&min&baseline&read.&&
Positive& DMR& occurred& in& a& concentrationKdependent& manner,& with& concentrationKresponses&
calculated& from&the&above& traces&presented& in&Fig! 4.9.& &All& traces&are&baseline&corrected& from&cells&
treated& with& vehicle& only,& with& concentrationKresponses& increasing& from& yellow& (lowest&
concentration)& to& red& (highest& concentration).& & Concentrations& used& for& each& compound& are&



















Figure! 4.9!GPR35! agonists! produce! responses! in! a! concentration9dependent!manner! in! the!DMR!
assay! using! HT929! cells& Human& colorectal& adenocarcinoma& HTK29& cells& endogenously& expressing&
human& GPR35&were& incubated& overnight& in& plates& containing&waveguide& grated& biosensors.& & DMR&
was&monitored&using& the&Epic&BT®& system,&with&positive&DMR&occurring&5&min&post& ligand&addition&
plotted& against& ligand& concentration.& & The& ability& of& compound& 1& (A),& bufrolin& (B),& lodoxamide& (C),&
amlexanox&(D),&cromolyn&(E),&and&doxantrazole&(F),& to& induce&DMR&is&presented.& &Zaprinast& (dashed&
lines)&is&presented&as&a&reference&agonist&(originally&shown&in&Fig!3.13).&Each&dataset&represents&the&
mean& of& three& independent& experiments& carried& out& in& quadruplicate& ±& SEM,& with& efficacy&
normalised&as&a&percentage&of&the&maximum&zaprinast&response.&
HT-29 Cells

















































































































































































Ligand pEC50a Emaxb pEC50a Emaxb pEC50a Emaxb









6.77%±%0.08 99.%9%±%3.2 5.59%±%0.01 99.8%±%0.7
Compound41 9.31%±%0.09*** 104.9%±%2.5 8.13%±%0.09*** 86.0%±%3.5 %7.60%±%0.03 %100.2%±%1.3





Lodoxamide 8.53%±%0.05*** 108.4%±%2.2 8.38%±%0.02***
Bufrolin




fold& decrease& (P& ≤& 0.05)& between& the& DMR& and& IPKOne& assay& systems& (Fig! 4.9C).& & For&
amlexanox,&potency&in&the&DMR&system&was&some&4Kfold&higher&(P&≤&0.05)&than&IPKOne&and&








One&of& the&most& important&aspects&of&assessing& ligandKinduced&signalling&via&HTK29&
cells&was&to&verify&that&the&response&generated&was&indeed&emanating&from&GPR35.&&In&order&
to&assess& this,& Schild&analysis&was& carried&out&using& the&GPR35&antagonist/& inverse&agonist&
MLK145.&&However,&since&GPR35&displayed&constitutive&activity&in&the&HTK29&cell&system&(data&
not& shown),& increasing&MLK145& concentration& was& accompanied& with& a& depression& to& the&




cells& in& the& DMR& assay& system.& & By& constraining& the& basal& and&maximal& DMR& response& of&
zaprinast& and& lodoxamide,& it& can& be& observed& that& incubation& with& fixed,& increasing,&
concentrations& of& MLK145& rightward& shifted& the& concentration& response& curves& of& both&
agonists& (Fig! 4.10A/B).& & This& suggested& that& the&DMR&peaks& of& zaprinast& and& lodoxamide,&
therefore,&were&generated&as&a&result&of&GPR35&agonism&in&the&HTK29&cell&system.&
&
4.3.3# A# calculation# of# agonist# bias# between# βEarrestinE2,# IP1# accumulation,# and# DMR#
pathways&
#
Transduction& coefficients& were& calculated& for& compound& 1& and& the& mast& cell&
stabiliser/&GPR35&agonists& to& identify& if&pathway&bias&existed&between& the&βKarrestinK2,& IP1&





Figure!4.10!ML9145! is! competitive!with! zaprinast! and! lodoxamide! in! the!DMR!assay!MLK145&was&
preKincubated&with&HTK29&cells&for&30&min&before&the&addition&of&zaprinast&(A)&or&lodoxamide&(B)&for&5&
min.&&Data&are&presented&as&the&DMR&responses&at&35&min&post&initial&antagonist&addition.&&Zaprinast&
represents& the&mean&±&SEM&of& two& independent&experiments,&while& lodoxamide& represents&an& the&
mean&±&SEM&of&four& independent&experiments&with&each&condition&assessed& in&duplicate.& &Data&are&


















































































calculated& pathway& bias& profile& between& IPKOne& and& BRET& assays& was& also& displayed& for&
comparison&purposes&although&it& is&appropriate&to&note&that&the&experimental&analysis&was&
carried&out&in&distinct&cell&lines&(Table!4.10).&&Interestingly,&compound&1&acted&with&clear&bias&





the& DMR& pathway& (Table! 4.10).& & Bufrolin,& cromolyn,& and& doxantrazole,& meanwhile& acted&
without& bias& while& lodoxamide& displayed& preference& toward& the& βKarrestinK2& recruitment&
pathway&(Table!4.10).&&
& Thus,& it& appears& that& a& subset& of& mast& cell& stabilisers& also& act& with& an& ability& to&
activate& GPR35,& and& at& human& GPR35& this& has& been& demonstrated& to& occur& in& a& cell& line&
endogenously& expressing& the& receptor.& & Unlike& the& MRCT& compounds& presented& herein&
however,&lodoxamide&and&bufrolin&do&not&appear&to&interact&with&the&GPR35&antagonist&MLK
145&in&a&simple&competitive&manner.&&The&characterisation&of&these&ligands&is&presented&fully&
in& the& publication& authored& by&Mackenzie& et& al.,& 2014,&which& also& presents& the&molecular&



















Compound DMR IP-One DMR IP-One
Zaprinast 6.68 6.4 1 1 1
Amlexanox 6.56 6.18 0.76 0.6 1.27
Bufrolin 9.05 8.79 234.4 245.5 0.95
CompoundF1 9.46 7.95 602.6 35.5 17
CromolynF 6.27 6.22 0.39 0.66 0.59
Doxantrazole 6.14 5.82 0.29 0.26 1.11
Lodoxamide 8.63 9.05 89.1 446.7 0.2
Compound DMR BRETF DMR BRETF
Zaprinast 6.68 5.56 1 1 1
Amlexanox 6.56 5.12 0.76 0.36 2.11
Bufrolin 9.05 7.8 234.4 173.8 1.35
CompoundF1 9.46 7.53 602.6 93.3 6.46
CromolynF 6.27 5.14 0.39 0.38 1.02
Doxantrazole 6.14 5.01 0.29 0.28 1.03
Lodoxamide 8.63 8.4 89.1 691.8 0.13
Compound BRETF IP-One BRETF IP-One
Zaprinast 5.56 6.4 1 1 1
Amlexanox 5.12 6.18 0.36 0.6 1.67
Bufrolin 7.8 8.79 173.8 245.5 1.41
CompoundF1 7.53 7.95 93.3 7.94 0.09
CromolynF 5.14 6.22 0.38 0.66 1.74
Doxantrazole 5.01 5.82 0.28 0.26 0.93













suitable&as& therapeutics&and&exist&primarily&as& tool& compounds& for& screening&campaigns& to&
elucidate& common& structural& motifs& that& are& important& for& activation& of& the& receptor.&&
Previous&small&molecule&compound&library&screening&efforts&at&GPR35&identified&pamoic&acid&








of& 100,000& small& molecules& using& the& DiscoveRx’s& PathHunter& βKarrestinK2& translocation&
enzyme&complementation&assay,&as&detailed&in&NeetooKIsseljee&et&al.,&2013.&&From&this&effort,&
GPR35& hit& compounds& with& distinct& structural& properties& were& profiled& and& assessed& in& a&
number& of& different& pharmacological& outputs& against& species& orthologues& of& GPR35.& & This&
study&culminated&in&the&identification&of&‘compound&1’&((4K{(Z)K[(2Z)K2K(2Kfluorobenzylidene)K
4KoxoK1,3KthiazolidinK5Kylidene]methyl}benzoic&acid)),&which&was&the&most&potent&agonist&of&
GPR35& reported& at& that& time,&with& a& potency&of& 25&nM& in& the&BRET& assay.& Previously,& the&




NeetooKIsseljee& et& al.,& 2013).& & Subsequently,& lodoxamide& and& bufrolin,& as& reported& herein&
and&in&Mackenzie&et&al.,&2014,&became&the&most&potent&ligands&of&GPR35,&with&EC50s&in&the&
BRET&βKarrestinK2& recruitment& assay& of& 4.2& nM&and& 14.8& nM.& &More& recently& Funke& et& al.,&
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(2013)& also& reported& a& potent& ligand& of& human&GPR35,& named& PSBK13253.& In& the& BRET&βK
arrestinK2& recruitment& assay,& PSBK13253& generates& an& EC50& of& 35& nM& (my& unpublished&
finding).&&Thus,&compound&1,&PSBK13253,&and&pamoic&acid&act&within&a&similar&potency&range&
at& the& human& receptor.& & These& compounds& are& reasonably& potent& and& are& useful& for&
understanding&of&the&pharmacology&of&the&human&receptor;&however,&their&use&is&impractical&




have& provided& in& terms& of& understanding& GPR35& receptor& pharmacology,& functional&
selectivity&(also&known&as&pathway&bias)&and&species&selectivity.&
& &




although,&with& the&exception&of& the& tricyclic& compound&5,& they&all& share&a& carboxyl& group.&&
The&mast&cell& stabilisers& lodoxamide&and&bufrolin&also&contain&carboxyl&groups,&but&akin& to&
pamoic&acid&and&cromolyn&they&are&dicarboxylates&(Fig!4.4;&Fig!3.1).& &This&suggests&that&the&
carboxyl& group& of& GPR35& ligands& may& be& important& for& receptor& recognition& and/or&
activation&(Jenkins&et&al.,&2010;&Deng&and&Fang&2012b;&Deng&et&al.,&2012d;&Funke&et&al.,&2013),&
however& ligands& that& do& not& contain& carboxylic& acids& can& activate& GPR35.& & These& ‘nonK
carboxylic&acid’&ligands&include&zaprinast&(which&contains&a&triazole&group),&doxantrazole&and&
pemirolast,& (which& contain& a& tetrazole& group)& that& act& as& carboxylic& acid& bioisosteres;&
phenols& such&as&nitecapone,& tolcapone& (Deng&et&al.,&2012b),&quercetin,& luteolin& (Jenkins&et&
al.,& 2010)& and& wedelolactone& (Deng& and& Fang& 2012a);& and& melanonitrile& containing&
molecules& (Deng&et&al.,&2011b).& &Thus,&although&there& is&not&an&absolute&requirement&for&a&
carboxyl&group&to&bind&or&to&activate&human&GPR35,&at&the&very&least&GPR35&ligands&appear&
to& be& negatively& charged& or& are& electron& withdrawing& (Jenkins& et& al.,& 2010;& Deng& et& al.,&
2011b;&2012d;&Deng&and&Fang,&2012b;&Funke&et&al.,&2013).&&&
For& ligands& that& contain& a& carboxyl& group& however,& this& group& is& imperative& for&
function.& & An& example& to& support& this& is& demonstrated& with& the& ethyl& ester& derivative& of&
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kynurenic& acid,& which& was& inactive& in& a& βKarrestinK2& recruitment& assay& at& human& and& rat&
GPR35& (Jenkins& et& al.,& 2011).& & Structure& activity& relationship& (SAR)& studies& performed& by&
researchers& based& at& Corning& also& indicated& that& changing& the& carboxylic& acid& to& an& ethyl&
ester& rendered&the&novel&structure& [3,2Kb]thiopheneK2Kcarboxylic&acid& inactive& (Deng&et&al.,&
2011b).& However,& Funke& and& colleagues& indicated& that& human& GPR35& relied& less& on& the&
negative&charge&than&either&mouse&or&rat,&as&the&ethyl&ester&of&8KbenzamidoKchromenK4KoneK
2Kcarboxylic&acid&was&able&to&recruit&βKarrestinK2&to&human&but&not&rodent&GPR35&(Funke&et&
al.,& 2013).& & Since& data& indicate& that& GPR35& ligands& containing& an& acid& bioisostere& are&
significantly&rodent&selective&(such&as&doxantrazole,&pemirolast)&(Mackenzie&et&al.,&2014),&it&is&
likely& that& ligands& with& charge& differences& preferentially& interact& with& one& GPR35& species&
orthologue&over&the&other.&
In& this& context,& since& pamoic& acid& was& a& dicarboxylic& acid& with& marked& species&
selectivity&toward&human&GPR35,&it&was&suggested&that&human&GPR35&was&likely&to&contain&
two&positively&charged&binding&regions&within&the&ligand&binding&pocket,&with&rat&GPR35&only&
having&one&positively& charged& region.& & This& theory&however,&was& invalidated& following& the&
identification&of&lodoxamide&and&bufrolin&as&human&and&rat&equipotent&agonists.&&Thus,&there&
must& be& distinct& structural& properties& within& these& ligands& that& enable& their& crossKspecies&
activity.& & Indeed,& site& directed& mutagenesis& efforts& (described& in& Chapter! Five)& used& in&
conjunction& with& receptor& homology& modelling,& indicated& that& the& cyano& group& of&
lodoxamide&and& the&propyl& appendage&of&bufrolin& interacted&with& a&human& specific& valine&
residue&at&position&2.60& (Mackenzie&et&al.,& 2014).& & Therefore,& it& appeared& that& lodoxamide&
and& bufrolin& achieved& their& equipotent& activity& at& human& and& rat& GPR35& by& binding&
differently& between& the& two& species& of& receptor.& & Understanding& which& residues& are&
meditating&these&differences& is&of&the&utmost& importance&for&the&rational&design&of&species&










including& luteolin,& ellagic& acid,& gallic& acid,& morin,& dicoumarol,& quercetin,& furosemide,&
nedrocromil,&nivimedone,&and&cromolyn&(Jenkins&et&al.,&2010;&Yang&et&al.,&2010;&Deng&et&al.,&
2012b;&Deng&and&Fang&2012a;&Yang&et&al.,&2012;&NeetooKIsseljee&et&al.,&2013;&Mackenzie&et&
al.,& 2014).& & Importantly,& this& body& of& work& indicated& that& not& all& mast& cell& stabilisers& are&
GPR35&agonists,&as&demonstrated&by&the&lack&of&activity&of&ketotifen&fumarate&and&tranilast&
at&GPR35&(Table!4.5).&&Of&the&mast&cell&stabiliser&compounds&that&activate&GPR35,&most&have&
been&marketed& as& ophthalmic& solutions.& & These& include& cromolyn& (Opticrom®),& amlexanox&
(Elics®),& lodoxamide& tromethamine& (Alomide®),& nedrocromil& sodium& (Alocril®),& and&
pemirolast& potassium& (Alamast®).& & Bufrolin& and& doxantrazole& have& not& been& marketed&
commercially.&&Unlike&cromolyn&and&counterparts,&the&nonKGPR35&agonist&ketotifen&fumarate&
(Zatidor®)& is& a& secondKgeneration& histamine&H1& receptor& antagonist& and& therefore& displays&






to&mast&cells&however,&as&various& reports& indicate& the&presence&of&GPR35# in&basophils&and&
eosinophils&(Yang&et&al.,&2010),&natural&killer&cells& (Fallarini&et&al.,&2010),&CD14+&monocytes,&
dendric&cells,&peripheral&blood&lymphocytes&(Wang&et&al.,&2006a),&and&neutrophils&(Barth&et&
al.,& 2009;& Wang& et& al.,& 2006a).& & Furthermore,&GPR35& expression& is& upregulated& following&
exposure& of& primary& human& macrophages& to& the& polycyclic& aromatic& hydrocarbon&
benzo(a)pyrene& (Sparfel& et& al.,& 2010).& & In& mouse&GPR35& was& found& to& be& expressed& to& a&
higher& level& in& proKinflammatory& thioglycollate& elicited& peritoneal& macrophages& following&
activation& by& LPS& when& compared& with& antiKinflammatory& bone& marrow& derived&
macrophages& (Lattin& et& al.,& 2008).& & Based& on& this& information,& it& seems& likely& that& the&
function&of&GPR35& is& not& exclusive& to& the&modulation&of&mast& cell& responses.& & Indeed,& the&
aforementioned& GPR35& ligands& can& modulate& the& release& of& proKinflammatory& mediators&
including&histamine&and&TNFKα&from&both&mast&cell&and&nonKmast&cell&populations&(Yanni&et&





consider& the& use& of& a& GPR35& antagonist& to& dissect& whether& the& emanating& responses& are&
actually&a&result&of&GPR35Kspecific&activation.& & Investigations&should&focus&on&pathways&and&
processes& that& are& shared& amongst& different& immune& cell& populations& and& not& simply& by&
mast& cells.& & GPR35& has& been& shown& to& play& a& direct& role& in& leukocyte& extravasation,& as&
kynurenic&acid&induced&adhesion&of&leukocytes&to&vascular&endothelial&cells&and&shedding&of&
neutrophil& LKselectin& from&human&peripheral&monocytes& in&a&manner& that&was&significantly&







& Derivatives& of& LPA& have& been& indicated& to& act& as& endogenous& ligands& of& human&
GPR35,&with&their&activity&leading&to&an&increase&in&[Ca2+]i&(Oka&et&al.,&2010).&&When&GPR35&is&
present,& the& increase& in& [Ca2+]i& was& greater& than& that& observed& in& nonKGPR35& transfected&
cells& (Oka&et&al.,&2010).& &Since&GPR35&does&not&couple&to&Gαq& (at& least& following&treatment&
with&zaprinast,&Jenkins&et&al.,&2012)&and&if&LPA&is&directly&interacting&with&GPR35,&it&must&do&
so&in&a&ligand&biased&manner.&&Further&to&this,&application&of&LPA&to&cells&expressing&human&
GPR35&does&not& result& in&βKarrestinK2& recruitment& (Southern&et& al.,& 2013),& revealing,& quite&
intriguingly,& that& ligands& with& this& profile& of& ligand& bias& at& GPR35& would& not& have& been&
detected&by&widely&used&(βKarrestinK2&recruitment)&assays&for&this&receptor.&
As& the& activation& of& GPR35& by& LPA& has& never& been& confirmed& by& an& independent&






CIDK2745687& and& small& interfering& RNAs& were& found& to& attenuate& the& kynurenic& acid&
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kynurenic& acid& and& zaprinast& reduce& [Ca2+]i&mobilisation.& & However,& it& is& possible& that& LPA&
acts&as&an&antagonist&of&GPR35&to&increase&[Ca2+]i,&as&the&mode&of&action&of&LPA&has&not&been&
determined&at&GPR35.& &This&may&also&explain&why&LPA&did&not& stimulate& recruitment&of&βK
arrestinK2& (Southern& et& al.,& 2013).& & Further& evidence& to& support& the& role& of& GPR35& in& the&
modulation&of&[Ca2+]i&mobilisation&was&generated&in&a&very&recent&paper&that&claims&to&have&
found& the& true& endogenous& ligand& of& GPR35:& an& orphan& chemokine& CXCL17& (MaravillasK
Montero& et& al.,& 2014).& & Importantly& this&work& (although& it& does& not& provide& evidence&of& a&
direct&association&between&the&two&proteins)&indicates&that&in&cells&expressing&GPR35&there&is&
an& increase& in& [Ca2+]i& mobilisation& following& application& of& CXCL17& to& transfected& human&
monocytic& leukaemia& THPK1& cells& and& transfected&HEK293& cells& (MaravillasKMontero& et& al.,&
2014).& & Importantly,& and&unlike& the&previous& two&papers,& this& study& indicated& that&CXCL17&
acted& in& a& Gαi/o& dependent&manner,& as& the& increase& in& [Ca2+]i& mobilisation& was& abolished&





to& block& [Ca2+]i&mobilisation& at&mouse& and& rat& GPR35?& Is& CIDK2745687& acting& in& a& species&
selective,&ligand&biased&manner?&&
Species& selective& ligand& bias& has& not& been& widely& reported,& although& one& study&
detailed& this& for& the& κKopioid& receptor& (κOR).& & Pentazocine,& a& κKopioid& receptor& partial&
agonist,&was&found&to&be&significantly&more&potent&in&the&activation&of&p38&MAPK&at&human&
κOR& compared& with& rat& κOR,& while& both& species& orthologues& responded& equally& to&
phosphorylate&ERK&when&activated&with&the&same&ligand&(Schattauer&et&al.,&2012).&&My&data&
present&an& interesting&profile&of& functional& selectivity,&with& the& ligand&bias&of& compound&1&
being&completely&reversed&between&human&and&rodent&orthologues&of&GPR35&(Table!4.3).&&At&
human& GPR35,& compound& 1& strongly& couples& GPR35& to& the& βKarrestinK2& recruitment&
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rodent& orthologues& are& responsive& to& CIDK2745687& however,& as& neither& CIDK2745687& nor&
MLK145&substantially&reduced&the&zaprinast&signal&at&rat&GPR35& in&the&presence&of&Gαq13& in&
the& IPKOne&assay&(Section!3.8),&other&than&perhaps&fullKlength&G&proteins&may&be&required.&&
Thus,& future& studies& may& wish& to& assess& CIDK2745687& and& MLK145& antagonism& of& cAMP&






now& a& large& number& of& chemically& diverse& ligands& available& (Table! 1.3;& Table! 1.4).& & Drug&
discovery&efforts&with&the&MRCT&identified&a&large&number&of&chemically&diverse&ligands&that&
activated& human&GPR35,& however&most& of& these& acted&with& relatively& low& potency& at& the&










& GPCRs& are& placed& under& considerable& evolutionary& pressure& to& maintain&
responsiveness& to& their& endogenous& ligand(s)& in& order& to& retain& responsiveness& to& their&
biological& cue(s).& & This& is& particularly& apparent& for& receptors& that& modulate& ancient& and&
conserved&evolutionary&functions&such&energy&homeostasis,&reward,&and&wakefulness.&&A&key&
molecule& in& these&processes& is&orexin&A.& &The&amino&acid& sequence&of&orexin&A& is& identical&
Chapter&Four:&GPR35&Drug&Discovery&!
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al.,& 1999;& Peyron& et& al.,& 2000).&When& a&GPCR& is& involved& in& biological& processes& that& have&
diverged& over& time& however,& the& degree& of& evolutionary& pressure& to&maintain& the& ligandK
binding&pocket&is&reduced&and&may&be&altered&to&meet&the&new&and&specific&requirements&of&
the& organism.& & The& most& notable& examples& of& this& are& receptors& that& are& involved& in&
immunity,& exemplified& mainly& by& studies& involving& the& histamine,& chemokine,& and&
proteinaseKactivated& receptors.& & Such& marked& species& selectivity& has& been& attributed& to&
vastly&different&concentrations&of&the&endogenous&molecule&produced&between&species,&the&
absence&of&a&rodent&counterpart&to&the&endogenous&human&ligand,&or&receptors&carrying&out&
completely&distinct& functions& in&different&species& (Strasser&et&al.,&2013;&Zlotnik&et&al.,&2006;&
Coughlin,&2005;&NakanishiKMatsui&et&al.,&2000;&Steinhoff&et&al.,&2005).&&
& As& described& in& Section! 4.4.3,& GPR35& appears& to& play& a& role& in& the& chemotaxis& or&
migration& of& leukocytes& to& the& site& of& inflammation& (Barth& et& al.,& 2009).& & It& is& therefore&
important& to& note& that& there& are& marked& differences& in& the& composition& of& these& cells&
between&human&and&mouse,&with&peripheral&blood&containing&a&ratio&of&50K70&%&neutrophils&
to& 30K50%& leukocytes,& in& human& and& 75K90& %& leukocytes& to& 10K25& %& neutrophils& in& the&
mouse&(Mestas&and&Hughes,&2004).&&Furthermore,&mice&lack&twentyKor&so&of&the&αKdefensins&
present& in& rat& and& human,& and& completely& lack& expression& of& myeloid& defensins& in& their&
neutrophil&population&(Eisenhauer&et&al.,&1992;&Shanahan&et&al.,&2011).&&It&is&therefore&quite&






Zlotnik& and& Yoshie,& 2000).& & Fittingly,& the& orphan& chemokine& CXCL17& was& most& recently&
reported& as& an& endogenous& ligand& of& human& GPR35& (MaravillasKMontero& et& al.,& 2014).&&




the& protein& sequence& is& not& completely& conserved& (Fig! 4.11),&with& human& and& rat& CXCL17&
sharing&62&%&identity,&human&and&mouse&sharing&71&%&identity,&and&ratKandKmouse&sharing&
80& %& identity.& & Thus& it& is& plausible& that& this& ligand& acts& in& a& species& selective& manner& at&
GPR35.& & This& is& not& a& foregone& conclusion& however,& and& it&may& be& pertinent& to& note& that&
although& the& histamine& H1,& H2,& and& H3& receptors& display& significant& species& selectivity& to&






human&and&rat&GPR35& in&an&equipotent&manner& (Fig! 4.5).& &This& is& important&as& it& indicates&
firstly& that& it& is& possible& to& achieve& ligands& that& act& in& the& same& concentration& range& at&
GPR35,& and& secondly,& it& provides& ligands& that& can& be& assessed& in& comparison& with& those&
displaying&marked&species&selectivity&to&enable&identification&of&residues&important&in&ligand&
binding& at&GPR35.& & Indeed,& although& it& has& been&well& documented& that& species& selectivity&
hinders& the& pathway& towards& assessment& of& preKclinical& efficacy,& the& differences& in&
responses&between&species&orthologues&can&also&be&looked&upon&as&a&useful&means&to&help&
decipher& receptorKligand&binding& interactions.& &This&approach&has&been&successful& in&aiding&
characterisation&of& the& free& fatty& acid& receptors,& namely& FFA2&and&FFA3,&whereby&a& single&
negatively&charged&residue&in&ECL2&was&found&to&differ&between&the&human&and&mouse&that&
differentially&regulated&the&potency&of&the&endogenous&ligand&propionate&and&also&the&level&
of& ligandKfree& constitutive& activity& observed& (Hudson&et& al.,& 2012a).& & Furthermore,& a& single&
residue& between& human& and& bovine& FFA2& was& identified& and& when& reciprocally& altered,&
generated& pharmacology& at& the& human& receptor& that& was& similar& to& bovine& responses;&
addition& of& a& second& mutation& to& human& FFA2& completely& ablated& responsiveness& to&
endogenous& ligands,& but& importantly,& retained& the& ability& to& respond& to& synthetic& ligands&
(Hudson& et& al.,& 2012b).& & This& led& to& the& development& of& a& Receptor& Activated& Solely& by&







Mouse           MKLLASPFLLLLPVMLMSMVFSSPNPGVARSHGDQHLAPRRWLLEGGQECECKDWFLQAP 60 
Rat             MKLLASPFLLLLTGMFTATVSSSPNQEVARHHGDQHQAPRRWLWEGGQECDCKDWSLRVS 60 
Human           MKVLISSLLLLLPLMLMSMVSSSLNPGVARGHRDRGQASRRWLQEGGQECECKDWFLRAP 60 
                **:* *.:****. *: : * ** *  *** * *:  *.**** ******:**** *:.. 
 
Mouse           KRKATAVLGPPRKQCPCDHVKGREKKNRHQKHHRKSQRPSRACQQFLKRCHLASFALPL  119 
Rat             KRKTTAVLEPPRKQCPCDHVKGSEKKNRRQKHHRKSQRPSRTCQQFLKRCQLASFTLPL  119 
Human           RRKFMTVSGLPKKQCPCDHFKGNVKKTRHQRHHRKPNKHSRACQQFLKQCQLRSFALPL  119 
                :**  :*   *:*******.**  **.*:*:****.:: **:******:*:* **:*** 
&
Figure! 4.11! CXCL17! sequence! alignment! indicates! shared! sequence! between! species& FullKlength&
protein& sequences& were& downloaded& from& NCBI& nucleotide& for& human,& mouse,& and& rat& CXCL17&
(http://www.ncbi.nlm.nih.gov/nuccore)&and&aligned&using&the&multiple&sequence&alignment&function&
from& ClustalW& (http://www.ebi.ac.uk/Tools/msa/clustalw2).& An& asterisk& indicates& a& conserved&












no& consensus& had& been& reached& on& the& endogenous& ligand& of& GPR35& at& the& time& of& this&

























Species& selectivity& surrounding&GPR35& has& been& documented& for& almost& all& ligands&
reported.&&Most&notably,&the&proposed&endogenous&ligand&of&GPR35,&kynurenic&acid,&suffers&
from& pronounced& species& selectivity,& as& although& activating& the& rat& orthologue& at& a&
concentration& obtainable& under& physiological& conditions& (pEC50& 7.13&±& 0.16)& (Wang& et& al.,&
2006a),&at&the&human&receptor&kynurenic&acid&is&close&to&inactive&(Oka&et&al.,&2010;&Jenkins&et&
al.,& 2011).& & Even& the& GPR35& reference& compound,& zaprinast,& displays& species& selective&
characteristics& (Taniguchi& et& al.,& 2006)& with& a& receptor& preference& of& rat>mouse>human&
(Jenkins&et&al.,&2012).&
Species& selectivity& is& not& unique& to& GPR35,& and& has& been& documented& for& various&
other&GPCRs& including& the& free& fatty& acid& receptors& FFA2& and& FFA4& (Hudson& et& al.,& 2012a;&
2012b;&2013a;&2013b;&2013c)&and&the&histamine&H1,&H2,&H3&and&H4&receptors&(Strasser&et&al.,&
2009,& Preuss,& 2007;& Yao& et& al.,& 2003;& Igel& et& al.,& 2010;& Strasser& et& al.& 2013).& & Comparisons&
between& species& orthologues& are& commonplace& within& the& drug& development& process.&&
Animal&models,& particularly& rodents,& are& employed& to& validate& the& pharmacodynamic& and&
toxicological& profile& of& ligands& prior& to& progression& toward& the& latter& stages& of& drug&
development&(Hughes&et&al.,&2011).&&Thus,&early&identification&and&understanding&of&species&
selectivity& is& key& to& the& successful& profiling& of& ligands& during& the& later& stages& of& drug&
development&efforts.&
& &
5.1.1# Investigating# the# mode# of# ligand# binding# using# GPR35# ligands# with# various# species#
selectivity#profiles&
&
In&some& instances,& for&orthologues&with&high&sequence&similarity,& the&divergence&of&
only& one& amino& acid& is& sufficient& to& mediate& species& selective& responses,& such& as& for& the&








The& human& selective& ligands&were& represented& by& the& previously& described& GPR35&
ligands&pamoic&acid& (Chapter! Three),&and&compound&1& (Chapter! Four),&which& in& the&BRETK
based&βKarrestinK2& recruitment& assay& acted&with& partial& and& full& efficacy,& respectively,& and&
generated&species&selective&profiles&of&h>r>m&(Fig!5.1A/B;&Table!5.1).& &The&rodent&selective&
compounds& chosen& for& investigation&were& zaprinast& and&amlexanox& (Chapter! Four),&which&
acted&with&full&and&partial&efficacy&respectively,&and&generated&species&selectivity&profiles&of&
r>m>h& (Fig! 5.1C/D;&Table! 5.1).& & The& human& and& rat& equipotent& pair& of& ligands& chosen& for&
assessment& herein& were& the& mast& cell& stabilisers& and& newly& identified& GPR35& agonists,&







Fang,& 2012a;& 2012c;& Funke& et& al.,& 2013;& NeetooKIsseljee& et& al.,& 2013),& and& for& this& reason&
sequence& alignments& were& performed& with& other& GPCRs& that& are& activated& by& carboxylic&
acids& (Fig! 5.3).& &This& sequence&alignment& indicated& that&R3.36&was&conserved&amongst& the&
hydroxycarboxylic,&oxoeicosanoid,&and&GPR35&receptors.& &The&importance&of&this&residue&at&








a& series& of& species& swap&mutations,&whereby& arginine& residues&were&mutated& to& the& nonK
arginine&present& in& the&opposite& species& orthologue.& & Four& arginine& residues:& R4.62& in& rat,&





acid& (A),& compound& 1& (B),& zaprinast& (C),& amlexanox& (D),& lodoxamide& (E),& and& bufrolin& (F)& were&
assessed& using& human& (red),& mouse& (blue),& or& rat& (green)& FLAGKGPR35KeYFP& constructs& for& their&






































































































































































































































Zaprinast 5.59$±$0.01 99.8$±$0.7 6.09$±$0.03*** 99.8$±$1.0 +$0.50 7.01$±$0.02*** 99.3$±$0.9 +$1.42
Amlexanox 5.38$±$0.05 59.4$±$1.5*** 6.58$±$0.04*** 79.3$±$1.5*** +$1.20 7.63$±$0.07*** 55.3$±$0.1*** +$2.25
Pamoic.Acid 7.25$±$0.05 57.6$±$1.7*** Inactive NR NA $4.87$±$0.10*** 19.2$±$1.3*** ;$2.38
Compound.1 7.55$±$0.03 99.9$±$1.1 4.83$±$0.06*** 65.1$±$2.5*** ;$2.72 5.14$±$0.08*** 41.7$±$1.8*** ;$2.41
Lodoxamide $8.38$±$0.02 102.0$±$1.0 4.74$±$0.09 100.5$±$6.7 ;$3.64 7.90$±$0.02*** 102.3$±$0.8 ;$0.48









of&doxantrazole,&and& the& tricyclic& structure&of&amlexanox,&which&are& representative&of&a&number&of&




















































































Figure! 5.3! Arginine! 3.36! is! conserved! at! the! hydroxycarboxylic,! oxoeicosanoid,! and! GPR35!
receptors& FullKlength& protein& sequences& were& downloaded& from& NCBI& nucleotide&
(http://www.ncbi.nlm.nih.gov/nuccore)&and&aligned&using&the&multiple&sequence&alignment&function&
from& ClustalW& (http://www.ebi.ac.uk/Tools/msa/clustalw2)& to& provide& sequence& alignments&
between& a& segment& of& transmembrane& domain& 3& containing& the& arginine& 3.36& residue& for& human&
GPR35,& hydroxycarboxylic& acid& (HCA1,& HCA2,& and& HCA3),& and& oxoeicosanoid& (OXE)& receptors& (A).&&
R3.36& is& also& conserved& between& human,& mouse,& and& rat& orthologues& of& GPR35& (B).& & The& highly&
conserved&DRY&sequence&of&the&class&A&family&of&GPCRs&is&also&indicated&in&bold.&&An&asterisk&indicates&







Figure! 5.4! Arginine! residues! that! differ! in! sequence! between! human! and! rat! GPR35! FullKlength&
human& GPR35a& and& rat& GPR35& protein& sequences& were& downloaded& from& NCBI& nucleotide& and&
aligned& using& the&multiple& sequence& alignment& function& from& ClustalW.& & Amino& acids& with& shared&
identity&are&marked&*,&conserved&amino&acids&are&indicated&with&a&colon&and&semiKconserved&amino&













Human   MNGTYNTCGSSDLTWPPAIKLGFYAYLGVLLVLGLLLNSLALWVFCCRMQQWTETRIYMT 60 
Rat     MNNTN----CSILPWPAAVNHIFTIYLVLLLVLGLLLNGLALWVFCYRMHQWTETRVYMT 56 
        **.*     .* *.**.*::  *  ** :*********.******* **:******:*** 
 
Human   NLAVADLCLLCTLPFVLHSLR-DTSDTPLCQLSQGIYLTNRYMSISLVTAIAVDRYVAVR 19 
Rat     NLAVADVCLLCSLPFVLYSLKYSTSDTPICQLSQGIYLVNRYMSISLVTAIAVDRYVAVR 16 
        ******:****:*****:**: .*****:*********.********************* 
 
Human   HPLRARGLRSPRQAAAVCAVLWVLVIGSLVARWLLGIQEGGFCFRS-TRHNFNSMAFPLL 178 
Rat     HPLRARELRSPRQAGAVCVALWVIVVTSLVLRWRLGIQEGGFCFSSQNRYNFSTTAFSLL 176 
        ****** *******.***..***:*: *** ** ********** * .*:**.: **.** 
 
Human   GFYLPLAVVVFCSLKVVTALAQRPPTDVGQAEATRKAARMVWANLLVFVVCFLPLHVGLT 8 
Rat     GFYLPLAIVVFCSLQVVTALARRPATDVEQVEATQKATRMVWANLAVFIICFLPLHLILT 6 
        *******:******:******:**.*** *.***:**:******* **::******: ** 
 
Human   VRLAVGWNACALLETIRRALYITSKLSDANCCLDAICYYYMAKEFQEASALAVAPSAKAH 298 
Rat     VQVSLNLHTCAARNIFSRALTITAKLSDINCCLDAICYYYMAKEFQDASLRATA-SSTPH 295 
        *::::. ::**  : : *** **:**** *****************:**  *.* *:..* 
 
Human   KSQDSLCVTLA 309 
Rat     KSQDTQSLSLT 306 






















R4.62L& (rat),& R6.58Q& (human),& and& R7.32S& (human).& & Additionally,& and& since& it& was&
hypothesised& that&R6.58&and&R7.32&were&acting& together&at& the& top&of& the&human&binding&
pocket,& a& double&mutant&was& created& that& encoded&R6.58Q& and&R7.32S& in& human&GPR35.&&
Equally,&gain&of&arginine&mutants&were&generated&by&reversing&the&species&swaps,&such&that&
S164R& (rat),& L4.62R& (human),&Q6.58R& (rat),& S7.32R& (rat)& and& the&double&mutant&Q6.58R&and&
S7.32R& (rat)& were& generated.& & Each& mutant& receptor& was& confirmed,& using& the& FLAG& NK
terminal&epitope&tag&with&cell&surface&ELISA,&as&being&expressed&at&the&cell&surface.&&To&assess&






To&determine&whether& loss&of& arginine& residues&R164S,&R6.58Q,&and&R7.32S&affected&
ligand&binding&at&human&GPR35,&each&category&of&ligands&was&assessed&in&terms&of&losses&or&









≤& 0.001),& respectively& (Fig! 5.5B;& Table! 5.2).& & The& potency& of& the& rodent& selective& ligands&
zaprinast&and&amlexanox&was&less&affected&by&the&R164S,&R6.58Q,&and&R7.32S&forms&of&human&
GPR35.& &At&R6.58Q&human&GPR35&zaprinast&generated&a&small&but&significant&(P&≤&0.001)&3K
fold&decrease& in&potency& from&wild& type,&while&at&R7.32S& there&was&a& small&but& significant&
2.5Kfold&increase&(P&≤&0.001).&&Expression&of&R164S,&meanwhile,&did&not&significantly&affect&the&










experiments& carried& out& in& duplicate.& & Efficacy& was& normalised& as& a& percentage& of& the& maximal&
zaprinast&response&generated&at&each&individual&mutant.&&! &
FLAG-Human GPR35a-eYFP


























































































































































































































Ligand pEC50 pEC50b ΔpEC50c pEC50b ΔpEC50c pEC50b ΔpEC50c
Pamoic%Acid 7.25$±$0.05 6.00$±$0.04***$ 0$1.25 6.34$±$0.15$*** 0$0.91 6.07$±$0.05***$ 0$1.48
Compound%1 7.55$±$0.03 6.94$±$0.04*** 0$0.61 5.84$±$0.09*** 0$1.71 6.48$±$0.03*** 0$1.90
Zaprinast 5.59$±$0.01 5.11$±$0.05*** 0$0.48 5.99$±$0.09*** +$0.40 5.65$±$0.04 +$0.06
Amlexanox 5.38$±$0.05 5.54$±$0.11 +$0.16 5.86$±$0.15* +$0.47 5.18$±$0.08 0$0.20
Lodoxamide 8.38$±$0.02 $8.19$±$0.09 0$0.19 6.83$±$0.01*** 0$1.55 6.13$±$0.11*** 0$1.12


















Since& the&arginine& residues&positioned&at&6.58&and&7.32&were&believed& to&be&acting&
with&R3.36&to&coordinate&ligand&binding&between&the&top&and&bottom&of&the&binding&pocket,&
respectively,& and& given& their& close& proximity&within& ECL3,& I& decided& to& test&whether& R6.58&
and& R7.32&were& acting& together& to& orchestrate&βKarrestinK2& recruitment& at& human&GPR35.&&
The&effect&of&pamoic&acid&was&completely&ablated&following&expression&of&the&R6.58Q/R7.32S&
construct,& equating& to& a& ≥& 1778Kfold& reduction& in& potency,& while& for& compound& 1& the&
reduction&in&potency&was&200Kfold&(P&≤&0.001)&(Fig!5.6A/B;&Table!5.3).&&The&rodent&selective&
ligands& zaprinast& and& amlexanox& conversely& were& not& affected& to& a& similar& extent,& and&









swaps& at& rat& GPR35.& & Addition& of& arginine& residues& Q6.58R,& S7.32R& and& the& double&




Figure!5.6!R6.58!and!R7.32!act! together! at!human!GPR35! to! recruit!β 9arrestin92!Using&the&BRETK
based&methodology&of&βKarrestinK2&recruitment,&the&effect&of&wild&type&(black),&R6.58Q&(red),&R7.32S&
(blue)&and&R6.58Q/R7.32S&(green)&was&monitored&on&response&to&pamoic&acid&(A),&compound&1&(B),&
zaprinast& (C),& amlexanox& (D)& lodoxamide& (E),& and& bufrolin& (F).& & Data& are& the& mean& ±& SEM& of& a&
minimum&of&three& independent&experiments&carried&out& in&duplicate.& &Efficacy&was&normalised&as&a&
percentage&of&the&maximal&zaprinast&response&generated&at&each&individual&mutant.&&! !
FLAG-Human GPR35a-eYFP










Arg 6.58 Gln, Arg 7.32 Ser




































































































Arg 6.58 Gln, Arg 7.32 Ser










































































































Pamoic%Acid 7.25$±$0.05 6.00$±$0.04*** ,$1.25 6.34$±$0.15*** ,$0.91 <4 N/A
Compound%1 7.55$±$0.03 6.94$±$0.04*** ,$0.61 5.84$±$0.09*** ,$1.71 5.25$±$0.20*** ,$2.30
Zaprinast 5.59$±$0.01 5.11$±$0.05*** ,$0.48 5.99$±$0.09*** +$0.40 5.08$±$0.05*** ,$0.51
Amlexanox 5.38$±$0.05 5.54$±$0.11 +$0.15 5.86$±$0.15* +$0.47 5.74$±$0.11 +$0.35
Lodoxamide 8.38$±$0.02 $8.19$±$0.09 ,$0.19 6.83$±$0.01*** ,$1.55 <4 N/A







acid& and& 34Kfold& (P& ≤& 0.001)& for& compound& 1& (Fig! 5.7A/B;&Table! 5.4).& & However,& although&




pamoic& acid,& while& for& compound& 1& this& was& 6.8Kfold& (P& ≤& 0.01).& & Expression& of& the& S161R&
mutant& increased& the& potency& of& pamoic& acid& 5.1Kfold& (P& ≤& 0.05)& at& rat& GPR35,& while& for&
compound&1&there&was&no&alteration&of&the&potency&from&the&wild&type&response&(Fig!5.7A/B;&
Table! 5.4).& & Although& the& potency& was& increased& for& pamoic& acid& following& mutation& of&
Q6.58R,&S7.32R&and&the&double&Q6.58R/S7.32R&mutant,&the&efficacy&was&low&(Emax&<&20&%)&for&
all&but&the&S7.32R&mutant&(Emax&57.6&±&1.2&%)&(Fig!5.7A).&&Compound&1&also&acted&with&partial&
efficacy& at& rat&GPR35& (Emax& 41.7&±& 1.8&%),& but& the& efficacy& generated& at& each&mutant&was&
higher&than&that&associated&with&pamoic&acid&(Fig!5.7B).&&
Expression&of& the&single&or&double&Q6.58R&and&S7.32R&mutants&did&not& significantly&










& The& last& species& selective& arginine& residue& assessed&was& rat& R4.62& (L4.62& at& human&
GPR35)& and& following& site&directed&mutagenesis,& constructs& that& expressed&R4.62L& (rat)& or&
L4.62R& (human)&were& generated.& & Although& pamoic& acid& and& compound& 1& did& not& display&
high& potency& at& wild& type& rat& GPR35,& expression& of& R4.62L& completely& ablated& such&
responses&(Fig!5.8A/B;&Table!5.5).& &Expression&of&the&equivalent&mutation&at&human&GPR35&








amlexanox& (D)& lodoxamide& (E),&and&bufrolin& (F).& &Data&are& the&mean&±& SEM&of&a&minimum&of& three&
independent&experiments&carried&out& in&duplicate.& &Efficacy&was&normalised&as&a&percentage&of& the&
maximal&zaprinast&response&generated&at&each&individual&mutant.&&& !
FLAG-Rat GPR35-eYFP










Gln 6.58 Arg, Ser 7.32 Arg
Ser 161 Arg




































































































Gln 6.58 Arg, Ser 7.32 Arg
Ser 161 Arg









































































































Ligand pEC50 pEC50b ΔpEC50c pEC50b ΔpEC50c pEC50b ΔpEC50c pEC50b ΔpEC50c
Pamoic%Acid $4.87$±$0.10$ $5.83$±$0.14* +$0.96 $6.20$±$0.06*** +$1.33 $6.41$±$0.35*** +$1.54 5.58$±$0.17 +$0.71
Compound%1 5.14$±$0.08 6.52$±$0.08*** +$1.38 5.97$±$0.04** +$0.83 $6.67$±$0.24*** +$1.53 $5.31$±$0.17 +$0.17
Zaprinast 7.01$±$0.02 6.97$±$0.08 4$0.04 7.03$±$0.06 +$0.02 6.77$±$0.20 4$0.24 6.43$±$0.04** 4$0.58
Amlexanox 7.63$±$0.07 7.47$±$0.06 4$0.16 7.75$±$0.08 +$0.12 7.21$±$0.21 4$0.42 7.12$±$0.05* 4$0.51
Lodoxamide 7.90$±$0.02 8.09$±$0.08 +$0.19 8.25$±$0.08 +$0.35 8.15$±$0.20 +$0.25 7.45$$±$0.03* 4$0.45











human& (filled& squares),& rat& (filled& circles),& human& L4.62R& (open& squares)& and& the& rat& R4.62L& (open&
circles)& GPR35& was& measured& on& response& to& pamoic& acid& (A),& compound& 1& (B),& lodoxamide& (C),&
bufrolin& (D)& zaprinast& (E),& and& amlexanox& (F)& using& the& BRETKbased&βKarrestinK2& recruitment& assay.&&
Data&are&the&mean&±&SEM&of&a&minimum&of&three&independent&experiments&carried&out&in&duplicate.&&
Efficacy& was& normalised& as& a& percentage& of& the& maximal& zaprinast& response& generated& at& each&
individual&mutant.&&& !
FLAG-GPR35-eYFP







Rat GPR35 WT 
Rat Arg 4.62 Leu
Hum GPR35a WT 
Hum Leu 4.62 Arg

































































































Rat Arg 4.62 Leu
Rat GPR35 WT 
Hum GPR35a WT 
Hum Leu 4.62 Arg











































































































Pamoic%Acid 7.25$±$0.05 7.53$±$0.03 +$0.28 $4.87$±$0.10$ <4 NA
Compound%1 7.55$±$0.03 7.81$±$0.03 +$0.26 5.14$±$0.08 <4 NA
Lodoxamide $8.38$±$0.02 8.82$±$0.05*** +$0.44 7.90$±$0.02 6.58$±$0.07*** 3$1.32
Bufrolin 7.83$±$0.02 8.09$±$0.05* +$0.26 8.00$±$0.02 7.00$±$0.04*** 3$1.00
Zaprinast 5.59$±$0.01 6.01$±$0.02*** +$0.42 7.01$±$0.02 5.98$±$0.02*** 3$1.03










increase& in& the& potency& for& lodoxamide& following& expression&of& L4.62R&human&GPR35& (Fig!
5.8C;& Table! 5.5).& & Similarly,& bufrolin& recorded& a& 10Kfold& (P& ≤& 0.001)& reduction& in& potency&
following& expression& of& R4.62L& rat& GPR35& and& a& 1.8Kfold& increase& in& potency& (P& ≤& 0.05)&
following&expression&of&L4.62R&human&GPR35&(Fig!5.8D;&Table!5.5).&&This&trend&was&observed&
in& the& potencies& of& zaprinast& and& amlexanox.& & Zaprinast& showed& a& 10.7Kfold& (P& ≤& 0.001)&








ligand& binding,& species& conserved& residues& were& identified& via& receptor& modelling& efforts&
based&on& the&β2Kadrenergic& receptor& (Rasmussen& et& al.,& 2007;& Cherezov& et& al.,& 2007),& and&
more&recently,&the&PAR1&receptor&(Zang&et&al.,&2012)&that&were&likely&to&be&involved&in&ligand&
binding&at&human&GPR35.& &Residues&at&positions&3.32,&3.36,&4.60&and&7.43&were&chosen&for&





























& Since& the& R4.60A& mutant& was& found& to& be& unresponsive& in& the& βKarrestinK2&
recruitment&assay&(data&not&shown),&an&R4.60M&mutant&was&generated&and&assessed&herein.&&
The& ability& of& zaprinast& (Fig! 5.10A)& to& recruit& βKarrestinK2& was& completely& abolished& at&
R4.60M& human& GPR35,& although& all& of& the& other& ligands& tested& retained& at& least& some&
functionality&at&this&form&of&GPR35&(Table!5.7).&&It&is&for&this&reason&that&the&data&presented&




mutation& at& rat&GPR35& completely& ablated& the& ability& of& amlexanox& to& recruit&βKarrestinK2&
(Fig!5.10B;&Table!5.7).&&Pamoic&acid&meanwhile&generated&a&33Kfold&(P&≤&0.001)&reduction&in&
potency& at& R4.60M& human& GPR35& but& was& not& significantly& affected& by& the& equivalent&
mutation&at&rat&(Fig!5.10C;&Table!5.7).&&Similarly,&compound&1&recorded&a&190Kfold&(P&≤&0.001)&
reduction& in& potency& at& R4.60M& human& GPR35& and& was& not& significantly& affected& by&
expression&of&R4.60M&rat&GPR35&(Fig!5.10D;&Table!5.7).&Unlike&the&humanKselective&ligands,&
however,&the&potencies&of&lodoxamide&(Fig!5.10E)&and&bufrolin&(Fig!5.10F)&were&significantly&
reduced& following& mutation& of& R4.60M& in& both& human& and& rat& GPR35& (Table! 5.7).&&
Lodoxamide&recorded&a&170Kfold&decrease&in&potency&(P&≤&0.001)&at&R4.60M&human&GPR35,&






employed& in& the& BRETKbased& methodology& of& βKarrestinK2& recruitment.& & The& effects& of& wild& type&
human& (filled& squares),&wild& type& rat& (filled& circles),& human&R4.60M& (open& squares),& or& rat& R4.60M&
(open& circles)& were& measured& on& response& to& zaprinast& (A),& amlexanox& (B),& pamoic& acid& (C),&
compound&1&&(D),&and&lodoxamide&(E).&&Data&are&the&mean&±&SEM&of&a&minimum&of&three&independent&
experiments& carried& out& in& duplicate.& & Efficacy& was& normalised& to& the& percentage& of& the&maximal&
zaprinast& response& generated& at& each& individual& mutant& (rat)& or& the& maximal& wild& type& zaprinast&
response&(human).&& &
FLAG-GPR35-eYFP







Rat Tyr 3.32 Leu
Rat GPR35 WT 
Hum GPR35a WT 






























































































125 Rat GPR35 WT










































































Ligand pEC50 pEC50b ΔpEC50c pEC50 pEC50b ΔpEC50c
Zaprinast 5.59$±$0.01 Inactive NR 7.01$±$0.02 5.06$±$0.18*** <$1.95
Amlexanox 5.38$±$0.05 NT NA 7.63$±$0.07 5.93$±$0.08*** <$1.70
Pamoic%Acid 7.25$±$0.05 Inactive NR 4.87$±$0.10$ 4.77$±$0.16 <$0.10
Compound%1 7.55$±$0.03 Inactive NR 5.14$±$0.08 4.53$±$0.17* <$0.61
Lodoxamide 8.38$±$0.02 Inactive NR 7.90$±$0.02 5.99$±$0.21*** <$1.91




























Hum Arg 4.60 Met
Hum GPR35a WT 


































































































Hum Arg 4.60 Met
Hum GPR35a WT 
Rat GPR35 WT













































































































Ligand pEC50 pEC50b ΔpEC50c pEC50 pEC50b ΔpEC50c
Zaprinast 5.59$±$0.01 Inactive NR 7.01$±$0.02 5.10$±$0.06*** ;$1.91
Amlexanox 5.38$±$0.05 4.35$±$0.08*** ;$1.03 7.63$±$0.07 Inactive NR
Pamoic%Acid 7.25$±$0.05 5.73$±$0.06*** ;$1.52 $4.87$±$0.10$ 4.76$±$0.30 ;$0.11
Compound%1 7.55$±$0.03 5.27$±$0.06*** ;$2.28 5.14$±$0.08 4.92$±$0.20 ;$0.22
Lodoxamide 8.38$±$0.02 6.15$±$0.05*** ;$2.23 7.90$±$0.02 5.18$±$0.13*** ;$2.72







potency& (Fig! 5.10E;&Table! 5.7).& & Expression& of& R4.60M&also& affected& the& bufrolin& response&









to& the& Y3.32L& and& R3.36A& mutations& however,& alteration& to& the& human& wild& type& D7.43&
sequence& completely& abolished& βKarrestinK2& recruitment& for& all& ligands& assessed& herein,&
despite& receptor& delivery& to& the& cell& surface& (Fig! 5.11;& Table! 5.8).& & Following& expression&
D7.43A& rat& GPR35& zaprinast& recorded& a& 5.8Kfold& increase& (P& ≤& 0.001)& in& potency,& while&
amlexanox&was&not&significantly&affected&(Fig!5.11A/B;&Table!5.8).&&For&pamoic&acid&the&Emax&
increased&to&69.8&±&3.3&%&(P&≤&0.001)& from&19.2&±&1.3&%,&but&potency&was&not&significantly&
affected& (Fig! 5.11C).& &Compound&1&also&recorded&an& increase& in&efficacy& (Emax&94.6&±&1.9&%&
from&41.7&±&1.8&%)&(P&≤&0.001)&and&was&associated&with&a&380Kfold&increase&in&potency&(P&≤&
0.001)& following& expression& of& D7.43A& (Fig! 5.11D;& Table! 5.8).& & This& increase& actually&
abolished&the&species&selective&difference&between&human&and&rat&GPR35&for&compound&1&








of& ligand,& consistent& with& enhanced& constitutive& activity& of& the& receptor.& & However,& the&
equivalent& mutation& of& the& human& receptor& (D7.43A)& was& not& constitutively& active& (Fig!
5.12B).& & This&phenomenon&extended& to& residues&other& than&D7.43A,&and& included&Q6.58R,&




coKtransfected& with& βKarrestinK2KRenilla& luciferase& and& mutant& or& wild& type& FLAGKGPR35KeYFP&
constructs&were&assessed&using&the&BRETKbased&methodology&of&βKarrestinK2&recruitment.&&The&effect&
of& human&GPR35& (filled& squares),& rat& GPR35& (filled& circles),& human&D7.43A& (open& squares)& and& rat&
D7.43A& (open&circles)&was&measured&on& response& to& zaprinast& (A),& amlexanox& (B),& pamoic&acid& (C),&
compound&1&(D)&lodoxamide&(E),&and&bufrolin&(F).&&Data&are&the&mean&±&SEM&of&a&minimum&of&three&
independent&experiments&carried&out&in&duplicate.&&Efficacy&was&normalised&to&the&percentage&of&the&
maximal& zaprinast& response& generated& at& each& individual& mutant& (rat)& or& the& wild& type& zaprinast&
response&(human).&









































Rat Asp 7.43 Ala
Hum GPR35a WT 


































































































Rat Asp 7.43 Ala
Hum Asp 7.43 Ala










































































Ligand pEC50 pEC50b ΔpEC50c pEC50 pEC50b ΔpEC50c
Zaprinast 5.59$±$0.01 Inactive NR 7.01$±$0.02 7.77$±$0.05*** +$0.76
Amlexanox 5.38$±$0.05 Inactive NR 7.63$±$0.07 7.23$±$0.11 >$0.40
Pamoic%Acid 7.25$±$0.05 Inactive NR $4.87$±$0.10 5.07$±$0.09 +$0.20
Compound%1 7.55$±$0.03 Inactive NR 5.14$±$0.08 7.72$±$0.09*** +$2.58
Lodoxamide $8.38$±$0.02 Inactive NR 7.90$±$0.02 7.67$±$0.06 >$0.23



































































































& The& differences& in& species& selectivity& displayed& by& selected& GPR35& ligands& were&
assessed& upon& response& to& ‘species& swap’& mutations& in& an& effort& to& identify& residues&
important&for&ligand&function.&&Since&there&was&no&radiolabelled&ligand&available&at&this&time,&




presented& herein& indicated& for& the& first& time& the& reliance& of& the& human& selective& ligands&
pamoic&acid&and&compound&1&on&positively&charged&arginine&residues&in&ELC2&(R164)&and&ELC3&
(R6.58&and&R7.32).& &Reciprocal&mutations&made&at& these&residues& increased&the&potency&of&
pamoic& acid& and& compound& 1& at& rat& GPR35,& and& therefore& presented& the& first& molecular&
evidence&for&the&basis&of&species&selectivity&at&GPR35.&&




not& interact& with& a& series& of& conserved& residues& to& result& in& their& equipotency& between&
species,&and&therefore&it&is&quite&remarkable&that&two&ligands&with&such&high&potency&at&both&
human& and& rat& orthologues& of& GPR35& have& been& identified.& & The& majority& of& reciprocal&
mutations& generated& did& not& affect& the& potency& of& zaprinast& and& amlexanox& to& any& great&
extent,&with&the&exception&of&the&species&conserved&residue&R4.60,&which&when&mutated&to&





acting& in& a& distinct& manner.& & This& discussion& places& the& findings& presented& herein& in& the&





achieve! their! equipotent! responses& Receptor& homology& models& for& human& (A/B)& and& rat& (C/D)&
GPR35&in&complex&with&lodoxamide&(A/C)&or&bufrolin&(B/D)&based&on&the&crystal&structure&of&the&PAR1&
receptor& (Zhang&et&al.,&2012),& generated&by&my&collaborator&Dr.&Gianluigi&Caltabiano& (Mackenzie&et&
al.,& 2014).& & Species& conserved& residues& R3.36& and& R4.60& act& alongside& D7.43& at& the& base& of& the&
binding&pocket& to& tether& the&carboxylic&acid&moiety&of&each&agonist.& &At&human&GPR35,& residues& in&
ECL2& (R164)&and&ECL3& (R6.58&and&R7.32)&coordinate& ligand&binding&at& the& top&of& the&binding&pocket.&&
Rat&GPR35&does&not&contain&arginine&residues&in&these&positions&and&relies&on&an&arginine&residue&at&
the&top&of&TM4/&bottom&of&ECL2&(R4.62)&for&ligand&binding.&&Valine&2.60&is&a&residue&present&in&human&








& In&GPR35,& R3.36& is&widely& conserved&between& species& including& the& fruit& bat,&whale,&
cow,&rodents,&and&man&suggesting&that& it&plays&an& important&and&conserved&function&(data&
not& shown).& & Indeed,& for& both& human& and& rat& GPR35,& mutation& of& R3.36A& completely&
abolishes& all& ligand& responses& without& ablating& cell& surface& delivery& (Jenkins& et& al.,& 2011;&
Mackenzie& et& al.,& 2014).& & This& finding&was& also& observed& upon&mutation& of& R3.36A& in& the&
HCA1&and&HCA2&receptors,&with&the&suggestion&that&R3.36&is&critical&for&carboxylic&acid&binding&
of& lactate&and&nicotinic& acid,& respectively& (Liu&et& al.,& 2009;& Tunaru&et& al.,& 2005;&Kuei& et& al.,&
2011).& &For& this& reason&therefore,& it&was&hypothesised& that&R3.36&was&a& residue&critical& for&
carboxylic& acid& binding& at& the& base& of& the& ligand& binding& pocket& at& both& human& and& rat&
GPR35.&&In&an&independent&study,&R3.36&was&also&described&as&a&residue&that&played&a&role&in&







rescue&cell& surface&expression&of&GPR35&R3.36A& indicated&that&R3.36& is&not&critical& for&CIDK
2745687& interaction& with& GPR35.& & In& this& context,& it& would& be& of& interest& to& determine&
whether& expression& of& R3.36A& could& also& be& rescued& by&MLK145,& since&MLK145& contains& a&
carboxyl& group& and&may& require& R3.36& for& ligand& binding& (whereas& CIDK2745687& contains&
only& an&ethyl& ester).& This& group&also& indicated& that&R3.36& is& not&directly& involved& in& ligand&
binding& in& rat&GPR35,&as&an&alteration& in& sequence& from&P5.43&at&human& to&S5.43& in& rat& is&
predicted& to& shift& TM5& by& approximately& 4& Å& to& a& position& unfavourable& for& R3.36& ligand&
interaction&(Lane,&2011).&&This&is&distinct&from&the&model&generated&from&the&data&presented&





& The& hydroxycarboxylic& acid& receptor& family& consists& of& the& HCA1K3& receptors& that&
respond& endogenously& to& 2KhydroxyKpropanoic& acid& (lactate),& 2KhydroxyKbutyric& acid& (a&
keytone),& and& 3KhydroxyKoctanoic& acid& (a& βKoxidation& intermediate),& respectively& (Ahmed,&
2011).& & In& terms& of& sequence& similarity,& GPR35,& the& oxoeicosanoid& (OXE)& and& GPR31&
receptors&are&closely&related&to&this&family,&and&these&receptors&are&unique&amongst&class&A&
GPCRs& in& that& they& all& contain& the& residue& R3.36.& & The&OXE& and&GPR31& receptors,& akin& to&
HCA1K3,& are& activated& by& endogenous& hydroxycarboxylic& acids& derived& from& lipoxygenase&
activity,& namely& 5KoxoK6,8,11,14Keicosatetraenoic& acid& and& 12K(S)KhydroxyK5,8,10,14K
eicosatetraenoic&acid,&respectively&(Hosoi&et&al.,&2002;&Jones&et&al.,&2003;&Guo&et&al.,&2011).&&
R3.36&therefore&appears&to&be&a&central&feature&of&hydroxycarboxylic&acidKbinding&GPCRs,&but&
it& is& of& interest& to& note& that& hydroxycarboxylic& acid& ligands& have& not& been& suggested& as&
agonists&of&GPR35.&&Although&GPR35&responds&to&numerous&carboxylic&acid&and&dicarboxylic&
acid& ligands,& a& conserved& arginine& residue& at& position& 3.36& is& not& a& required& feature& for&
general& carboxylic& acid& binding,& and& this& residue& is& not& present& in& the& FFAR& or& the&
dicarboxylic& acid& binding& succinate& and& oxoglutarate& receptors& (Fig! 5.14).& & From& these&






& In& addition& to& R3.36,& the& HCA1K3& receptors& also& require& the& presence& of& an& arginine&
residue&in&TM6&and&a&conserved&sequence&motif&(CxSF)&in&ECL2&(Fig!5.15)&for&ligand&binding&
(Tunaru&et&al.,&2005;&Liu&et&al.,&2009).&&The&cysteine&residue&of&ECL2&forms&a&highly&conserved&
disulphide& bond& with& C3.25& in& most& family& A& GPCRs& that& effectively& tethers& ECL2& to& the&
helical&bundle,&provides&conformational&constraint,&and&can& influence& ligand&entry& into& the&
binding&pocket&(Wheatley&et&al.,&2012).&&This&sequence&is&CFRS&in&human&GPR35&and&CFSS&in&
rat&GPR35,&and&was&investigated&herein&by&reciprocal&mutation&of&R164S&and&S161R&at&human&
and&rat&GPR35,&respectively.& &R164&was&found&to&be& important&for& ligand&function&at&human&
GPR35&for&the&human&selective&and&equipotent&but&not&rat&selective& ligands&(Fig!5.5;&Table!
5.2),& while& the& reciprocal&mutation& at& rat& GPR35& (S161R)& actually& significantly& reduced& the&





3.36! that! is! not! conserved! across! all! carboxylic! acid9binding! GPCRs& Sequence&alignments&of& TM3&
including&the&‘DRY’&motif&or&equivalent&sequence&in&bold,&alongside&the&conserved&arginine&residue&at&
position&3.36&that&is&thirteen&residues&preceding&the&DRY&motif,&in&bold.&&Those&containing&R3.36&are&
the&hydroxycarboxylic& acid& receptors&HCA1& (GPR81),&HCA2& (GPR109A),&HCA3& (GPR109B),&GPR31&and&
the&oxoeicosanoid&(OXE)&receptor&1;&class&A&carboxylic&acid&ligand&binding&GPCRs&that&do&not&contain&
the&R3.36& residue& include& the& free& fatty& acid& receptors& 1K4& and&GPR84,& the& succinate& (GPR91)& and&
oxoglutarate&(GPR99)&receptors.!
& &
GPR35 T N R Y M S I S L V T A I A V D R Y V
HCA1 M N R A G S I V F L T V V A A D R Y F
HCA2 M N R Q G S I I F L T V V A V D R Y F
HCA3 M N R Q G S I I F L T V V A V D R Y F
GPR31 L S R S V G M A F L A A V A L D R Y L
OXE T N R T A S V V F L T A I A L N R Y L
GPR35 T N R Y M S I S L V T A I A V D R Y V
FFA1 F P L Y A G G G F L A A L S A G R Y L
FFA2 S S I Y C S T W L L A G I S I E R Y L
FFA3 T T I Y L T A L F L A A V S I E R F L
FFA4 L S G S V T I L T L A A V S L E R M V
GPR84 A S N S V S I L T L C L I A L G R Y L
SUC A N L Y T S I L F L T F I S I D R Y L












hGPR35 ! G I Q E G G F C F R S T R H N F N S ! ! ! ! ! !
rGPR35 ! G I Q E G G F C F S S Q N R Y N F S ! ! ! ! ! !
HCA1 C V Q E T A V S C E S F I M E S A N G W H ! ! ! !
HCA2 I Q N G G A N L C S S F S I C H T F Q W H ! ! ! !
HCA3 I Q N G P A N V C I S F S I C H T F R W H ! ! ! !
OXE ! ! ! ! ! G P S C L S Y R V G T K P S A S L R W H
GPR31 ! ! A Q N S T R C H S F Y S R A D G S A S L R W H
SUC V I T D N G T T C N D F A S S G D P N Y N L I Y S
OXG T N R T N R S A C L D L T S S D E L N T I K W Y N
Chapter&Five:&Investigating&Species&Orthologue&Selectivity&of&Ligands&at&GPR35&!
! 215&
ECL2& plays& a& different& role& between& GPR35& species& orthologues& and& that& the& equipotent&
ligands&rely&on&distinct&contacts&to&modulate&binding&between&species.&&Further&differences&in&
this&region&between&species&are&likely&based&on&sequence,&as&rat&GPR35&contains&an&NKlinked&
glycosylation& consensus& sequence& (NKXKS/T)& that& is& absent& from& the& ECL2& of& human.&&





& ELC2& has& also& been& implicated& as& a& negative& regulator& of& constitutive& activity,& with&
various& ionic& locks& forming& between& ECL2,& TM5& and& TM7& that& maintain& receptors& in& an&
inactive&state&(Massotte&and&Kieffer,&2005;&Klco&et&al.,&2005).& &Constitutive&activity&has&only&
been&confirmed& for&human&GPR35& in& the& IPKOne&assay& (Fig! 3.9),& since& the& inverse&agonists&
MLK145&and&CIDK2745687&are&markedly&human&selective&and&do&not&block&agonist& induced&
responses& at& the& rodent& orthologues.& & Despite& this,& however,& it& is& likely& that& human& and&
rodent&orthologues&of&GPR35&display&constitutive&activity.&&This&is&based&on&findings&obtained&
from&the&BRETKbased&βKarrestinK2&recruitment&assay&that&showed&that&rat&GPR35&generated&

















rat& species& orthologue,& since& reciprocal& mutations& at& 6.58& and& 7.32& ablate& ligand&
functionality&of&the&humanKselective&and&equipotent&ligands&at&human&GPR35&(Fig!5.6;&Table!
5.3),& but& there& is& little& effect& on& ligand& binding& at& rat& GPR35& following& alteration& to& this&
sequence& (Fig! 5.7;& Table! 5.4).& & This& is& with& the& exception& of& the& humanKselective& ligands&
pamoic&acid&and&compound&1,&which&significantly&gain&potency&over&the&wild&type&response&
following&mutation&of&both&Q6.58R&and&S7.32R& in& rat&GPR35.&This& suggests& that&R6.58&and&





& The&dicarboxylic& acid& receptors& succinate& and&oxoglutarate& also& require& two&arginine&
residues&at&the&top&of&TM6&and&TM7&(R6.55,&R7.36),&in&addition&to&two&basic&residues&at&the&
base&of& the&binding&pocket& (R3.29,&H3.33),& that&coordinate&dicarboxylic&acid& ligand&binding&
(He&et&al.,&2004).&&They&therefore&form&a&mechanism&of&dicarboxylic&acid&binding&that&utilises&
residues& that& are& distinct& from& human& GPR35.& & Molecular& homology& modelling& efforts&
indicate& that& human& GPR35& contains& R3.36& and& R4.60& at& the& base& of& the& binding& pocket&
(R4.60&is&a&unique&residue&of&GPR35&amongst&all&the&carboxylic&acidKbinding&GPCRs),&and&R164,&
R6.58&and&R7.32&at&the&top&(Mackenzie&et&al.,&2014).&&Interestingly&rat&GPR35&is&again&distinct&
in& that& it& contains& R3.36& and& R4.60& at& the& base& but& only& R4.62& at& the& top& of& the& binding&
pocket,&since&rat&GPR35&lacks&the&two&arginine&residues& in&ECL3&(Fig!5.4)& (Mackenzie&et&al.,&
2014).&&However,&it&is&important&to&note&that&rat&GPR35&contains&a&unique&histidine&residue&in&




that,& given& the& different& results& generated& between& species& orthologues& with& previously&
described& species& conserved& residues,& human& and& rat& GPR35& will& interact& and& rely& to&
different& extents& upon& alteration& of& R165/R167& and& R7.33,& although& this& remains& to& be&
assessed&directly.&
& In&accordance&with&the&involvement&of&ECL2&and&since&both&R6.58&and&R7.32&appear&to&




crystal& structures& of& the& closely& related& P2Y12& receptor& (which& was& not& available& during&
receptor& homology& efforts& as& part& of& this& project)& and& the&CXCR4& receptor& (which& did& not&
appear& to& be& relevant& to&GPR35& until& the& recent& suggestion& of& CXCL17& as& an& endogenous&
ligand&of&GPR35)& indicate& the& involvement&of& an& ‘ECL4’& in& ligand&binding& (Wu&et& al.,& 2010;&
Zhang& et& al.,& 2014).& & ECL4& is& created& as& the& result& of& the& formation& of& a& disulphide& bond&
between& a& cysteine& residue& in& the& NKterminal& region& and& a& conserved& cysteine& residue& in&
ECL3,&which&acts&to&pull&ECL4&over&the&ligandKbinding&pocket&(Szpakowska&et&al.,&2014).&&The&
conserved&cysteine&is&present&in&ECL3&of&both&human&and&rat&GPR35,&but&the&cysteine&residue&
in& the&NKterminus& is&differentially&positioned&between& the&species&orthologues& (human&C8,&
and&rat&C6,&from&the&NKterminus).&&Furthermore,&since&the&NKterminus&of&rat&is&four&residues&
shorter& than& human& GPR35a,& it& is& likely& that& the& exact& positioning& and& structure& of& ECL4&
would&be&distinct&between&the&two&species&orthologues&of&GPR35.&&In&light&of&this,& it&would&
be&very& interesting& to&determine& the& role&of&ECL4& in& ligand&binding&and&species& selectivity,&
especially& since& this& disulphide& bond& does& not& appear& to& be& critical& to& GPCR& structural&
stability&(Zhang&et&al.,&2014)&and,&therefore,&this&can&be&assessed&directly.&&Figure!5.16&depicts&




5.3.4# Y3.32# and# D7.43# are# species# conserved# residues# at# human# and# rat# GPR35# that# are#
generally#involved#in#GPCR#activation#
&




al.& 2014),& Y3.33& and& Y7.35& form& a& hydrogen& bond& that& forms& the& base& of& the& orthostericK
binding&pocket.&&These&residues&are&present&in&human&GPR35&at&positions&Y3.32,&and&Y7.36,&
but& rat& GPR35& does& not& contain& a& tyrosine& residue& in& this& position& in& TM7.& &Mutation& to&






terminal& region&of&human&GPR35& (red)& shown& in&association&with&ECL3& through& the& formation&of& a&






rat& binding& pockets& may& be& distinct,& with& Y3.32& forming& critical& structural& and& functional&
contacts&at&human&GPR35.&
& The& topological& residue& at& 7.43& is& implicated& in& the& binding& of& both& agonist& and&





species,&or& simply& that& the&BRETKbased&βKarrestinK2&assay& is&not&suitable& for&assessment&of&
constitutive& activity& at& human&GPR35& since& the& equivalent&D7.43A&mutation& at& human&did&
not&lead&to&constitutive&βKarrestinK2&recruitment&in&the&BRET&assay&(Fig!5.12A).&&Mutation&of&
D7.43A&also&affected& ligand&binding,&which&completely&ablated&all& responses&at& the&human&
orthologue& without& affecting& cell& surface& delivery.& Most& interestingly,& at& rat& GPR35,&
compound&1&displayed&a&2.6& log& increase& in&potency&(an&EC50&of&7.2&µM&at&wild&type&to&1.9&
nM&at&D7.43A)&and&a&67&%&gain&in&efficacy&(Emax&42&%&at&wild&type,&109&%&at&D7.43A)&to&record&
a&response&that&was&now&akin&to&that&generated&at&human&GPR35&(EC50&2.8&nM,&Emax&100&%)&
(Fig! 5.11;& Table! 5.8).& & Interestingly,& the& GPR35& ligands& containing& a& protonated& nitrogen&
residue& –& compound& 1,& zaprinast,& doxantrazole,& and& pemirolast& –& all& displayed& significant&









determine& residues& important& for& each& of& humanKselectivity,& rodentKselectivity& and&
equipotency.& & Specifically,& arginine& residues& expressed& in& the& human& receptor& (R164,& R6.58&
and&R7.32)&were&found&to&be&necessary&for&human&selective&and&equipotent&ligandKinduced&
βKarrestinK2& recruitment.& & Addition& of& these& arginine& residues,& moreover,& increased& the&




study& led& to& the& first& molecular& characterisation& of& ligand& binding& at& GPR35& and,& in&
conjunction& with& receptor& homology& efforts& based& on& the& crystal& structure& of& the& PAR1&
receptor,& indicated& that&while&both&human&and& rat&GPR35& coordinate& ligand&binding&using&
R3.36,& R4.60,& D7.43& and& Y3.32& at& the& base& of& the& ligand& binding& pocket,& at& the& top& the&
binding&pocket&human&GPR35&relies&on&R164,&R6.58&and&R7.32,&while&rat&GPR35&utilises&R4.62.&&
It&will&be&of&interest&now&to&determine&whether&‘ECL4’&is&involved&in&ligand&binding&at&GPR35&
and&what& effect&mutation& of& this& region&may& have& on& the& potency& and& efficacy& of& GPR35&
ligand& responses.& &Verification&of&CXCL17&as&an&endogenous& ligand&of&GPR35&will&offer& the&
opportunity& to& further& investigate& ligand& binding& at& GPR35,& with& particular& focus& on&
negatively&charged&residues&in&the&NKterminal&and&extracellular&loops&of&the&receptor.&&Since&
peptide&ligands&tend&to&bind&to&the&extracellular&surface&of&the&GPCR,&verification&of&CXCL17&
as& an& endogenous& ligand& of& GPR35& could& indicate& that& the& small&molecule& binding& site& of&
GPR35& is& in& fact&an&allosteric,& rather& than&orthosteric,&binding&site.& & Investigation&of&GPR35&
signalling&in&the&presence&of&CXCL17&and&whether&small&molecule&agonists&act&as&positive&or&





















diseases& including& heart& disease,& inflammatory& bowel& disease& and& primary& sclerosing&
cholangitis,& in&addition&to&physiological& ligand/receptor&association&studies&that&have&linked&
GPR35& to& antinociception& and& antiKinflammatory& disease& states& (Mackenzie& et& al.,& 2011).&&
However,& the& basic& physiological& function& of& GPR35& has& remained& poorly& characterised,&
sixteen&years&after&the& initial&discovery&of&GPR35&as&a&GPCR&(O’&Dowd&et&al.,&1998).& &This& is&
mainly&a& result&of& a& lack&of& consensus&on& the&endogenous& ligand,& as&many&of& the&putative&
ligands& either& act&with& potency& that& is& unlikely& to& be& achieved&under& normal& physiological&
conditions,& and/or& act& with& prominent& effects& at& other& biological& targets& (Table! 1.2).&&
Because&of&this,&a&number&of&largeKscale&highKthroughput&screening&efforts&were&carried&out&
by& both& the& academic& and& industrial& sectors,& and&have& yielded& a& large& array& of& chemically&









(Chapter!Three).& &From&this,& I& found&a&number&of&assay&formats&that&would&be&suitable& for&
ligand& characterisation& including& the& [35S]GTPγS& with& immunoprecipitation& assay& for&
assessment& of& fullKlength& Gα13& responses& emanating& from& GPR35;& the& IPKOne& assay& with&
chimeric&Gαq&subunits&that&routed&GPR35&responses&through&the&IP3&pathway;&a&highKcontent&
imaging& platform& using& ArrayScan™& technology& that& monitored& CKterminally& eYFPKtagged&
receptor&construct&internalisation;&and&the&labelKfree&DMR&platform&that&monitored&receptor&
activation&in&cell&lines&endogenously&expressing&GPR35.&&Of&the&assay&platforms&assessed,&the&





βKarrestinK2& recruitment& assay,& followed& by& the& IPKOne& assay& for& assessment& of& G& protein&
responses,&and&the&DMR&format&to&ensure&responses&correlated&with&those&generated&in&cells&
endogenouslyKexpressing&GPR35&(Chapter!Four).&
& In& the& process& of& characterising& assay& outputs& for& assessment& of& GPR35& function& I&
found& that& the& GPR35& antagonists& MLK145& and& CID2745687& acted& as& inverse& agonists& in&
systems&displaying&constitutive&activity,&and&that&the&interaction&between&βKarrestinK1&or&βK
arrestinK2& and&GPR35&was& shortKlived& rather& than& sustained.& & Future& research& efforts&may&
wish& to& determine&whether&GPR35& is& constitutively& active& in& endogenously& expressing& cell&
lines,&which&could&be&assessed&by&application&of&the&inverse&agonists&CID2745687&or&MLK145&
and&monitoring& responses& using& DMR& technology.& & If& GPR35& is& found& to& be& constitutively&
active& under& native& physiological& conditions,& it&may& be& pertinent& to& question&whether& the&
endogenous&ligand&of&GPR35&may&in&fact&be&an&inverse&agonist&rather&than&agonists&such&as&
kynurenic& acid& or& LPA.& & Assessment& of& inverse& agonism& has& previously& not& been& possible&








whether& the& human& and& rodent& orthologues& of& GPR35& couple& endogenously& through& the&
same& pathways& or& whether& compound& 1& uniquely& biases& the& receptor& between& different&
pathways.&&LigandKinduced&pathway&bias&has&yet&to&be&comprehensively&assessed&at&GPR35,&
mainly&because& the& involvement&of&particular&pathways&emanating& from& this& receptor&and&
their& subsequent& physiological& profiles& remain& to& be& clarified.& & However,& from& a&
pharmacological& perspective,& it&would&be&of& interest& to&use& some&of& the& ligands& identified&
herein&to&perform&an&acrossKpathway&assessment&of&their&function&and&assess&any&potential&
pathway&bias& that&may&emanate& from& these& responses.& &As& yet&no&GPR35& ligand&has&been&






& The& majority& of& GPR35& agonists& identified& from& the& compound& library& screen&
displayed&marked&human&selectivity,&and&it&was&determined&that&mostly&all&of&these&ligands&–&
although& chemically& diverse& –& contained& a& carboxylic& acid& group.& & For& this& reason& GPR35&
appears&to&be&activated&promiscuously&by&a&wideKvariety&of&ligands,&many&of&which&act&with&
low& potency.& & These& have& actually& complicated& understanding& of& GPR35& receptor& biology&
since& GPR35& is& not& likely& to& be& the& primary& target& of& many& of& these& ligands& in# vivo.& & By&
examination&of&the&previously&associated&functions&of&the&large&number&of&ligands&reported&
as& agonists& of& GPR35,& I& began& to& question& whether& mast& cell& stabilisers& were& generally&
mediating& function& through& activation& of& GPR35.& & To& extend& this,& a& number& of& mast& cell&
stabilising& compounds& were& assessed,& including& amlexanox,& bufrolin,& cromolyn,&
doxantrazole,& lodoxamide,& and&pemirolast,& tranilast,& ketotifen& fumarate,& and& the&mast& cell&
activator&compound&48/80.&&Interestingly,&only&a&subset&of&mast&cell&stabilisers&was&found&to&
activate& GPR35.& & This& raises& a& number& of& intriguing& questions& for& future& research& efforts,&
including&those&that&focus&on&the&basic&biological&profile&of&GPR35&in&the&context&of&the&mast&
cell.& & Is& the&mechanism& by& which& GPR35Kactive& ligands& prevent& degranulation& one& that& is&
associated&with&GPR35&or&are&these&ligands&all&acting&at&distinct&biological&targets&to&carry&out&
this&function?&&In&this&context,&it&would&be&of&interest&to&probe&the&role&of&mast&cell&activation&
and& leukocyte& adhesion& in& GPR35& knockout& mice,& and& to& determine& if& there& are& any&
abnormalities& arising& in& the& immune& system& of& these& animals& that& could& be& subsequently&
associated&with&the&lack&of&expression&of&GPR35.&&&
& The& identification& of& two& highly& potent& agonists& –& lodoxamide& and& bufrolin& –& of&
human&and&rat&GPR35&as&described&herein&was&an&important&milestone&for&GPR35&research&
(Mackenzie&et&al.,&2014).& & Identification&of& these& ligands&enabled&the&first&detailed&study&of&
the& receptorKbinding& pocket& of& GPR35& to& be& carried& out,& in&which& responses& produced& by&
ligands&that&acted&with&marked&profiles&of&species&selectivity&between&human&and&rat&GPR35&
were& compared&with& the& newly& discovered& species& equipotent& ligands& at& various& receptor&
mutants&(Chapter!Five).&&My&study&of&GPR35&species&selectivity&and&ligand&binding&identified&





to& alanine,& due& to& the& size& and& charge& differences& between& these& molecules,& but& should&
theoretically&be&more&informative&of&the&differences&between&the&ligand&binding&pockets&of&
the&human&and& rat&orthologues.& & Since& the& ‘species& swap’&mutants&were&only&assessed& for&
their& ability& to& recruit& βKarrestinK2& to& GPR35,& it& may& be& pertinent& to& now& move& towards&
assessment& of& these& mutants& with& the& newly& reported& GPR35& radiolabelled& agonist& PSBK
13253&(Funke&et&al.,&2013;&Thimm&et&al.,&2013),&to&determine&if&these&mutations&are&affecting&
affinity& of& the& ligand& at& the& receptor,& or& simply& the& ability& of& the& receptor& to& recruit& βK
arrestinK2.&&In&the&case&of&the&latter,&therefore,&it&could&be&worth&probing&the&same&mutants&
and&their&responses&in&the&IPKOne&or&Gα13&[35S]GTPγS&systems&to&determine&their&effects&on&G&
protein& recruitment.& & This&may& provide& a&more& thorough& understanding& of& the&molecular&
links&between&ligand&binding&and&distinct&pathway&signalling,&which&will&help&in&assessing&the&
physiological&function&and&signalling&pathways&of&GPR35.&&
& Finally,& the& most& pressing& issue& that& requires& attention& with& regards& to& future&
research&efforts&at&GPR35&is&the&identification&of&antagonist&molecules&that&block&responses&
arising& from& the& rodent& receptors.& & This& is& particularly& important& since& the& majority& of&
physiological& functionKbased& studies& surrounding& GPR35& have& been& carried& out& in& rats& or&
mice,& with& these& studies& using& shRNA,& RNAi,& or& actually& applying& the& humanKspecific&
antagonist& compounds& to& these& systems& to& infer& a& function& for&GPR35.& & It& is& possible& that&
these& compounds&act& as&biased& inverse&agonists& that& can&prevent&activation&of& the& rodent&
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